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2Abstract
TRPA1 is a member of the TRP superfamily; localised to neural and non-
neuronal sites. TRPA1 is activated endogenously by products of oxidative
stress, where its expression on sensory neurones leads to the release of
vasoactive neuropeptides.  Exogenous agonists of TRPA1, mustard oil and
cinnamaldehyde, have been shown to cause concentration-dependent
vasorelaxation of blood vessels via a variety of mechanisms. My PhD used
TRPA1 WT and KO mice to investigate the potential for TRPA1 to alter
peripheral artery tone and the implications of this on systemic blood
pressure.  I also studied the development of angiotensin II induced
hypertension and associated pathologies.
Wire myography using murine TRPA1 WT and KO mesenteric arteries
showed cinnamaldehyde to cause concentration-dependent vasorelaxation
comprising a TRPA1 dependent component, which was endothelial
independent and mediated by CGRP and hyperpolarisaton.    Basal blood
pressure monitoring by both tail cuff plethysmography and telemetry
showed no overall effect of TRPA1 deletion on basal hemodynamics.
However, TRPA1 KO mice displayed a previously unreported hyperactivity
phenotype, measured by both telemetry and voluntary wheel running.  14
day infusion of angiotensin II by osmotic minipump induced similar
hypertension in both TRPA1 WT and KO mice.  Hypertrophy of the heart
was seen in both genotypes, but of significantly increased magnitude in
TRPA1 KO mice.  Further analysis of associated inflammatory biomarkers
by RT qPCR and MSD multiplex ELISA showed upregulation of pro-
oxidative genes in hypertensive mice of both genotype.  This was
significantly greater in hypertensive TRPA1 KO mice than in hypertensive
TRPA1 WT mice.   These findings may partially explain the increase in
hypertrophy in these mice.  Angiotensin II infused mice of both genotypes
showed increases in chemokine and cytokine expression.  Striking, increases
in IL6 and MCP-1 seen in hypertensive WT mice were significantly blunted
in hypertensive KO mice, suggesting that TRPA1 may differentially
modulate inflammatory responses.
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Chapter 1 - Introduction
Transient Receptor Potential Ankyrin 1 (TRPA1) is a non selective cation
channel, known to be activated by a range of exogenous noxious
compounds, and endogenous products of oxidative stress.  Identified just
over 10 years ago, TRPA1 is classically expressed on sensory neurones and
has developed a fingerprint of activity associated with neurogenic
inflammation.  It is now becoming the target of anti-inflammatory drug
development, particularly in the field of lung inflammation.  However, the
contribution of TRPA1 to cardiovascular regulation is currently unclear.
Several studies suggest that TRPA1 agonists can alter activity of the
cardiovascular system, such as blood pressure, heart rate and vascular tone.
Nevertheless, no thorough investigation has been conducted into the
contribution of the TRPA1 receptor to these events.  This thesis will present
the data collected during my PhD, where I have investigated the role of
TRPA1 in cardiovascular regulation.  Present literature describing the
relevant background will be summarised in this introduction.  Firstly, I will
discuss the role of sensory neurones and neuropeptides in the vascular
system.  I will then introduce the TRP channel family, first describing the
classical member Transient Receptor Potential Vanilloid 1 (TRPV1), which
shows many parallels with TRPA1 activity and a clearer role in
cardiovascular disease.  I will then discuss the TRPA1 receptor in depth,
including agonists, antagonists and current evidence for a role in mediating
cardiovascular regulation.  The chapter will end with a summary of aims for
the thesis.
Sensory Neurones And Neuropeptides
Sensory Neurones
Sensory neurones are small diameter fibres which transduce sensory
information via action potentials to the central nervous system.  These
nerves can be sub-classified to Aβ, Aδ or C-fibres by their decreasing extent
of myelination, with C-fibres being completely demyelinated and thus the
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slowest of the sensory neurones. Further categorisation can be done on the
basis of their mode of activation.  Sensory neurone axons are predominantly
derived from cell bodies lying in Dorsal Root Ganglia (DRG), originating
close to the spinal cord.  They innervate almost all organs of the body and
have both efferent and afferent signalling roles.  These nerves are grown,
maintained and modulated by growth factors, such as Nerve Growth Factor
(NGF) (Petruska and Mendell, 2004).  Projections from the DRG into the
spinal cord produce pain signalling in the brain when stimuli are strong.
Afferent signals are passed into the outer lamina of the spinal cord, where
synapses with spinothalamic tract neurones occur, taking the information to
the brain.  The passage of information is modulated by inhibitory
interneurones in the spinal cord, and influenced by peripheral and central
signalling (Iggo et al., 1985). Further sub-types of sensory neurones exist,
for example cranial nerves originating from the brain stem, which form
pressure baroceptors and chemosensitive branches in the airway. Sensory
neurone subtypes can express similar receptors, but with widely differing
functions.  This depends on their neuropeptide content and integration with
other neural circuits or humoral factors (Marmigère and Ernfors, 2007).
DRG derived sensory neurones are the predominant form of sensory
neurones in the peripheral vasculature and will be the focus of this thesis.
Peripheral blood vessels are richly innervated by DRG derived sensory
neurones, in particular by C-fibres.  Fibre terminals are responsive to a wide
range of stimuli and can interact with a huge range of factors in their
microenvironment via expression of specialised receptors.  Activation of C-
fibres leads to the efferent release of neuropeptides, which can cause an
acute neurogenic inflammatory response when tissue levels are elevated.
Classic clinical effects include swelling, redness, heat, pain and possibly
loss of function. These symptoms and associated mechanisms are well
conserved among mammalian species, making the study of neurogenic
inflammation highly applicable in animal models. Neuropeptides are
generally considered to be small peptides, typically 4-40 amino acids, which
show neural origins.  To date, more than 50 neuropeptides have been
characterised (Lotti et al., 1995).  The two best known vasoactive
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neuropeptides are Substance P (SP) and Calcitonin Gene Related Peptide
(CGRP), which have been well characterised.
Neuropeptides
CGRP
CGRP is a member of the calcitonin peptide family and acts on its
heteromeric G-protein coupled CGRP receptor, comprised of 2 subunits; the
Calcitonin Like Receptor (CLR) and Receptor Activity Modifying Protein 1
(RAMP1) (McLatchie et al., 1998).  It is one of the most potent vasodilators
of peripheral blood vessels identified to date (Brain et al., 1985).  The
majority of its vascular actions are via CGRP receptors expressed on
arteriole smooth muscle cells and endothelium. CGRP signalling
predominantly occurs via increases in cyclic Adenosine Monophosphate
(cAMP) and Protein Kinase A (PKA) activation, which then goes on to
phosphorylate targets and alter their function. In endothelial cells PKA
activates endothelial Nitric Oxide Synthase (eNOS) and Nitric Oxide (NO)
production, inducing relaxation in opposing smooth muscle.  In vascular
smooth muscle cells, direct CGRP receptor activation leads to PKA induced
calcium desensitisation and opening of Adenosine Triphosphate (ATP)
sensitive potassium channels (KATP), leading to hyperpolarisation and
relaxation (Wimalawansa et al, 1996).  CGRP has been implicated in many
cardiovascular diseases, particularly those of the macrovasculature, where it
has been suggested to play a protective role in diseases such as hypertension
(Deng and Li, 2005) and myocardial infarction (Franco-Cereceda and Liska,
2000).  However, the precise mechanisms of activity remain unclear.  It also
has roles in microvascular disease, such as localised acute inflammation,
migraine (Brain and Grant, 2004, Edvinsson and Goadsby, 1994) and angina
(Franco-Cereceda and Liska, 2000).  CGRP has demonstrated both pro and
anti-inflammatory actions on immune cells.  These include increasing
neutrophils attachment to human umbilical vein endothelial cells (HUVEC)
cells (Sung et al., 1992) but reducing activation of macrophages and




SP is a member of the tachykinin family.  It has a wide range of actions
occurring via three recognised neurokinin (NK) receptors, NK1, NK2 and
NK3.  However, most vascular activities are reported to be through NK1
activation. SP has effects on many cell types but the most prominent
include causing increased microvascular permeability by acting on venular
endothelial cells to loosen their cell-cell adhesion interactions, leading to
plasma extravasation. As SP and CGRP are co-released from C-fibre
terminals, their combined vascular actions propagate the formation of
oedema (Brain and Grant, 2004). See figure 1.1 for a schematic of the main
effects of CGRP and SP in the microvasculature. While NK1 expression in
post-capillary venules is thought to mediate the majority of SP induced
plasma extravasation (Saria, 1984, Palframan et al., 1996). Several studies
show SP-induced oedema to be heavily dependent on release of vasoactive
mediators from mast cells, including serotonin and histamine, where SP
induces degranulation via NK1 dependent and independent mechanisms
(Costa et al., 2001, Saban et al., 2002, Krumins and Broomfield, 1992). SP
can also cause upregulation of adhesion molecules on microvascular
endothelial cells (Steinhoff et al., 2003) contributing to cell accumulation,
particularly of neutrophils (Bánvölgyi et al., 2004).  SP induced activation
of incoming and resident inflammatory cells, including neutrophils,
produces further vasoactive mediators and propagates the acute
inflammatory response (Holzer, 1998, Costa et al., 2001).  However, SP
responses can differ based on the local environment.  Activation of NK1
contributes to neutrophil accumulation in inflamed but not naïve murine
skin, showing it to have a potentially important immunomodulatory role in
disease (Cao et al., 2000). NK1 is also expressed on arteriole endothelial
cells where activation of G-protein (Gq/11) mediated PLC activation
downstream of the receptor leads to calcium increases and PKC activation.
This ultimately induces NO production which also contributes to
vasodilation (Maggi, 1995, Petersson et al., 1995).
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Sensory Neurones And Neuropeptides In Cardiovascular
Regulation
It has been postulated that neurogenic inflammation plays a strong role in
the formation and propagation of a variety of diseases, including asthma,
chronic obstructive pulmonary disease (COPD), arthritis, inflammatory
bowel disease and psoriasis.  Thus gaining a better insight into the initiation
of mediator release and their downstream responses is an important and
relevant topic in the study of many diseases, in addition to the
cardiovascular implications.
Resistance vessels are important determinants of total peripheral resistance.
These vessels are also highly innervated by sensory neurones, terminating at
the media/adventitia border and reaching into the smooth muscle layer;
therefore being ideally placed to control vessel tone. There is reportedly a
level of tonic background neuropeptide release which has been implicated in
the control of basal blood pressure (Watson et al., 2002).  Sensory neurones
have an undoubted role in cardiovascular disease.  Many activating stimuli
are at elevated levels in cardiovascular disease and can cause release of
neuropeptides, these include mediators such as bradykinin, endothelin and
also increases in wall tension (Watson et al., 2002).  Therefore sensory
neurones may become activated in disease settings.  In terms of
hypertension, sensory nerve depletion is thought to increase disease
susceptibility (Wang, 2005).  This is likely related to a loss of neuropeptide
induced vasodilatation and suppression of pressor agents.
Several studies have investigated the relationship between CGRP and
hypertension.  In spontaneous models of hypertension, CGRP levels
commonly decrease as blood pressure increases, however, more acute
models often show increases in CGRP protein or receptor expression, acting
as a compensatory mechanism against overactive pressor mechanisms
(Watson et al., 2002, Li and Wang, 2005, Deng and Li, 2005).  Similarly,
angiotensin II (Ang II) has been shown to reduce the release of CGRP, and
this may promote hypertension formation (Kawasaki et al., 1998).  These
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studies also suggest that spontaneous hypertension models may form due to
a lack of CGRP mediated protection.  Similar relationships have been noted
in patients with essential hypertension, however measurable plasma CGRP
levels in patients can be both increased and reduced (Deng and Li, 2005,
Smillie and Brain, 2011).  These differences may reflect the diverse nature
of essential hypertension pathogenesis.  CGRP knock-out (KO) mice have
been produced to lack αCGRP protein and characterised in many studies,
some showing a hypertensive phenotype.  This is thought to be due to an
increase in Renin Angiotensin System (RAS) activity (Li et al., 2004, Deng
and Li, 2005), although this has not been found in all studies (Lu et al.,
1999) and may reflect differences in the method of genetic deletion.
Similarly, neonatal degradation of sensory neurones through application of
destructive doses of capsaicin, produces salt sensitivity characterised by
insufficient suppression of the RAS and exacerbated vasoconstrictor
response to salt load (Wang and Wang, 2005), which may be related to a
loss of CGRP mediated vasodilatation.  CGRP has been shown to reduce
blood pressure when infused to both normotensive and hypertensive rats
(Ando et al., 1990), alters baroreflex sensitivity and sympathetic tone in the
mouse (Sabharwal et al., 2010) and is positively inotropic and chronotropic
when given systemically in man (Franco-Cereceda et al., 1987).
SP also has demonstrated roles in cardiovascular regulation.  Myogenic
artery constriction, a decrease in small blood vessel diameter due to
increased blood pressure, is suppressed after C-fibre ablation (Scotland et
al., 2004).  This is thought to be related to a loss of SP. Previous studies
using NK1 receptor antagonists have also demonstrated increases in blood
pressure in acute experimental hypertension models, signifying that SP may
be acting to counter-act blood pressure increases (Watson et al., 2002).
Therefore, sensory neurones (and the neuropeptides that they contain) can
have important roles in cardiovascular control and are suggested to have
protective effects against the onset of cardiovascular disease, in particular
hypertension.
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Transient Receptor Potential channels
To date, 28 mammalian Transient Receptor Potential (TRP) channels have
been identified (Yao and Garland, 2005) and divided by homology into six
different subfamilies, namely Transient Receptor Potential Vanilloid
(TRPV, 1-6 members), Transient Receptor Potential Melastatin (TRPM, 1-8
members), Transient Receptor Potential Canonical (TRPC, 1-7 members),
Transient Receptor Potential Mucolipin (TRPML, 1-3 members), Transient
Receptor Potential Polycystin (TRPP, 1-3 members) and TRPA (1 member
only).  Further isoforms and subfamilies can be found in lower vertebrate
and invertebrates. TRP channels comprise homo or heterotetramers of six
transmembrane domain (TM) subunits, with a pore-loop structure lying
between TM five and six, forming a non-selective cation channel.
Intracellular amino and carboxy terminals confer much of the channel
regulation.  TRP receptors are widely distributed and can be activated or
modulated by an extensive range of local stimuli.  Intensive research in the
field has identified a vast array of reported physiological and pathological
TRP functions, which is reflected in their low sequence homology.  Faulty
TRP channels, due to genetic mutations, are recognised as being directly
responsible for some disease states, such as TRPP channels in polycystic
kidney disease, and TRPML channels in mudocolipidosis IV, a disease
involving lysosomal storage disorders.
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Figure 1.1; Sensory Neurone Activation In The Microvasculature. Neuronal activation by receptors leads to
calcium influx and release of vasoactive neuropeptides, in particular SP and CGRP.  Activation of NK1 receptors on
endothelial cells by SP causes release of cell to cell adhesions, causing oedema. NK1 on smooth muscle cells and leukocytes
causes weak vasodilatation and leukocyte accumulation respectively.  CGRP receptors (CGRPR) expressed on endothelial
cells cause potent vasodilatation via eNOS activation and production of NO.  This diffuses in to the opposing smooth muscle




TRPV1 is a classical member of the TRP superfamily and has been well
researched.  Its’ activity forms the basis of many drugs both in
development and in clinical use.  It is of special interest to this thesis as it
shares many similarities to TRPA1, both in localisation and activity.  Many
of the mechanisms identified for TRPV1 may also be relevant to TRPA1.
Additionally, much of this research also demonstrates the role of sensory
neurones in physiology and pathology.
TRPV1 was identified by Caterina et al (1997) as the molecular binding
site for capsaicin, an extract from hot chillies. It has since been shown to be
expressed in numerous tissues, but most notably in small unmyelinated C
and Aδ type sensory neurons (Caterina et al., 1997). It is also expressed at
lower levels in a diverse range of non-neuronal tissues, including
endothelial cells, smooth muscle cells and fibroblasts of the vasculature
(Gunthorpe and Szallasi, 2008).  Moderate levels of capsaicin activate
TRPV1 causing release of neuropeptides and inducing classic
physiological signs of acute inflammation.  This is accompanied by an
acute burning pain followed by desensitisation or hyperalgesia depending
on dose.  Tachycardia, hyperthermia, sweating and a fall in metabolic rate
can also occur (Szolcsányi, 2004, Caterina, 2007). Many other direct and
endogenous agonists have since been demonstrated, including protons
(pH<6) and heat (>43°C) (Caterina et al., 2000). Additionally, TRPV1 can
be sensitised by many commonly occurring tissue components, including
many inflammatory mediators, acting via their G-protein receptors and
leading to intracellular phosphorylation of receptor termini. This has led to
the designation of TRPV1 as a polymodal receptor, where many activators
and sensitisers work synergistically, reducing the activation threshold to
physiological levels and ultimately causing channel activation (Szolcsányi,
2004). Studies from our group have shown that TRPV1 has an important
role in pain and inflammation (Keeble et al., 2009, Keeble et al., 2005),
particularly in arthritis (Russell et al., 2009).  Our group have uncovered
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the importance of ROS in both the activation and downstream activities of
the TRPV1 receptor, including vasodilatation (Starr et al., 2008 , Keeble et
al., 2009).  Neuropeptide release is a key component in all of these findings
and continues to be a theme throughout our work.
Repeated application of the TRPV1 agonist capsaicin can be used to
deplete sensory neurones of their neuropeptide store. Larger doses
desensitise C-fibres in adults and causes irreversible C-fibre destruction in
neonates, both forming commonly used experimental techniques for the
study of sensory neurones.
Mice lacking TRPV1 have been investigated by many research groups.
Caterina et al (2000) and Davis et al (2000) demonstrate that sensory
neurones from TRPV1 KO mice have severe deficits in sensing vanilloids,
protons and heat (>43°C), producing higher pain thresholds to capsaicin
and reduced thermal hyperalgesia during in vivo inflammation models.
TRPV1 KO neurones respond normally to non-painful mechanical stimuli
(Caterina et al., 2000), indicating no role for TRPV1 in physiological
mechanical sensation. However, the role of TRPV1 in sensing mechanical
stimuli is still controversial (Inoue et al., 2009) and there is still strong
evidence for a TRPV1 role in inflammatory mechanical hyperalgesia
(Fernandes et al., 2011).
Studies investigating the efficacy of TRPV1 antagonism in a range of
disease models have shown promise (Szallasi et al., 2007).  Many TRPV1
antagonists are now available, with some currently in advanced clinical
trials.  Antagonists function through a range of distinct binding sites,
however the most efficacious compounds block all modes of activation
(Immke and Gavva, 2006, Szallasi et al., 2006).  Preclinical studies have
implicated TRPV1 in numerous disease areas, including pain,
inflammatory bowel disease, interstitial cystitis, urinary incontinence,
airway disease, pancreatitis and migraine (Immke and Gavva, 2006). All
these diseases are linked to sensory neurone dysfunction.  KO studies show
mice lacking TRPV1 activity to have a relatively normal phenotype,
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retaining the ability to detect noxious heat and with few other side effects
(Szallasi et al., 2006), increasing the interest in using such antagonists
clinically.  However, there have been problems with changes in core body
temperature in preclinical trials of TRPV1 antagonists (Kym et al., 2009).
TRPV1 blockade represents a novel mechanism of analgesia, preventing
pain at the source instead of traditional analgesics which often aim to block
or reduce pain transduction or disease resultant inflammation.  Treatment
of mice with a TRPV1 antagonist has been shown to reverse inflammatory
thermal hyperalgesia by up to 70% (Immke and Gavva, 2006).  Other
studies have revealed a role for TRPV1 in chronic hyperalgesia (Bölcskei,
et al., 2005, Keeble et al., 2005, Fernandes et al., 2011).  However,
although acute TRPV1 activation classically leads to neurogenic
inflammation, some chronic inflammation studies have suggested TRPV1
can have anti-inflammatory and analgesic actions in some settings, which
has subsequently been attributed to sensory neurone release of somatostatin
(Helyes et al., 2004).  The circumstances in which it becomes a
predominant release product are not yet clear.
Although only a fraction of the currently pursued TRPV1 drugs are
agonists, presumably due to the associated acute pain on administration.
Their value in chronic disease states has also been undoubtedly proven
(Immke and Gavva, 2006) as they provide long term desensitisation of pain
neurones.  TRPV1 agonists are currently in very advanced clinical trials for
osteoarthritis, neuralgias, headaches, migraine, cystitis and other
neurogenic pain conditions (Immke and Gavva, 2006).  They are also
commonly used in non-prescription medicines for muscle pain.
TRPV1 In Cardiovascular Disease
As TRPV1 is the classical receptor associated with C-fibre activation,
much of the current work investigating cardiovascular disease and C-fibres
has been based around it. TRPV1 KO mice have a normal hemodynamic
profile at rest, apart from a specific loss of the Bezold-Jarisch reflex in
response to the agonist anandamide.  This response is intact in WT animals
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and characterised by a brief episode of hypotension and bradycardia
(Pacher et al., 2004, Pozsgai et al., 2010).  Many other studies have
identified roles for TRPV1 and C-fibres in cardiovascular disease
pathogenesis and propagation.
TRPV1 has proposed renal and non-renal roles in regulation of blood
pressure, both related to neuropeptide release.  TRPV1 in the kidney is
thought to modulate pressure or osmotic regulation of the renal system
(Cohen, 2007).  Activation of TRPV1 in isolated kidneys causes a decrease
in renal perfusion pressures and an increased glomerular filtration rate,
thought to be result of CGRP and SP release (Li and Wang, 2008).  These
actions can have a role in the control of blood volume and content.
Exogenous application of CGRP and SP mimics this result, causing
diuresis (Wang et al., 2008).  Ablation of C-fibres confers sensitivity to salt
induced hypertension.  Wang and colleagues have shown this may be due
to TRPV1 becoming unregulated on a high salt diet, with its function
impaired in salt sensitive animals (Wang et al., 2008).  They also show
TRPV1 deletion exacerbates kidney damage on a high salt diet and in
deoxycorticosterone acetate (DOCA) salt/uninephrectomised mice (Wang
et al., 2008, Wang and Wang, 2009).  More recently, Yang et al (2010)
have investigated the effects of long term capsaicin feeding (7 months) on
TRPV1 WT mice and genetically hypertensive rats.  They found increases
in endothelial dependent vasodilation, likely meditated by an increase in
eNOS activity, corresponding to decreased blood pressure in capsaicin fed
hypertensive rats.  This study is particularly interesting as it provides a link
between sensory neurones and endothelial dysfunction, a common
manifestation in cardiovascular diseases.  However, basal blood pressure
does not differ in TRPV1 KO mice, suggesting that TRPV1 is not
necessary for the control of basal blood pressure (Pacher et al., 2004).
TRPV1 and sensory neurones also have proposed protective roles during
ischaemia-reperfusion (IR) injury.  Neuropeptides, particularly CGRP, are
thought to be important in preconditioning of the heart, a phenomenon that
may confer some protection in angina (Zhong et al., 2007, Li and Peng,
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2002).  TRPV1 derived SP also shows importance in reducing IR injury
and this is supported in TRPV1 KO studies (Wang and Wang, 2005).
Furthermore, Sexton et al (2007) show IR injury to up-regulate TRPV1,
with less vasodilatation seen in TRPV1 KO than WT hearts during
ischaemic events.  Together, these studies support a protective role of
TRPV1 and sensory neurones in cardiovascular events, likely via
neuropeptide release.
Interplay Between TRPA1 And TRPV1
In depth neuronal expression studies by Kobayashi et al (2005) shows 96%
of all TRPV1 expressing neurones are C-fibres, and within these 67% also
express TRPA1.  When investigated alone, the TRPA1 expressing
population is nearly always found to co-express TRPV1.  With such high
levels of co-expression and similarities in functional mechanisms,
interaction between the two receptors has been proposed and is of ongoing
interest within the field.  Investigations have identified many agonists to
activate both receptors, though potency can vary, for example black pepper
and garlic extracts (Okumura et al., 2010, Koizumi et al., 2009).
TRPA1 KO mice have been shown to retain their responses to capsaicin
(MacPherson et al., 2006).  Furthermore, TRPV1 KO mice retain their
responses to mustard oil (Bánvölgyi et al., 2004).  These studies indicate
that expression of each receptor is independent of the other and that each
receptor has distinct agonists and pathways of C-fibre activation. Deletion
of one receptor does not lead to a general decline in nerve function, but a
selective loss of agonist sensitivity.  This allows us to selectively study the
role of TRPA1 and its agonists. However, capsaicin desensitisation studies
have shown effects on TRPA1 function, diminishing MO induced ear
oedema (Inoue et al., 1997). This could be occurring either by cross
desensitisation or depletion of neuronal neuropeptides, suggesting that the
activity of these receptors may be linked.  Concentrations of capsaicin used
to induce desensitisation should not induce nerve damage (Winter et al.,
1995).  Further work supports the theory of cross-desensitisation
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specifically between these two TRP channels via calcineurin and
dephosphorylation mechanisms (Penuelas et al., 2007).  Several additional
publications have described dependence on TRPV1 for normal TRPA1
currents and desensitisation patterns (Salas et al., 2009, Akopian et al.,
2007). Other studies show a stronger effect with loss of 4-ONE contractile
effect on bronchus rings (Taylor-Clark et al., 2008a) and cyclopentenone
prostaglandin induced release of neuropeptides (Materazzi, et al., 2008)
after capsaicin application.  These could indicate that some agonist
responses demand both TRPV1 and TRPA1 activity.  Another study by
Bandell et al (2004) show TRPV1 KO to abolish cinnamaldehyde (a
TRPA1 agonist) induced hyperalgesia, indicating a stronger functional
association between the receptors.  This has also been suggested to be due
to possible functional TRPA1/V1 heteromultimer expression (McMahon
and Wood, 2006, Staruschenko et al., 2010).  Functional couplings have
also been demonstrated in a number of studies.  Pecze et al (2009) showed
specific TRPV1 desensitisation using resiniferatoxin, a potent TRPV1
agonist, also removes TRPA1 from the membrane. Weinhold et al (2010)
have also described synergistic relaxation of urethral muscle strips when
both TRPA1 and TRPV1 agonists are applied.  Bandell et al (2004) have
also described TRPV1 activation of TRPA1 during responses to
bradykinin, as both TRPV1 and TRPA1 are needed in these responses, but
cation influx through the TRPA1 channel seems key.
KO of TRPA1 resembles KO of TRPV1 in response to bradykinin,
additionally indicating a functional interaction between the two is needed
for the full response (Bautista et al., 2006). Cross sensitisation has also
been suggested as topical capsaicin application caused cold sensitivity in
monkeys (Kamo et al., 2008). It is feasible that TRPV1 sensitisation by
bradykinin could lead to influx of calcium on activation and cross
sensitisation of TRPA1 and subsequent pain (Bandell et al., 2004).
Therefore, although TRPV1 and TRPA1 alone display interesting
pharmacology and distinct functions, great potential exists for interaction
with each other, as well as with other receptors on the plasma membrane.
This effect is likely to be location specific.
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Sensory Neurones And The Central Control of Blood Pressure
Systemic blood pressure is controlled by the balance of peripheral
vasculature resistance and pressure output from the mechanical action of
the heart. These factors can be altered in several ways; one of which is via
neural signals from the central nervous system.
Centrally derived autonomic signals are a major determinant of blood
pressure, providing fine control of the cardiopulmonary system via
alterations in the sympathetic and parasympathetic efferent balance.
Sympathetic efferent neurones are key to the control of blood pressure,
signalling on a beat-to-beat basis in line with the cardiac cycle.  They
innervate key organs with control over the circulatory system, including the
heart, kidney, resistance arteries and adrenal gland.  A detailed review of
the role of sympathetic efferent neurones in the control of systemic blood
pressure is available by Guyenet (2006).  A shift towards a predominantly
sympathetic drive in the circulatory systems occurs physiologically, for
example in exercise or following trauma, predominantly producing an
increase in blood pressure via augmented cardiac output (via the beta 1
(β1) adrenoceptor) and vasoconstriction (via the alpha 1 (α1)
adrenoceptor).  Sympathetic outflow is largely controlled by activity of the
rostal ventrolateral medulla in the brainstem, which is modulated by
afferent inputs from several brain regions, including the nucleus tractus
solarius, hypothalamus, and direct neural input from the spinal cord.
Parasympathetic efferent signalling opposes increases in blood pressure
predominantly via a decrease in heart rate, occurring via inhibition of the
sino-atrial node (Moreira et al., 2011, Guyenet, 2006).   Numerous brain
regions and humoral factors can contribute to the fine autonomic control of
blood pressure, for example during mental stresses (Saha, 2005).
Several complex systems feed information to the brain, determining the
appropriate level of sympathetic and parasympathetic efferent tone.  Within
this system, C fibre neurones can provide feedback to the central nervous
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system, translating in to the ability to modulate systemic blood pressure.
Three types of C-fibre efferents can provide blood pressure modulation via
central signalling; baroceptor linked fibres, nociceptors and glucose
sensitive fibres (Guyenet, 2006).  These can operate in a feedback or feed
forward mechanism, e.g. activation of baroceptor fibres can reduce
sympathetic efferent function, while activation of chemosensitive and
glucose sensitive fibres (by tissue metabolites and hypoglycaemia) can
increase sympathetic outflow, for example during exercise.  The
modulation provided by each fibre type is determined by the brain regions
innervated.
A key type of C-fibre which contributes to feedback control of blood
pressure are baroceptor linked fibres.  These originate from baroceptors in
the carotid sinus, aortic arch and atria, innervating the cardiopulmonary
centre of the brainstem via the vagus or glossopharageal cranial nerves.
These baroceptors can also be found in this location on A fibres (type 1a),
which are thicker, myelinated neurones with faster conduction and
activation at lower pressures. Populations of A and C fibre baroceptors in
the cat carotid nerve have been characterised by Fidone and Sato (1969),
with baroceptor A fibres being of large diameter (3-5 µm diameter),
myelinated and conduct faster than C-fibres (4-53m/s vs 2-3m/s). In
anesthetised rabbits, A type fibres have been shown to provide beat to beat
control of heart rate via inhibition of sympathetic and augmentation of
vagal parasympathetic efferent neurones, while C-fibres are recruited at
higher pressures, augmenting the parasympathetic response to reduce blood
pressure (Kardon et al., 1975).  In this way, initial activation of A-fibres
leads to a reduction in the sympathetic tone, predominantly redcuing
systemic blood pressure via peripheral vasodilation.  The C-fibre
component contributes to longer term control of blood pressure via heart
rate. This was confirmed in another study by Seagard et al (1993) using
anesthetised dogs and selective inhibition of neurone populations by anodal
blockade and anesthetic treatment.  Anodal blockade involves application
of hyperpolarising current, resulting inability to pass action potentials
through a nerve area.  At lower currents there is selective hyperpolarisation
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of larger, myelinated fibres, but smaller C-fibres are also affected with
larger currents. Anaesthetic blockade occurs in a reciprocal manner,
preferentially affecting smaller C-fibres at lower levels, extending to larger
myelinated A fibres at higher concentrations.  This study demonstrated that
selective blockade of C-fibre baroceptors in the carotid sinus caused a
significant elevation in blood pressure, while blockade of A-fibre
baroceptors caused a loss in baroceptor sensitivity to increased perfusion
pressures.  Collectively, these studies suggest that C-fibre baroceptors
provide a larger magnitude and longer lasting depressor influence on blood
pressure than equivalent numbers of A-fibres.
Sympathetic efferent neurones also contribute to the control of blood
pressure via their extensive innervation of the kidney, an organ produceing
several humoral factors with the ability to control several functions of the
vasculature, renin release and ion/water excretion.  In many models of
hypertension there is increase renal sympathetic efferent function (Grisk
and Rettig, 2004).  Chemosensitive C-fibres can also contribute to the
control of systemic blood pressure in the kidney via central and local
mechanisms.  This is demonstrated in rat studies, where neonatal
degradation of chemosensitive neurones using capsaicin produces salt
sensitive hypertension caused by impaired renal excretion of water and
sodium (Wang et al., 2008).  This salt sensitivity was later shown to be
prevented by sympathetic nerve depletion using guanethidine (Wang et al.,
2001), demonstrating the inhibitory action of chemosenstive C-fibres on
renal sympathetic neurones controlling kidney function.  In a reciprocal
manner, activation of chemosensitive nerves by local pressor agents, such
as angiotensin II and endothelin, can lead to the local release of
neuropeptides including CGRP.  CGRP can dilate local vasculature,
increase glomerular perfusion and water/sodium excretion, but can also
inhibit the production of further pressor agents.  This has a diuretic effect,
reducing blood volume and pressure.  For a review of the role of
chemosensitive neurones in the renal modulation of blood pressure, see
Wang and Wang (2007).
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The TRPV1 channel is now known to be the receptor for capsaicin, a
compound which has been historically used to investigate the role of C-
fibres in blood pressure control.  In 1955, Toh et al showed in anesthetised
cats that intra-venous capsaicin application into the carotid sinus induced
reflex hypotension, bradycardia and apnoea, which they found to be
vagally mediated and abolished when the sinus nerve is cut. This suggests
the activation of baroceptors, which are additionally chemosensitive to
capsaicin.  However, intra-arterial applied capsaicin in the intestine causes
a paradoxical hypertension, increases in heart rate, cardiac output and
respiratory rate, which was abolished by severing of the nervous supply to
the region, suggesting involvement of afferent nerves. This was later
investigated again by Jones et al (1990), using anesthetised dogs.  They
additionally showed intra-arterially administered capsaicin to induce a
delayed decrease of renal sympathetic nerve activity, which was shown to
be reflex mediated as it was lost on baroceptor denervation or vagotomy.
Renal sympathoexciation is often seen in pressor responses, causing
vasoconstriction and decreases in renal blood flow, leading to a decline in
glomerular filtration rate and excretory function.  In combination, these
studies demonstrate that baroceptor C-fibres are also chemosensitive and
express receptors such as TRPV1.  Activation of these nerves leads to an
acute decrease in blood pressure, predominantly due to a centrally
mediated increase in parasympathetic tone.  However, the acute of
capsaicin on chemosensitive C-fibres in muscle tissue is a transient
increase in blood pressure, due to a reflex increase in sympathetic tone.
This is later corrected by baroceptors. Similar reflex responses have also
been shown to occur in the lung, where laryngeal instillation of capsaicin in
dogs has been shown to cause a decrease in blood pressure and bradycardia
via vagal neurones.  Vagal afferents innervate the nucleus tractus solitaries
in the brain, which influences the dorsal nucleus of the vagus and the
medullary respiratory centres, causing a range of cardiorespiratory effects
(Mutoh et al., 1997).  Similar reflex changes in blood pressure have also
been described for the TRPA1 agonist cinnamaldehyde, potentially
suggesting that TRPA1 may also be expressed in these neurones and be
able to modulate blood pressure in response to agonists (Harada et al.,
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1982, Pozsgai et al., 2010).  TRPA1 could potentially be activated in
pathological conditions, such as hypertension and systemic inflammation,
where high levels of reactive oxygen species may exist and activate the
receptor.
Chemosensitive neurones can inhibit sympathetic efferent function at both
central and peripheral terminals.  This effect is also reciprocated by
sympathetic signalling, where pre and post-synaptic α2 adrenoceptor
activation in spinal cord and cardiopulmonary centres of the brainstem,
leads to inhibition of C-fibre signalling.  The physiological importance of
this was demonstrated by Donnerer et al (1988), who showed using
pharmacological tools, that the sympathetic system provides tonic feedback
to the cardiopulmonary medullary centre, supressing its activity via α2
adrenoceptor activation.  They also demonstrate that α2 adrenoceptor
activation reduces the cardio depressor effect of capsaicin administration in
vivo, suggesting that sympathetic stimulation depresses baroceptor induced
pressure reflexes; a feature which may be important in pathophysiological
pressor scenarios.
C-fibre neurones, which are known to express TRPA1 and TRPV1, have
demonstrated several mechanisms of blood pressure control.  This can
occur locally, via the release of vasodilative peptides, but can also occur
via parts of the central nervous system.  C-fibres that innervate baroceptors
have been shown to control long term blood pressure levels, providing
feedback and initiating parasympathetic reflexes from the medulla.  These
neurones are also chemosensitive to compounds such as capsaicin and
cinnamaldehyde, which can initiate acute reflex changes in blood pressure.
Chemosensitive C-fibres in other tissues, for example skeletal muscle beds,
have also been shown to induce reflex changes in blood pressure,




The TRPA1 receptor has undergone a rapid ascent to fame, going from a
little known TRP channel to becoming a potentially valuable anti-
inflammatory drug target within little more than 10 years of its discovery.
First identified in 1999 as the single member of the TRPA family, it has a
similar structure to the better known TRPV1 receptor, but with numerous
ankyrin repeats in its amino (N) terminal (Jaquemar et al., 1999). The 16
Å crystal structure of TRPA1 has been very recently published (Cvetkov et
al., 2011). TRPA1 activation is commonly associated with pain and
localised inflammation mediated by neuropeptide release from C-fibre
terminals (Andrè et al., 2008, Andrade et al., 2008). A recent publication
has described a familial gain of function mutation in TRPA1 that is
responsible for a rare human episodic pain syndrome (Kremeyer et al.,
2010).
TRPA1 Expression
Although initially identified as a protein poorly expressed in human
fibroblasts and lost on oncogenic transformation (Jaquemar et al., 1999);
Story et al (2003) were the first to specifically characterise TRPA1
expression by northern blot, showing it to be co-expressed with TRPV1 in
DRG neurones, but not found in other tissues at detectable levels. Recent
expression studies, using a range of techniques, have provided evidence
that TRPA1 may occur in other neuronal tissues, including trigeminal
(Kobayashi et al., 2005), vagal (Nassenstein et al., 2008), nodose, (Nagata
et al., 2005) and sympathetic neurones (Andrade et al., 2008), spinal cord
motorneurones (Anand et al., 2008), presynaptic terminals of the substantia
gelatinosa (Kosugi et al., 2007) and neurones of the superior cervical
ganglia (Smith et al., 2004).  Nociceptors innervate a range of tissues
including heart, lungs, bladder and intestine, and are likely to be the major
source of pro-algesic and inflammatory TRPA1 actions. TRPA1 has also
been identified in non-neuronal tissues including basal keratinocytes
(Gratzke et al., 2009, Streng et al., 2008, Anand et al., 2008), inner ear
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(Corey et al., 2004), dental pulp fibroblasts (El Karim et al., 2011), basal
urothelial cells (Gratzke et al., 2009), olfactory epithelium (Nakashimo et
al., 2010), airway epithelium and smooth muscle cells (Nassini et al.,
2012), cerebral artery endothelial cells (Earley et al., 2009) and smooth
muscle cells of intestine (Dong et al., 2010).  The role of TRPA1 on many
of these cell types is currently unknown and suggests functions in addition
to noxious sensation. Although the regulation of TRPA1 expression levels
is not well studied, Hatano et al (2012) have recently shown upregulation
of TRPA1 expression in response to cytokines via nuclear factor kappa-
light-chain-enhancer of activated B cells (NFκB) and Hypoxia Inducible
Factor 1 alpha (HIF1α) transcription factors. TRPA1 activity has
particularly been implicated in respiratory diseases, which often comprise a
large C-fibre component.  However, if TRPA1 antagonists are to be further
developed for clinical use, it will be important to investigate the
contribution of non-neuronal expression to physiological processes.
TRPA1 Activation
Method of Activation
Activation of functional TRPA1 homotetramer leads to opening of the
central cation pore, allowing influx of cations into the cell.  A recent study
by Karashima et al. (2010) has used electrophysiology techniques to
predict a pore diameter of at least 11 Å, with a relative basal PCa/PNa of
just under 5.  This, in line with other publications, indicates that TRPA1
has a relatively large pore with high calcium permeability when compared
to other TRP channels, including TRPV1.  Cation influx is of great
importance in delineating TRPA1 function, as downstream mediators are
activated by intracellular calcium concentration increases.  This in turn
triggers events such as neuropeptide vesicle exocytosis from sensory
neurones (Andrè et al., 2008). Influx of cations is also important in
triggering local membrane depolarisation, which activates voltage
dependent sodium channels and amplifys the depolarisation.  This will then
form an action potential and afferent signalling to central synapses.
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In vitro studies show that the majority of compounds activating TRPA1 are
electrophilic and form covalent modifications of N terminal cysteines
(Hinman et al., 2006).  The location of these residues is shown in figure
1.2.  However, some non-electrophilic compounds have been shown to
activate TRPA1 via a more traditional binding mechanism (Peterlin et al.,
2007), such as Tetrahydrocannabinol (THC). It is proposed to bind in a
more classical ligand binding site.  THC has been shown to not cause cross
desensitisation with other agonists (Peterlin et al., 2007), further indicating
the mechanisms of activation are distinct. THC is a weak agonist if applied
extracellularly as it is poorly diffusible into the cell, however, once inside it
is reported to be one of the most potent TRPA1 agonists (Cavanaugh et al.,
2008), suggesting that membrane permeability is an important determinant
of TRPA1 agonist potency.  Activation can also occur via sensitisation of
the receptor, proposed for agonists such as calcium (Cavanaugh et al.,
2008).  This polymodal type mechanism is similar to that seen for TRPV1.
The role of bradykinin in sensitising the TRPA1 receptor has been well
investigated, ultimately activating the receptor via release of intracellular
messengers. In vivo TRPA1 KO studies have shown reduced thermal and
mechanical hyperalgesia responses to intraplantar injected bradykinin, and
decreased responses to bradykinin applied to trigeminal neurones from
TRPA1 KO mice (Bautista et al., 2006 , Kwan et al., 2006). Bradykinin
has also been shown to potentiate TRPA1 currents and nociception created
by MO or cinnamaldehyde activation in vitro (Wang et al., 2008a, Bandell
et al., 2004).  Bradykinin acts on its own (BK) receptors to activate
phospholipase C (PLC).  This then has multiple actions that may lead to
TRPA1 activation.  PLC mediated degradation of phosphatidylinositol 4,5-
bisphosphate (PIP2) may have a role in receptor regulation as PIP2 is a
membrane fatty acid which has inhibitory actions on many TRP channels
(Wang et al., 2008a).  Degradation of PIP2 forms the second messengers
diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3).  IP3 could
sensitise TRPA1 by causing intracellular calcium release.  DAG can form
arachidonic acid (AA) via DAG lipase enzymes, which is the perquisite for
prostaglandin agonists such as 15-d-PGJ2 and PGA derivatives (Wang et
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al, 2008a, Bandell et al, 2004).  Alternatively, TRPV1 activation by
bradykinin may have a role in sensitising co-expressed TRPA1 via influx
of calcium ions from the extracellular space (Wang et al., 2008a).
Modulation mechanisms acting on TRPA1 are being increasingly
investigated, with similarities to TRPV1 being discovered.  PLC and
protein kinase C (PKC) coupled receptors potentiate the activity of TRPA1,
demonstrating how inflammatory mediators can play a role in channel
activation (Wang et al, 2008a), potentially bringing it into play during
disease, where PLC and PKA are common signalling components
downstream of G-protein coupled receptors for many inflammatory
mediators. Upregulation in inflammatory and neuropathic environments is
also suggested to contribute to the development of both mechanical and
cold hyperalgesia during disease (Anand et al., 2008, Ji et al., 2008, Obata
et al., 2005).
TRPA1 Agonists And Their Role In Cardiovascular Regulation
The TRPA1 receptor displays sensitivity to a wide range of endogenous
and exogenous reactive compounds. Many exogenous agonists are well
known ingredients in traditional medicines or are known as irritants. There
is evidence that TRPA1 is involved in the pathophysiology of a number of
clinical diseases.  The most promising areas are inflammatory diseases of
the airway, such as asthma (Raemdonck et al., 2011), COPD (Caceres et
al., 2009) and cough (Birrell et al., 2009, Andre et al., 2009), which appear
to benefit from a reduction in TRPA1 activity and are exacerbated by
environmental irritants.  To date, there have been few investigations into
the role of TRPA1 in the vascular system.  Combined TRPA1 expression in
sensory neurones terminating in the vasculature and an agonist profile
showing potential activation in vascular events suggest that the receptor
would be ideally placed to play a role in cardiovascular regulation.
However, a common problem with TRPA1 agonists is their reactive nature
and lack of specificity.  The introduction of TRPA1 KO mice has improved
the ability of researchers to investigate TRPA1 activities, however much
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data is still derived from agonist studies.  Some of the key TRPA1 agonists
will be introduced in detail, along with evidence suggesting a role for the
receptor in cardiovascular control.
Exogenous Agonists
Mustard Oil (MO) / Allyl Isothiocyanate (AITC)
The most commonly used experimental TRPA1 agonist is AITC, the
chemical component of MO, wasabi and horseradish.  For the purpose of
this section, we will refer to MO only.  MO has been used in cooking for
thousands of years and is a large part of many traditional Asian diets and
remedies. It has been investigated for a range of actions, including
induction of gastrointestinal secretions and motility (Kojima et al., 2009,
Neutra et al., 1982), blood and tissue lipid changes (Watkins et al., 1995,
Singh et al., 1995), anti-tumor (Dwivedi et al., 2003), anti-bacterial (Turgis
et al., 2009) and anti-fungal (Winther and Nielsen, 2006) activities, and
also functions affecting the heart (Romana et al., 1983, Gopalan et al.,
1974). More recently, Iwasaki and co-workers showed that intra-venous
(i.v.) MO administration stimulates adrenaline secretion, which is
dependent on sensory neurones (Iwasaki et al., 2008).  A diet high in MO
has been correlated with a decrease in incidence of ischaemic heart disease
(Rastogi et al., 2004), but also increased levels of collagen deposition in
various organs, including the heart (Romana et al., 1983), highlighting
potential cardiovascular actions of TRPA1.
MO has a significant history in neurogenic inflammation research, where it
was recognised as an activator of neuronal C-fibres leading to
concentration dependent release of CGRP and SP (Louis et al., 1989b),
well before the identification of the TRPA1 receptor.  MO activation of
sensory neurones via TRPA1 causes pain, inflammation, microvascular
vasodilatation and thermal and mechanical hyperalgesia in mice (Jordt et
al., 2004, Andrade et al., 2008). The role of released neuropeptides is
demonstrated by the ability to reduce MO induced oedema by
administration of anti-CGRP antibodies (Louis et al., 1989a) and block it
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Figure 1.2; TRPA1 Reactive N Terminal Residues; showing some
common agonists known to activate TRPA1 via cysteine modification.
Residues which have been identified as important for receptor activation
are shown for relevant species. Other mechanisms of activation have been
identified, such as calcium binding to the EF hand domain and agonist
binding to an unknown hydrophobic pocket motif. Sensitisation of the
receptor can also occur via phosphorylation and changes in membrane lipid
composition. Antagonists are available to block agonist activation of
TRPA1. Residue information collected from mutagenesis studies (Hinman
et al., 2006, Chen et al., 2008, Takahashi et al., 2008 , Macpherson et al.,
2007a). Allyl Isothiocyante (AITC, equivalent to MO), hydrogen peroxide
(H202), cinnamaldehyde (CA), 15-d-prostaglandin J2 (15-d-PGJ2).
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with NK1 antagonism (Grant et al., 2005).  Mast cell derived mediators
(Inoue et al., 2006) and NO may also play more minor roles (Lippe et al.,
1993) in the inflammation.  More recently, MO has become an important
experimental tool in the study of TRPA1 activity. Denervation of an area
or genetic deletion of TRPA1 has been shown to block the pain and
inflammation caused by MO, demonstrating TRPA1 selectivity (Bautista et
al., 2006, Inoue et al., 2006, Kwan et al., 2006, Lippe et al., 1993).
MO has demonstrated vasoreactivity in several in vivo and ex vivo models.
However, contributing mechanisms differ greatly.  Current literature
investigating TRPA1 agonist induced vasoreactivity are shown in Table
1.1.  MO is known to cause release of neuropeptides from sensory
neurones, however this mechanism is not always seen to be of primary
importance for vasorelaxation. Hikiji et al (2000) and Louis et al (1989a)
show MO to cause C-fibre mediated dilation in vivo via neuropeptides in
the cat tooth pulp and rat hind paw respectively. Hikiji et al (2000)
demonstrated this using lidocaine, whereas Louis et al (1989a) used
systemically administered antibodies to CGRP and SP to show
neuropeptide involvement. Kunkler et al (2011) has more recently studied
MO induced vasodilation in the rat meningeal tissue, blocking increased
blood flow with the peptide CGRP receptor antagonist CGRP8-37 or the
TRPA1 antagonist HC-030031. Bautista et al (2005) also demonstrated
MO induced vasorelaxation of rat mesenteric arteries in vitro, which was
endothelial independent but sensory neurone and CGRP dependent.
At higher concentration of MO, as used by Lippe et al (1993) in the rat
hind paw, NO was found to play a large role in the vasodilation, being
reduced by i.v administration of the Nitric Oxide Synthase (NOS) inhibitor
L-NAME.  However, this was also accompanied by a decrease in overall
skin blood flow and could still be a product of C-fibre activation as some
neurones have been shown to produce NO (Morris et al., 1992).
To date, MO has been the agonist of choice when investigating the specific
role of TRPA1 in vasorelaxation.  In our recent publication, the increase in
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ear blood flow caused by topical MO was significantly reduced in TRPA1
KO mice (Pozsgai et al., 2010).  This is supported in a detailed paper by
Earley et al (2009) using isolated rat cerebral arteries, where TRPA1
antagonist HC-030031 reduced MO induced dilation of vessels under
myogenic tone.  However, this study did not investigate the involvement of
C-fibres or sensory neurones.  TRPA1 was found to be expressed on
endothelial cells, causing endothelium dependent vasodilation (Earley et
al., 2009). The role and location of TRPA1 were confirmed using
endothelial denudation and immunohistochemistry. Using a range of
pharmacological mediators, the authors of this paper were able to put
together a detailed mechanism, where TRPA1 activation causes calcium
influx in the endothelial cells, likely concurrently activating further
calcium release from cell stores.  This calcium then opens calcium
activated potassium channels (small conductance calcium activated
potassium channel (SKCa2+) and intermediate conductance calcium
activated potassium channel (KCa2+3.1) located on endothelial projections
into the smooth muscle layer, hyperpolarising the cell.  The
hyperpolarisation is then passed to vascular smooth muscle cells via
myoendothelial gap junctions or by creating areas of elevated extracellular
potassium (up to around 20 mM), which activates smooth muscle inwardly
rectifying potassium channels (KIR). KIR channels are specialised
potassium channels involved in repolarising cells following a
depolarisation stimulus and preferentially carry inwardly moving positive
current at the resting membrane potential, which is positive with respect to
the reversal potential for potassium.  As extracellular potassium is elevated,
the reversal potential for potassium is made more positive, reducing the
rectification of the KIR channel and allowing outward flow of potassium,
producing hyperpolarisation. This paper is by far the most detailed account
of MO induced, TRPA1 dependant, vasodilation and may be relevant to
intra-luminal sources of TRPA1 agonists. Such agonists could include
oxidants released from endothelial or blood cells, or blood borne chemical
agonists, including toxins.
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However, as with other TRPA1 agonists, the reactive nature of MO also
means there is potential for poor TRPA1 selectivity.  Of particular interest,
MO has been shown to activate TRPV1 (Ohta et al., 2007), most recently
at concentrations over 1mM (Everaerts et al., 2011), and has been shown to
inhibit TRPA1 activity at millimolar levels (Everaerts et al., 2011).  This is
supported by some studies showing TRPV1 activity is needed for full MO
signalling (Patil et al., 2010, Staruschenko et al., 2010, Salas et al., 2009).
See table 1.1 for a summary of concentrations used in each of the discussed
studies.
Cinnamaldehyde
Cinnamaldehyde is the main component of cinnamon oil.  Cinnamaldehyde
has long been used in traditional Chinese medicine for treatment of
circulatory and inflammatory diseases (Yanaga et al., 2006, Xue et al.,
2011) and is well used as a food and fragrance additive.  Reported
physiological actions of cinnamaldehyde include anti-diabetic (Subash
Babu et al., 2007), anti-platelet aggregation, anti-thrombotic, (Huang et al.,
2007) and anti-bacterial roles (Charles et al., 2008), along with anti-
inflammatory activity on endothelial and inflammatory cells (Liao et al.,
2008, Chao et al., 2008).  It is one of the few well recognised TRPA1
agonists that can be easily administered in vivo, which is necessary for the
investigation of vascular effects at both a local and systemic level.
Studies of cinnamaldehyde induced vasoreactivity are summarised in table
1.1. The mechanisms attributed differ more than that of MO.  10%,
cinnamaldehyde caused significant vasodilation in the human forearm skin,
measured by laser Doppler flowmetry in a study by Namer et al (2005).
This was accompanied by hyperalgesia formation, therefore suggesting C-
fibre involvement.  However, in a similar study by VanderEnde and
Marrow (2001) using 1% cinnamaldehyde in isopropyl alcohol water
applied to the human forearm skin, vasodilation measured by reddening of
area was found to be linked to high PGD2 levels, a vasodilatory
prostaglandin. This was reduced by aspirin, but not rofecoxib, a selective
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cyclooxygenase 2 antagonist, suggesting the involvement of
cyclooxygenase 1 enzyme.  This study also suggested that the source of
PGD2 may be macrophages or Langerhans cells in the skin.  These studies
suggest that the concentration may be an important factor in the mechanism
mediating cinnamaldehyde induced vasodilation.
Similarly, studies using aortic ring preparations have shown inherent
differences in mechanisms attributed to cinnamaldehyde induced
vasorelaxation, which may be related to concentration.  For example, Xue
et al, (2011) found no endothelial dependent component in the rat aorta,
whereas Yanaga et al (2006) found a partial endothelial dependent
component in the same model, which was NO-mediated and inhibited by
L-NAME.  Again, this may be due to the concentrations studied, as Xue et
al (2011) used concentrations in the nanomolar range, whereas Yanaga et
al (2006) used concentrations in the micromolar range.  However, both
suggest inhibition of cytoplasmic calcium increases in smooth muscle cells
as the mechanism for dilation, and also find no role for potassium channels,
prostaglandins and beta adrenergic receptors, as determined using the
relevant antagonists.  The targets bringing about the inhibition of calcium
movement in smooth muscle cells are not known but could be related to the
hyperpolarisation seen in other models via inhibition of voltage activated
calcium channel opening. Inhibiting mechanisms which increase calcium
in the cytosol alters the balance of calcium handling, favouring reuptake
and extrusion mechanisms and ultimately leading to a decrease in free
calcium, producing a vasodilation response.
Investigations of the systemic effects of TRPA1 activation are few, but
most have utilised cinnamaldehyde as the agonist of choice due to its
ability to be given i.v.  In the 1970’s, before the discovery of the TRPA1
receptor, Harada and colleagues published a set of five papers investigating
the effects of cinnamaldehyde on various systems in the mammalian body.
In publication two, Harada et al (1975) describe the effects of intra-arterial
cinnamaldehyde application on guinea pigs.  Cinnamaldehyde caused a
rapid drop in blood pressure, which was attributed to peripheral blood
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vessel dilation and an increase in femoral blood flow.  Limited effects were
seen on heart rate or respiration rate.  They went on to investigate the
effects on isolated hearts, showing positive chronotropic and inotropic
actions, leading to arrhythmias at high doses.  These effects rapidly
underwent desensitisation.  Similar actions were also recorded from
isolated atria.  In publication four, Harada and Saito (1978) show
cinnamaldehydes effect on isolated hearts can be antagonised by beta
adrenergic blockade and catecholamine depletion.  They also show that
cinnamaldehyde causes catecholamine release from isolate dog adrenal
gland.  This was followed up in a subsequent paper, demonstrating that the
cardiac effects of TRPA1 activation are indirectly mediated by a release of
catecholamines (Harada et al., 1982).  They showed that in vivo arterial,
venous and dermal infusion of cinnamaldehyde to dogs, causes release of
adrenaline from the adrenal gland through an unidentified mechanism
(Harada et al., 1982, Harada et al., 1975).  These findings showed parallels
with more recent findings of increased sympathetic outflow following i.v.
cinnamaldehyde dosing, which was dependent on sensory neurones
(Iwasaki et al., 2008) and is also supported by a recent study using
radiotelemetered spontaneously hypertensive rats.  Here, diesel exhaust
fumes were inhaled by conscious animals before an arrhythmic drug was
administered, increasing sympathetic mediated arrhythmias in a TRPA1
dependent manner, defined by the use of the TRPA1 antagonist HC-
030031 (Hazari et al., 2011).
Recently, our group has published the first evidence of TRPA1 dependence
for cinnamaldehyde effects in the cardiovascular system, using
cinnamaldehyde applied in vivo and ex vivo to TRPA1 WT and KO mice.
We showed that cinnamaldehyde applied into the hind paw causes an
increase in blood flow that was significantly reduced in TRPA1 KO mice.
Furthermore, application of cinnamaldehyde to isolated mesenteric arteries
caused endothelial independent vasorelaxation which was significantly
reduced in TRPA1 KO vessels. When given systemically, i.v.
cinnamaldehyde initiated a vaso-vagal response, similar to the Bezold-
Jarisch reflex, causing an initial drop in blood pressure and heart rate,
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followed by a more sustained increase in both (Pozsgai et al., 2010).  This
response is similar to that seen on systemic TRPV1 activation, which is
also lost on TRPV1 KO (Pacher et al., 2004). In our study, the mechanism
for cinnamaldehyde activity was found to be of vasovagal origin, lacking a
contribution of CGRP and SP, defined using systemic treatment with
neuropeptide antagonists.  The reflex showed concentration-dependence
and was significantly reduced on TRPA1 KO, and by application of
antagonists to the alpha one adrenergic receptor and to cholinergic
receptors (Pozsgai et al., 2010). The myography data presented in this
paper also features in this thesis and will be expanded upon.
Cinnamaldehyde has been shown to be metabolised in vivo by a number of
organs, including skin and plasma, forming cinnamic acid, which is later is
converted to benzoic acid and excreted in urine as hippuric acid (Cheung et
al., 2003, Chen et al., 2009b).  Therefore, consideration of cinnamaldehyde
metabolites is also valuable.  Previous investigation of i.v. dosing has
shown cinnamaldehyde to be unstable in blood and quickly oxidised to
cinnamic acid, which has a plasma half life of 1.7hrs (Yuan et al., 1992).
This toxicological study again showed cinnamaldehyde to cause an acute
drop in blood pressure.  Although not investigated in the more recent
publication by Pozsgai et al (2010), Harada et al (1975) found cinnamic
acid to be inactive in isolated tissues, posing questions as to the
physiological relevance of findings gained from acute doses of
cinnamaldehyde.
Most recently, a more chronic study has conducted 6 weeks of daily
cinnamaldehyde dosing (20mg/kg/day) and shown this to be associated
with reduced hyperglycaemia, inhibition of the decline in vascular
reactivity and prevention of the hypertension associated with
experimentally induced diabetes in rats.  No investigation of TRPA1
dependency was made but this suggests that cinnamaldehyde may have
actions on the vasculature and have potential as an anti-diabetic drug (El-
Bassossy et al., 2011).
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Cinnamaldehyde has been suggested to be one of most useful experimental
TRPA1 agonists.  It has relatively few other known targets, shows good
selectivity and potency on TRPA1 when expressed in cells in vitro, on ex
vivo neurones and during in vivo nociception assays (Bandell et al., 2004).
It does not activate TRPV1 or TRPV4 at concentrations up to 0.6mM
(Bandell et al., 2004), however it blocks TRPM8 completely at
concentrations of 5mM, and was originally identified as a TRPV3 agonist
using 0.5mM (Macpherson et al., 2006).  Of these only TRPV1 and
TRPV4 are well known to mediate vasodilation, however vasoreactivity
has been shown for TRPM8 and TRPV3 (Wang et al., 2006, Earley, 2011,
Johnson et al., 2009, Earley et al., 2010).  Conversely, Namer et al (2005)
have shown TRPM8 does not mediate changes in vascular tone. It is also
important to consider solvents, as ethanol is commonly used to dilute
cinnamaldehyde and is known activate TRPV1 channels at 2M on tissue
sections and 1ml/kg in vivo, stimulating the release of CGRP from
trigeminal neurones and causing vasodilation (Nicoletti et al., 2008).
Therefore, the literature suggests that concentrations less than 500μM in
minimal ethanol should provide TRPA1 selective agonism and would be
appropriate for the investigation of TRPA1 dependent activities.  This has
been the basis of my dosing schedules, where cinnamaldehyde has been
used to investigate TRPA1 induced vasorelaxation in the myograph using a
concentration response curve from 3-300μM.
Despite some difficulties, cinnamaldehyde is the preferred TRPA1 agonst
over MO (Bautista et al, 2006), as MO has shown residual effects in
TRPA1 KO mice at high doses (Kwan et al., 2006). However, some groups
consider cinnamaldehyde to underestimate the level of TRPA1 expression,
as it activates a smaller population of neurones than MO (Huang et al.,
2006) and does not identify all areas of TRPA1 expression shown using
immunohistological methods (Bautista et al., 2006).
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Publication Agonist Species Tissue Comments on dilation/increase in blood flow
Xue et al,
2011 Cinnamaldehyde Rat Aortic rings
70nM-7μM causes concentration dependent relaxation from phenylephrine
pre-constriction, not dependant on endothelium, NO, cGMP,
prostaglandins, beta adrenergic receptors, ATP sensitive potassium
channels and various other potassium channels blocked by TEA and BaCl2.
Reduced constriction by a range of calcium dependent agonists, indicating







A study from our group using 1μM i.pl cinnamaldehyde on the hind paw,
1% mustard oil topical to ears, measured by laser Doppler flowmetry.  3-
300μM cinnamaldehyde on mesenteric arteries in wire myograph, pre-
constricted against U46619. Largely smooth muscle derived.  All responses
were reduced or abolished in TRPA1 KO mice, therefore authors show a
TRPA1 mediated mechanism.
Yanaga et al,
2006 Cinnamaldehyde Rat Aortic rings
1μM-1mM causes concentration dependant relaxation to various
preconstruction agents.  Partially endothelium dependent and inhibited by
L-NAME, thus endothelium dependant component is thought to be
mediated by NO.  Not mediated by prostaglandins, beta adrenergic
receptors, activity of delayed rectifier or ATP sensitive potassium
channels.  May act via inhibition of cytoplasmic calcium increases and may
increase cAMP, as phosphodiesterase inhibition increases dilation.
Namer et al,
2005 Cinnamaldehyde Human Forearm skin
Topical 10% cinnamaldehyde, measured by Laser Doppler Flowmetry.





(Cinnamaldehyde) Human Forearm skin
Topical 1%, noted clinical signs of erythema, maximal at 10 minutes.
Aided by plasma analysis they show PGD2 as the main mediator, but of
unknown origin. Unlikely to be from mast cells as is not accompanied by
histamine release. Potentially macrophages or langerhans cells.
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Morris et al,
1999 Acrolein Rat Nasal Tissue
Airbourne concentrations of 10-44μg/L, measured by acetone vapour
uptake. Show accompanied oedema is reduced by capsaicin pre-treatment




oil Rat Meningeal Tissue
Nasal administration of 100μM mustard oil or 30μM acrolein, measured by
laser Doppler flowmetry.  Both blocked by CGRP antagonist, acreolin
blocked by TRPA1 antagonist HC-030031 (50μM).  Therefore also sight a
TRPA1 and CGRP dependant mechanism.
Bautista et al,
2005 Allicin, Mustard oil Rat
Mesenteric
Artery
Garlic extracts (Allicin, 100nM-10μM) and mustard oil (100nM-10μM)
cause concentration dependant vasorelaxation, inhibited by a non selective
TRP channel antagonist and a CGRP antagonist.
Earley et al,
2009 Mustard oil Rat Cerebral Artery
Pressure myography creating myogenic tone at 70mmHg perfusion
pressure, 3-100μM drug, diameter changes measured by image capture.
Endothelium dependant. Reduced by TRPA1 antagonist HC-030031
(3μM), also by inhibitors of KCa3.1 (TRAM34), SKCa (apamin) and KIR
(BaCl2). Not mediated by NO or prostaglandins.  Sight a mechanism where
TRPA1 activation leads to influx of calcium, which is perpetuated by IP3
receptors on the endoplasmic reticulum, leading to potassium efflux
through SKCa and KCa3.1 located on endothelium projections in to the
smooth muscle layer.  This is turn leads to hyperpolarisation of the
vascular smooth muscle via KIR channel activation by elevated potassium
in the local extracellular space and also hyperpolarisation passed from
endothelial cells via myoendothelial gap junctions.
Hikiji et al,
2000 Mustard oil Cat Tooth pulp
Application to second premolar tooth pulp cavity causes axon reflex
dilation of the canine tooth pulp, inhibited by lidocaine.  Indicates a C/Aδ
fibre mechanism.  Some fibres also mechanically activated.
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Table 1.1; TRPA1 Agonist Mediated Vasodilation. Table showing publications investigating vasodilation by TRPA1 agonists and
mechanisms attributed. Tetraethylammonium (TEA), all other abbreviations previously used in text and available in the abbreviation list.
Grant et al,
2005 Mustard oil Mouse Ear
Topical administration of 1% mustard oil, measured by laser Doppler
flowmetry.  Enhanced in NK1 KO mice, no effect of CGRP KO.
Lippe et al,
1993 Mustard oil Rat Hind Paw
Topical application of 5% drug, measured by in-fared emission
thermography.  50% reduction by i.v L-NAME, so NO implicated.
However, this was also accompanied by an increase in MAP, and decrease
in skin blood flow.
Louis et al,
1989 Mustard oil Rat Hind Paw
Topical application of 0.5% drug, measured by laser Doppler flowmetry.
Reduced by systemic antibodies to SP and CGRP, thus C-fibre mechanism
suggested.
Graepel et al,
2011 4-ONE Mouse Hind Paw
Another paper from our group using i.pl injection of 10nmol drug,
measured by laser Doppler flowmetry. Uses KO mice to demonstrate a
TRPA1 and CGRP dependant mechanism, independent of TRPV1.
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Other Exogenous TRPA1 Agonists
New agonists for TRPA1 have been consistently proposed since the
discovery of the receptor.  This has included pungent compounds including
allicin from garlic (Bautista et al., 2005) which has been shown to cause
relaxation of ex vivo perfused feline mesenteric vessels (Mayeux et al.,
1988), isolated rat pulmonary arteries via induction of endothelial-derived
NO production (Ku et al., 2002) and isolated mesenteric arteries via
endothelial independent relaxation mediated by sensory neurone derived
CGRP (Bautista et al., 2005). Garlic is also commonly used in traditional
anti-hypertensive remedies and may alter blood composition and lipid
levels, as defined from population studies using diets rich in allicin (Jain et
al., 1993, Banerjee and Maulik, 2002, Singh et al., 1995, Huang et al.,
2007).  Other TRPA1 agonists include extracts of wintergreen oil, ginger
and cloves (Anand et al., 2008, Bandell et al, 2004), extracts of perilla
frutescens, a food commonly used Asian cooking (Bassoli et al., 2009),
extracts of Szechuan pepper (Menozzi-Smarrito et al, 2009), various
terpenoids from natural plant sources (Iwasaki et al, 2009), icilin, formalin
(McNamara et al, 2007, Macpherson et al., 2007, Parada et al, 2001 ) tear
gasses (Brône et al., 2008), THC and various components of smoke.
Cigarette smoke causes contraction of bronchial rings and plasma
extravasation which can be blocked with the TRPA1 antagonist,
HC030031 or in TRPA1 KO mice (Andrè et al., 2008).  Acreolin is a
component of smoke and is also formed endogenously during inflammation
and in high temperature cooking.  It activates TRPA1 producing
neurogenic inflammation in rodent airways, which is lost on TRPA1 KO
(Michel, 2008, Andrè et al., 2008). Isolated neurones also do not respond
to acreolin when TRPA1 is knocked out (McNamara et al., 2007).
Acrolein has also been shown to cause vasodilation in the nasal and
meningeal tissue of rats (Morris et al., 1992, Kunkler et al., 2011). In both
of these studies C-fibre involvement is implicated, where Kunkler et al
(2011), additionally show acreolin induced dilation to be blocked with a
CGRP or TRPA1 receptor antagonist.
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Diffusion rate into the cell is likely to be one of the most important
determinants of TRPA1 agonist potency. Most of these new compounds
have poor selectivity for TRPA1 but could form an important basis for
further agonist or antagonist production. To date, the most potent agonists
are considered to be the tear gasses (CS, CR and CN) (Brône et al., 2008),
however, their selectivity has yet to be tested.  There is industrial interest in
developing selective TRPA1 agonists to aid research in the field.  We have
recently been part of a study characterising a new, selective, non
electrophilic and potent TRPA1 agonist called PF-4840154 (Ryckmans et
al., 2011).
TRPA1 has been located in auditory hair cells (Corey et al., 2004). It is
expressed at the onset of mechanical responsiveness where TRPA1
knockdown studies in mice virtually abolished hair cell transduction
(Corey et al., 2004). TRPA1 KO studies have since shown no loss of
hearing, and TRPA1 antagonism does not affect basal mechanical
thresholds in the paw (Eid et al., 2008).  However, interest in a role for
TRPA1 in mechanosensation still exists. TRPA1 KO mice show deficits in
detecting punctate mechanical stimuli (Kwan et al., 2006) and exhibit
reduced mechanical hyperalgesia formation in a Complete Freund’s
Adjuvant (CFA) induced arthritis model (Eid et al., 2008).  Kerstein et al
(2009) have recently showed antagonism of TRPA1 to reduce mechanical
perception and Zhang et al (Zhang et al., 2008) have shown hypertonic
solution to activate TRPA1 in HEK cell lines, possibly linked to
mechanosensation.  Recent reports from TRPA1 antagonists studies also
suggest a role in noxious mechanosensation in normal tissue (McGaraughty
et al., 2010).  Additionally, studies from our group have shown TRPA1 to
have a critical role in Tumour Necrosis Factor α (TNFα) mediated and
CFA induced joint hyperalgesia, both mimicing aspects of arthritis
(Fernandes et al., 2011).  These findings suggest potential for TRPA1
channels to participate in systemic blood pressure control via its proposed
action as a mechanosensor, particularly as the mechanism by which
vascular cells sense pressure is currently unclear.
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TRPA1 is also an important receptor in the field of cold sensation.  Story et
al (2003) originally characterised TRPA1 as a channel activated at
temperatures <17°C, where TRPA1 knockdown reduces cold induced
hyperalgesia formation. Although many other KO and antagonist treatment
studies have now been carried out, the role for TRPA1 in temperature
sensation is not yet clear. Results from TRPA1 receptor knockout studies
in mice are conflicting, with Bautista et al (2006) showing neurones from
TRPA1 WT and KO mice to have similar activity profiles when cooled
down to 6°C; whilst Kwan et al (2006) show TRPA1 KO mice to possess
behavioural deficits in cold plate tests undertaken at 0°C.  The mice used in
my research are derived from those derived by Kwan et al. Other studies
question the role of TRPA1 in cold sensation, showing many cold sensing
neurones do not express TRPA1 (Munns et al, 2007), while Ji et al (2008)
show cold hypersensitivity to correspond to upregulation of TRPA1, an
increased MO response and a lowered mechanical threshold.  However,
Jordt et al (2004) show neurones activated by cold are not responsive to
MO, indicating TRPA1 may not be involved.  More recently, further in
vitro and in vivo evidence to support the role of TRPA1 in cold sensation
has been recently published (Karashima et al., 2009) along with several
reviews of the topic, including Caspani and Heppenstall (2009), Kwan et al
(2009) and Wetsel (2011).  Despite the contradicting roles of TRPA1 in
physiological mechanical sensation, a role in cold hyperalgesia seems
better established, where several studies show inhibition using the TRPA1
antagonist HC-030031 (del Camino et al., 2010, da Costa et al., 2010).
Therefore TRPA1 mediated cold activation may be more relevant in
inflammatory conditions and could potentially play a role in the associated
cold hyperalgesia.
Endogenous TRPA1 Agonists
Identifying potent and selective endogenous ligands for TRPA1 has been
challenging, with an increasing number of compounds proposed over the
last few years.  To properly define the functional roles of TRPA1 in vivo, it
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will be important to identify the relevant endogenous agonists. As
reviewed by Chen and Kym (2009) and Bianchi et al., (2012), the TRPA1
protein has some notable protein, functional and pharmacological
differences between species.  However, studies show that the sensory
function of TRPA1 is evolutionarily conserved, with several common
ligands and activating mechanisms being identified across species.  This
suggestion is well supported by the positive identification of agonists using
cells transfected with human TRPA1, which has translated into animal
models, for example nitrooleic acid (Taylor-Clark et al., 2009) and ozone
(Taylor-Clark and Undem, 2010). Therefore current evidence suggests
that although caution should be exercised when interpreting functional
effects, many commonly used TRPA1 agonists that are well characterised
in rodent models will also be functional in humans.
Oxidative Stress
Oxidative stress produces two families of TRPA1 agonists; the first is
reactive oxygen species (ROS) themselves, the other is lipid peroxidation
products.
ROS, in particular H202, are proposed activators of TRPA1.  ROS occur
naturally at low levels and participate in basal cell signalling. However,
their levels are greatly increased in inflammation and they have proven role
in the pathogenesis and symptoms of disease (Bochkov, 2007).
Intraplantar injection of H202 causes pain which is reduced in TRPA1 KO
mice (Andersson et al., 2008, Keeble et al., 2009).  Additionally,
respiratory and pain responses associated with inhaled H202 are severely
reduced in TRPA1 KO mice (Bessac et al., 2008).  High levels of ROS are
found in cigarette smoke, therefore potentially explaining some of its
inflammatory nature (Bessac et al., 2008).  TRPA1 is also associated with
sensitivity to hydroxyl radicals (Hill and Schaefer, 2009).
ROS are important for the formation of compounds such as acreolin and
electrophilic alkenals as products of membrane peroxidation (Kondo et al.,
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2001).  4-hydroxynonenal (4-HNE) is an electrophilic alkenal formed by
membrane peroxidation during oxidative stress and tissue injury.  It has
been shown to activate TRPA1 in vitro at concentrations similar to those
found in human blood during disease states (Macpherson et al., 2007b,
Trevisani et al, 2007).  This causes release of CGRP and SP in vivo which
is lost in TRPA1 KO mice (Trevisani et al., 2007). 4-Oxo-2-nonenal (4-
ONE) is a similar compound to 4-HNE, but has a more electrophilic
structure and thus is 10 times more potent at activating TRPA1 (Andersson
et al., 2008, Taylor-Clark et al., 2008a).  Taylor-Clark et al (2008a)
showed 4-ONE to cause neuropeptide release from isolated C-fibres, an
effect lost in TRPA1 KO neurones.  Activation of TRPA1 was additionally
shown in human embryonic kidney cells (HEK) cells, also activating
TRPV1 at concentrations over 100 μM.  Our group has recently
investigated the activity of 4-ONE in TRPA1 WT and KO mice, showing it
to cause TRPA1 mediated vasodilation and nociception, while also
displaying some TRPA1 independent oedema (Graepel et al., 2011).
Studies looking at oxidative stress levels in hypertensive patients show
increased levels compared to normotensive patients.  There are also several
polymorphisms in ROS producing genes associated with increased risk of
hypertension (Touyz and Briones, 2011).  Lipid peroxidation product levels
increase during inflammation, including cardiovascular diseases, and have
shown links to pathogenesis (Bochkov, 2007).  However, their full clinical
relevance has not been determined.  4-HNE is the best characterised
TRPA1 activating lipid peroxidation product, shown to be present in
plasma at concentrations of around 0.07μM in early adulthood, increasing
with age to around 0.1μM in octogenerians (Poli et al., 2008, Kim et al.,
2006), this also co-insides with the age related increase in cardiovascular
risk.   It has also been shown to increase in the blood during several
neurological and cardiovascular diseases, such as myocardial infarction,
atherosclerosis and rheumatoid arthritis, where lipid peroxidation products
are potential markers of cardiovascular risk (Poli et al., 2008).
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Other Endogenous Agonists
Other endogenous agonists have also been described, however their poor
selectivity and potency means that there are relatively few relevant studies
available.  Other proposed activators include Hydrogen Sulphide (H2S)
(Streng et al., 2008), 5’6-epoxyeicosatrienoic acid (5’6-EET) (Sisigano et
al, 2012), a potential EDHF, calcium (Cavanaugh et al., 2008), which may
act via sensitisation rather than direct activation (Jordt et al, 2004) and pH
changes, where alkalisation has been shown to cause pain that is lost in
TRPA1 KO mice (Fujita et al., 2008 , Peterlin et al., 2007).  These pose
possible links to disease where changes in localised pH commonly occur.
Another family of proposed TRPA1 agonists are cyclopentenone
prostaglandins and isoprostones.  15-d-PGJ2 is a cyclopentenone
prostaglandin produced from non-enzymatic degradation of PGD2, the
most common tissue prostaglandin.  It has weak effects at prostaglandin
DP receptors and is thought to modulate NFkB signalling, but is largely
known as an activator of peroxisome proliferator-activated receptor gamma
(PPARγ).   Its levels are increased in disease and inflammation, where it
has largely anti-inflammatory actions (Taylor-Clark et al., 2008b, Kondo et
al., 2001, Scher and Pillinger, 2005, Jackson et al., 1999, Takahashi et al.,
2008 ).   15-d-PGJ2 has also demonstrated nociceptive activity, causing
acute pain.  This is blocked by the TRPA1 antagonist HC030031 and in
TRPA1 KO mice (Cruz-Orengo et al., 2008, Taylor-Clark et al., 2008b).
There are also no changes in blood pressure when 15-d-PGJ2 is i.v infused,
or general correlations between oxidised phospholipids and systolic blood
pressure (Collin et al., 2004, Ragino et al., 2005).  Other cyclopentenone
prostaglandins such as isoprostones and derivatives of prostaglandin A
(PGA) also activate C-fibres, causing neuropeptide release and pain, an
effect lost on KO of TRPA1 (Materazzi et al., 2008).
Another interesting TRPA1 agonist is NO, which has been shown to cause
nociceptive responses in mice via TRPA1 and TRPV1 at endogenous
levels (Miyamoto et al., 2009).  NO can sensitise pain pathways, however
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the settings in which it becomes painful are not yet clear.  Nitrated fatty
acids, formed under oxidative or nitrative stress, also potently activate
TRPA1 (Taylor-Clark et al., 2009). Activity was shown to be specific to
MO activated bronchopulmonary neurones and lost on TRPA1 KO or
antagonist treatment (Taylor-Clark et al., 2009). They are stable in human
plasma and commonly found at active concentrations during inflammation
e.g. asthma, COPD, IR injury, arthritis and in pollution.  However, they are
also known to activate many other pathways due to their chemical
reactivity (Taylor-Clark et al., 2009).
TRPA1 Antagonists And KO mice
The various uses of TRPA1 antagonists and KO mouse strains have been
detailed above.  These tools have been vital in determining the TRPA1
dependent effect of agonists in physiological and pathophysiological
processes.  There are currently only few available antagonists, and two KO
mouse strains. Development of further methods to highlight TRPA1
activity would be welcomed, particularly in light of the poor selectivity of
TRPA1 agonists.  While much information can be gained from agonist
studies, there is a need to identify the mechanisms at work.  In particular, a
lack of good quality and specific TRPA1 antibodies currently means that
localisation of TRPA1 expression is challenging.  A brief summary of
TRPA1 agonists is shown in figure 1.3.  Other tools to inhibit TRPA1
activity are available, including siRNA treatment, but these are
infrequently used and thus not discussed.
TRPA1 Antagonists
The possibility that TRPA1 is involved in pain and inflammatory
syndromes has led to TRPA1 antagonist development. Some of these are
shown in table 1.2.  At present, commonly available antagonists are limited
to HC-030031 (McNamara et al., 2007) or AP18 (Petrus et al., 2007).  HC-
030031, based on a xanthine core structure, has proven to be effective after
oral dosage, reducing inflammatory and neuropathic pain in animal models
(Eid et al., 2008).  Originally from Hydra Biosciences, it has shown good
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potency and selectivity to TRPA1 and has reportedly entered preclinical
investigations (Baraldi et al., 2010).  Newer compounds are now being
released, based on the HC030031 structure and with increased potency.
Most recently this has been demonstrated by publications using systemic
applications of Chembridge-5861528 from ChemBridge Corporation,
which was used to attenuate diabetic and MO induced mechanical
hypersensitivity (Wei et al., 2010, Wei et al., 2009).  This antagonist has
now been reproduced by Tocris, under the name TCS5861528 and is
commercially available.  Studies undertaken in this thesis will use both
HC-030031 and TCS5861528.
AP-18 represents an alternative TRPA1 antagonist, with an oxime derived
structure.  It was identified by Petrus et al (2007), where it blocked
cinnamaldehyde induced pain when co-injected in to murine hind paws.
Limitations of AP-18 have proved to be its localised action and a short
length of activity, however in some experimental designs these features
may be beneficial.  There are current attempts to improve on AP-18, some
of which have been published in a recent letter (DeFalco et al., 2010).  A
recent publication using systemic doses of A-967079, one of the new
compounds from Abbott laboratories based on the AP-18 core structure,
demonstrates a reduction in noxious mechanosensation in both normal and
inflamed (CFA-treated) rat hind limbs (McGaraughty et al., 2010).
The success of antagonists in animal studies has demonstrated the potential
for oral TRPA1 antagonists to be clinically useful.  A number of
pharmaceutical companies have filed patents and are known to be
increasing their profiles of potential TRPA1 antagonists, with many
entering clinical trials for treatment of inflammatory conditions.  See
Baraldi et al (2010) for a recent review.
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Figure 1.3; TRPA1 Receptor Agonists, TRPA1 is activated by many
exogenous and endogenous agonists, leading to influx of calcium into the
sensory neurone terminal and release of stored neuropeptide containing
vesicles.  The majority of these agonists are electrophilic and bind to the
receptors N-terminal via covalent interactions.  THC and icilin are
proposed to have a more traditional binding pocket mechanism located on
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Table 1.2; TRPA1 Antagonists. Table of TRPA1 antagonists, showing
their structure and determined IC50 (Nagata et al., 2005, Macpherson et al.,
2006, McNamara et al., 2007, Wei et al., 2009, Chen et al., 2009a,
McGaraughty et al., 2010).
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TRPA1 KO Mice
A growing number of research groups now have access to TRPA1 KO
mouse strains, developed originally by Kwan et al (2006) and Bautista et al
(2006) groups respectively.  Differences in the method of TRPA1 gene
deletion occur between these strains (Story and Gereau Iv, 2006), but both
produce clear loss of functional TRPA1.  However, both are commonly
also on mixed genetic backgrounds, representing problems for researchers
when extrapolating data to and from other mouse models.  Despite this,
TRPA1 KO mice are currently the best tool for investigating the role of
endogenous TRPA1 in vivo.
TRPA1 KO mice derived by Kwan et al (2006) were created by
replacement of the exons encoding the S5 and S6 pore forming domains,
with a cassette containing an internal ribosome entry site, a human
placental alkaline phosphatase gene and a polyadenylation sequence.
Endoplasmic reticulum retention and stop signals were also placed before
the cassette.  The product of this was a TRPA1 transcript that cannot form
a functional channel, and if produced, is retained in the endoplasmic
reticulum. These mice are now available to us, and studies in our group are
undertaken using this TRPA1 KO maintained on a mixed C57Bl/6J and
B6129PF2/J background.  They have also been used in various publications
from other groups and their genotype confirmed independently.
TRPA1 KO mice from Bautista et al (2006) were created by a similar
mechanism, deleting not only the pore loop but also much of the sixth
transmembrane domain.  These mice are available on a C57/BL6
background and are used by many experimental groups, with a proven
genotype.  Similar to those from Kwan et al (2006), these KO mice show
clear deficits in sensing TRPA1 agonists when compared to WT
littermates.  TRPA1 KO mice from Bautista et al (2006) are also reported
to show haplosufficiency, as heterozygous mice have an agonist sensitivity
lying between that of the WT and KO.
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The Role Of TRPA1 In Systemic Inflammatory Diseases
There is evidence that TRPA1 is involved in the pathophysiology of a
number of clinical diseases.  Many TRPA1 agonists have potential roles in
the formation and propagation of inflammatory diseases, for example ROS
(Bessac et al., 2008). Expression of TRPA1 has also been shown to
increase in response to inflammation (Hatano et al., 2012). TRPA1’s
sensitivity to oxidants also suggests it may play a role in pathogenesis of
inflammatory diseases involving high oxidative stress, such as ischemia,
diabetes and arthritis, many of which have vascular components.  There are
a number of disease areas where TRPA1 has gained particular attention,
and I propose that the background information presented in this
introduction suggests there may be undiscovered roles for TRPA1 in
cardiovascular regulation.
The most promising disease areas showing TRPA1 involvement are
inflammatory conditions of the airway, such as asthma, COPD (Caceres et
al., 2009) and cough (Birrell et al., 2009, Andre et al., 2009), which appear
to benefit from a reduction in TRPA1 activity and are exacerbated by
environmental irritants which can activate the receptor.  Neuropeptide
release in the lung following TRPA1 activation causes bronchial
contraction and tracheal plasma extravasation (Andrè et al., 2008).
TRPA1 antagonists and TRPA1 KO mice show protection during lung
disease models including asthma, where Caceres et al (2009) have shown
TRPA1 KO and administration of TRPA1 antagonist HC030331 to
dramatically reduce inflammatory processes and symptoms in a mouse
model of allergic asthma. Additionally, Raemdonck et al., (2011) have
recently shown TRPA1 activation on sensory neurones to initiate a central
reflex, causing bronchoconstriction in the late asthmatic response via
parasympathetic nerves.
Cigarette smoke inhalation is a major cause of COPD, inducing sensory
neurone derived, SP mediated, oedema in guinea pig bronchi models,
which can be blocked by TRPA1 KO and instillation of HC-030031 (Andrè
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et al., 2008).  Many TRPA1 agonists have also been identified as pro-
tussive agents, including cinnamaldehyde, MO and acreolin (Andre et al.,
2009, Birrell et al., 2009), thus antagonists may also have a place as future
cough remedies and be particularly valuable in treatment against irritant
exposure, including tear gases exposures and industrial disasters.  A recent
review of the role of TRPA1 in cough is available by Grace and Belvisi
(2011).
Success has also been demonstrated using TRPA1 antagonists and KO
mice to reduce pain and hyperalgesia in inflammatory disease models
originating in other areas of the body, including the CFA model of arthritis
and TNFα induced hyperalgesia (Eid et al., 2008, Fernandes et al., 2011).
Another potential therapeutic areas linked to TRPA1 activity is bladder
overactvity (Andersson et al., 2010), where activation of TRPA1 on
sensory neurones may be responsible for pain and inflammation of
haemorrhagic cystitis.  TRPA1 therapies may also be useful in the
treatment of bladder pain following some cancer chemotherapies, as
acreolin can be formed as a metabolite of drugs and can concentrate in
urine (Bautista et al, 2006).  Oxaliplatin is another anticancer drug which
has shown TRPA1 induced mechanical and cold hyperalgesia, also causing
CGRP mediated vasodilation of pulmonary arteries (Nassini et al., 2011).
Additionally, recent studies are now focussing on the role of TRPA1 in
dental pain due to injury and bleaching (Markowitz, 2010), as the  mouth is
densely innervated with sensory neurones.
All current disease areas associated with TRPA1 activity are related to the
activation of sensory neurones, where there is release of vasoactive
neuropeptides and pain signalling.  As described in section 1, sensory
neurones also have important roles in cardiovascular regulation, in
particular the neuropeptides CGRP and SP which oppose the onset of
vascular disease.  Several lines of evidence described in this introduction
demonstrate that sensory neurones and neuropeptides are activated by
TRPA1 agonists, many of which are increase in inflammatory vascular
disease and cause changes in vascular regulation to occur.  This is
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particularly clear at the vascular level, where several TRPA1 agonists
cause vasodilation, often found to be mediated by CGRP.  Several systemic
effects of TRPA1 agonist administration have also been shown,
particularly using cinnamaldehyde.  The cardiovascular roles of TRPA1
has also been the subject of my recent review (Bodkin and Brain, 2010).  I
now have access to a range of experimental tools, including TRPA1 KO
mice, which allow me to conduct this novel study of the effects of TRPA1
in cardiovascular regulation.
Hypothesis And Aims Of The Thesis
In the light of the highlighted evidence, I have formed a hypothesis that
TRPA1 is involved in the control of resistance vessel tone in vivo.  There,
it contributes to the control of blood pressure by keeping peripheral
resistance low and will resist the onset of hypertension by releasing
neuropeptides when it is activated by elevated levels of endogenous
agonists.  Genetic deletion of TRPA1 will lead to a loss of this process,
increasing basal blood pressure and resulting in susceptibility to
hypertension, resulting in increased systemic inflammation and worsened
hypertensive endpoints.
I have a number of experimental aims for this thesis;
 Investigate the basal cardiovascular phenotype of TRPA1 KO mice
compared to matched WT mice. I wish to particularly focus on
basal blood pressure control and will measure this in conscious
animals by both tail cuff plethysmography and telemetry.
 Analyse the role of TRPA1 in the vasorelaxant response to
cinnamaldehyde.  I will use isolated mesenteric arteries in a wire
myograph to study the nature of TRPA1 involvement in this
process and attempt to dissect the contributing signalling.
 Study the onset and endpoints of experimental hypertension in
TRPA1 WT and KO mice, investigating the potential roles of
TRPA1.  This will be done in terms of blood pressure, hypertrophy
and endpoint inflammation measures in matched TRPA1 WT and
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KO mice following implantation of an osmotic minipump infusing
Ang II subcutaneously over a 14 day experimental period.
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Chapter 2 - Materials and Methods
Animal Procedures
All animals were housed in a climatically controlled environment, on a 12
hour light (7am-7pm) /dark (7pm-7am) cycle, with free access to a normal
food diet and water.  Experiments were carried out in accordance with the
Animals (Scientific Procedures) Act 1986.  Both genders of mice (20-35g)
were used in these experiments.  C57BL/6-B6129P1/F2J mixed genetic
background TRPA1 KO and WT mice were a gift from Prof. S Bevan and
have been bred both homozygously and heterozygously in-house. Each
litter was genotyped and has been previously confirmed by both Prof. S
Bevan and Kwan et al. (Kwan et al., 2006).  CD1 mice (18-30g) were
purchased from Charles River, UK.  C57BL/6 αCGRP KO and WT mice
were a gift from Dr. A-M Salmon, Institute Pasteur, Paris, France who
have confirmed the genotype (Salmon et al., 1999), and have been
homozygously bred in-house and genotyped regularly. Male Wistar rats
(300-400g) were purchased from Harlan, UK.
Anaesthesia
For the majority of studies, no anaesthesia was necessary.  However, where
it was used, this was as brief as possible.  For surgical procedures, a deep
level of anaesthesia was maintained.  This was assessed by the loss of paw
or tail pinch reflex.  For recovery procedures, inhalation isoflurane (Abbott
Laboratories, UK), 3% in O2 carrier gas at 4L/minute was used.  Induction
was carried out in a chamber with the animal then transferred to a nose
cone.  Recovery was monitored in a clean home cage, under infra-red light.
For Laser Doppler flowmetry, anaesthesia was induced using i.p
administration of a ketamine (75mg/kg, NMDA receptor antagonist, an
anaesthetic and analgesic) and medetomidine (1mg/kg, alpha2-
andrenoceptro agonist, a sedative and analgesic) mix (Vetlar and Domitor,
Pfizer), made in fresh saline each occasion.
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Genotyping Of TRPA1 WT And KO mice
Genotyping of the mice was carried out using endpoint polymerase chain
reaction (PCR).  Genomic DNA was extracted from ear punches or tail
tips, collected using the appropriate tools.  PCR was carried out for the
TRPA1 gene or neomycin cassette using primers (Sigma, UK or Eurofins
DE); WT (5’-TCCTGCAAGGGTGATTGCGTTGTCTA-3’ and 5’-
TCATCTGGGCAACAATGTCACCTGCT-3’) and KO (5’-
CCTCGAATCGTGGATCCACTAGTTCTAGAT-3’ and 5’-
TCATCTGGGCAACAATGTCACCTGCT-3’).  Both the extraction
solutions and PCR mix were provided in a commercially available kit
(ExtractRED-N-Amp tissue PCR kit, Sigma, UK).  A thermal cycler
(Techne, Cambridge UK) was used to denature the DNA and activate the
Taq for 2 minutes at 94°C, then 34 cycles of 94°C for 30 seconds, 64°C for
30 seconds, 68°C for 30 seconds were used to amplify the gene of interest.
The product was then held at 4°C and analysed by agarose gel (1.8% w/v)
electrophoresis in TBE buffer (0.5% Tris-borate-EDTA buffer, BioRad)
with images taken under a UV camera (Syngene, G-Box).  WT band
appeared at 310 bp, mutant KO band appeared at 200 bp.  Both were
apparent in heterozygous animals.
Mouse Activity Wheels
The protocol for these measurements was developed in-house, based on
suggestions and guidance of Prof. M. Shattock. Litters of heterozygous
mice (2 months of age) had plastic wheels (13 cm diameter) added to their
home cage.  This was to acclimatise them to running on the wheels.  After
3 weeks, mice were separated into pairs of the same genotype and moved
to a quiet room. Mice were kept in littermate pairs to avoid social stress
affecting the running response. In most published studies mice are housed
singly for running experiments.  Pairs of mice were chosen for this study to
reduce potential stress from social separation and to reduce variation
between results.  Initial trials of paired mice suggested this was a preferable
adaptation to the model. Daily running was measured using a rotational
counter on loan from M. Shattock, which uses a Powerlab and Chart 5 to
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present the data. One side of the wheel circumference is painted dark.
Using this each turn of the wheel can be picked up by the powerlab as a
change in voltage change (approx 8V).  The intervals between these peaks
can be used to calculate wheel turning speed, whilst the number of
revolutions gives a measure of distance ran by the mice.  Most running
took place overnight and totals for each 24 hour period were collected over
a period of 7 days/6 nights.  Similar measurements are made of voluntary
exercise using other measurement systems, for example Ajojola et al
(2009), who studied the effect of exercise in a mouse atherosclerosis
model.  My data was also analysed for preferred speed of wheel
revolutions, showing running speed.  In nearly all current models use mice
that are single housed for running.  This was avoided in my study due to
the potential for stress responses, where I additionally found inter-cage
variability to be reduced when mice ran as pairs.
Measurement Of Blood Flow Using Laser Doppler Flowmetry
Cutaneous blood flow in the mouse was assessed using a non-invasive two-
channel laser Doppler flowmeter (Moor Instruments, UK) connected to a
PowerLab data acquisition system, which measures blood flow in a single
blood vessel (ADInstruments, UK) (Grant et al., 2005).  A probe was
placed directly on the surface skin of each ear. Baseline blood flow was
obtained from the laser Doppler flowmeter for 5 min. Cinnamaldehyde (1-
10% in 20µl) was applied topically on the ipsilateral ear and the
contralateral ear received vehicle (10% DMSO in ethanol) topically, and
blood flow responses were then recorded for 30 min. A dose of 10% of
cinnamaldehyde was found to produce the most significant reliable
increase in blood flow.   Blood flow data were recorded in arbitrary flux
units, which are proportional to blood flowing through the vessel. Results
are expressed as the integral of the recorded flux vs. time trace (× 103 flux
units).
74
Measurement Of Blood Pressure
Tail Cuff Plethysmography
Blood pressure was measured by mouse tail cuff using the CODA 6 system
(Kent Scientific, USA).  This is a non-invasive computerised system of
blood pressure acquisition, based on the principle of volume pressure
recordings.  This method has been shown to give a good correlation to
indwelling catheters and telemetry, and has been successfully used in
previous publications, including from this group (Feng et al., 2008, Bunag,
1973, Mahoney and Brody, 1978, Liang et al., 2009).  Several studies have
shown this method to be particularly suited to measurement of systolic
blood pressure in the physiological range (Bunag and Riley, 1974,
Mahoney and Brody, 1978).
This system has been well validated by the company against telemetered
animals, the gold standard technique for measuring rodent blood pressure.
The method of measurement is very similar to that used for humans, where
an occlusion cuff obstructs the flow of blood to the tail.  As this is slowly
deflated, a second cuff measures the characteristics of the returning blood.
Systolic blood pressure is measured as the appearance of swelling
following release of occlusion, diastolic pressure is calculated at ceasing of
swelling.  Twenty seconds of deflation time was recorded each cycle.
When using this technique, animals were trained on the machine for at least
7 consecutive days, until measurements were consistent.  In practice,
training data was collected daily for 2-3 weeks, at a similar time each day.
The protocol consisted of acclimatisation to a warmed (25°C) room for at
least an hour, then placing the animals in warmed tube restraints before
conducting five acclimatisation cycles and fifteen measurement cycles of
data acquisition.  For some studies, an additional warmed platform was
used under the restraints.  Cycles were discounted if the animal moved
during the measurement.  Average blood pressure readings
(Systolic/Mean/Diastolic) are expressed for each animal per day, and a
group average calculated from this, over many days where possible.  Three
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or more daily cycles must have been successfully collected for the animal’s
data to be used.
Telemetry
Blood pressure was also measured using implantable telemetry devices
(PA-C10, DSI, Netherlands).  This is the current gold standard of rodent
monitoring.  The advantages of this method over tail cuff plethysmography
include that it measures parameters in a more clinical setting, with free
running, undisturbed animals in their home cage.  It is considered a more
humane method and improves attainment of 3R’s principles.  Due to
reduced data variability, fewer mice are needed to provide statistical
significance.  Additionally, the animals involved are considered to undergo
less stress over the course of the experiment compared to serial tail cuff
measurements.  Restraint needed to undertake tail cuff plethysmography
has been shown to induce physiological signs of stress, including increases
in blood pressure, heart rate and plasma catecholamines (Kramer et al.,
2001), although actual pressure readings obtained can be similar with good
training (Krege et al., 1995).  With these benefits in mind, telemetry is now
well used for cardiovascular studies, in both academia and industry.
However, there are some disadvantages to keep in mind.  The telemetry
equipment is expensive to set up, with limited battery life in each probe.  It
also requires an initial surgery which is usually well tolerated, but requires
micro surgery which is invasive and can potentially lead to infection,
immune reaction or catheterised vessel remodelling (Mills et al., 2000).  In
my protocol, this will also be followed by a second smaller surgery, for
subcutaneous implantation of the osmotic minipump. This occurs 14 days
after the telemetry probe surgery. The transmitter itself is relatively bulky
for a mouse to carry and has been shown to reduce wheel running activity
(Mills et al., 2000), indicating it may affect the animals ability to exercise.
A good comparative review on telemetry is available from Van Viliet et al
(2006).
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During implantation, proper aseptic technique was observed and sterile tool
and drape packs were used (SLS, UK).  Items needed for the surgery were
autoclaved in batch packs, one for each animal.  The skin covering the
throat was shaved and treated with iodine tincture before and after the
surgery.  Mice >20g underwent surgery to cannulate the left common
carotid artery, with the probe tip inserted till it enters the aortic arch.
During the surgery, mouse eyes were protected from drying using eye gel
(Viscotears, Novartis) and analgesia was given in the form of intra-musclar
buprenorphine (50μg.kg, Vetergesic, Alstoe animal health).  The catheter
was secured using sterilised surgical braided silk (5.0, waxed, Pearsalls
sutures) and the transmitter body inserted into a sub-cutaneous pocket on
the animals right flank.  The pocket was irrigated with sterile saline to
reduce irritation and provide fluid resuscitation.  Outer skin was closed
with absorbable sutures (4.0, Ethicon, Johnson and Johnson, USA) in a
discontinuous pattern.  Animals were singly housed and monitored daily
for signs of pain or infection.  Telemetry probe recordings were collected
after implantation to check positioning, but baseline data was not collected
until 10 days post-surgery, when recovery had occurred.  Where probes
were re-used, they underwent cleaning and sterilisation by Tergazyme
(Alconox, USA) and Cidex (Cidex-OPA, Johnson and Johnson, USA),
following the guidelines provided by DSI.  Data was collected and
calculated by the DSI software (DSI Dataquest A.R.T.™ System, DSI,
Netherlands)
The PAC-10 telemetry probe measures a number of parameters, averaged
over the length of the reading;
Systolic Blood Pressure; Measured from peak of cardiac cycle as an
indication of the hearts ability to create force but, also reflects inherent
pressure in the system.
Mean Blood Pressure; Calculated from the systolic and diastolic blood
pressures by the Dataquest software.  Reflects average pressure seen by the
major vessels of the vascular system.
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Diastolic Blood Pressure; Measured from the base of the cardiac cycle,
showing the inherent pressure in the system caused a combination of vessel
tone, heart volume and blood volume factors.
Heart Rate; Measured as the number of cardiac pressure cycles per
minute. Controlled largely by autonomic influences.
Pulse Pressure; Measured as the difference between systolic and diastolic
blood pressures.  Shows the pressure developed by the heart, indicating
contractile characteristics.
Activity counts; An arbitary number to represent movement measured by
the accelerometer. Indicative of mouse spontaneous activity levels.
Experimental Hypertension
Implantation Of Ang II Filled Osmotic Minipumps
Ang II (Sigma, UK) was infused into mice at a rate of 0.23μl/hr (the flow
rate is batch specific and specified by the manufacturer upon purchase) in a
saline vehicle via a subcutaneously implanted Alzet minipump (Charles
River UK) in the mid-scalpular region.  Mice were aged 2.5-3 months and
weighed >20g. Surgical procedures were conducted in line with those
previously described for telemetry surgery,;i.e.aspetic technique. This
model is widely used and very reproducible. Our group has previously
published data successfully gained from this model using the same pressor
doses of Ang II (Liang et al., 2009). The concentration of Ang II was
adjusted so that each mouse received a dose of 1.1mg/kg/day.  Control
mice received an empty pump, known from previous studies to act
similarly to saline filled control pumps. However, I recognise that saline
filled controls would have been preferable. Blood pressure data was
measured by tail cuff plethysmography or telemetry, collected at least three
days ahead of mini-pump implantation and on the morning of the
implantation, but not for three days after the operation in the case of tail
cuff.  Telemetered animals were monitored immediately.  Implantation was
conducted under isoflurane anaesthesia and using surgical aseptic
technique.  Pain relief was administered before the short procedure in the
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form of intra-musclar buprenorphine (50μg.kg, Vetergesic, Alstoe animal
health).  The small wound needed was sutured up with absorbable sutures
in a discontinuous pattern or closed with tissue glue (Vetbond tissue
adhesive, 3M).  Animals were singly housed after the operation and
monitored daily for signs of pain or infection.
Termination Of Experimental Hypertension
Two weeks after implantation, the final blood pressure measurements were
taken and the mice sequentially terminated.  Blood was collected by
cardiac puncture and centrifuged at 2000 rpm for 15 minutes.  100μl
aliquots of plasma were snap frozen and stored at -80°C.  Final body
weight was recorded and mice dissected so that the heart, aorta, mesentery,
brain and DRG could be stored for future work.  Brains were grossly
dissected to dissociate brainstem, cortex and striatum structures.  Weights
of the overall heart, left ventricle free wall and right ventricle free wall
were recorded, along with that of the osmotic minipump to ensure it had
properly functioned.  Brain, DRG, heart, mesenteric vessels and lower
aorta portion were individually stored in RNA later (Sigma), left overnight
at 4°C, then stored at -80°C.
Echocardiography
Cardiac echocardiography was performed on a VEVO 770 with a mouse
scanhead (RMV 707B, 30HZ, VisualSonics, Inc., Toronto, Canada).  Other
available methods include Magnetic Resonance Imaging (MRI), Single-
photon emission computed tomography (SPECT) or Positron emission
tomography (PET), however these are expensive and not widely available.
They also often demand the use of radioactivity or long scanning times.  A
review of these techniques is available in Lahoutte (2007).  Measurements
of left ventricular (LV) mass taken during echocardiography have been
shown to correlate closely to those collected at necropsy, although absolute
values vary (Stypmann et al., 2006).  Echocardiography is now a relatively
common technique for the assessment of genetically modified mouse
phenotypes, and for the serial tracking of disease progression.
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Echocardiography is carried out as described in the materials and methods
of the published online video (Respress and Wehrens, 2010).  When
designing the experiment, there are a number of important considerations
raised in the literature.  Many of these considerations surround choice on
anaesthesia.  All anaesthetics depress cardiovascular responses and cause
reduction in heart rate and body temperature.  All of these will impact on
the functional measurements gained from echocardiography.  For these
reasons, use of light isoflurane anaesthesia was considered best practice
(Collins et al., 2003).  It has also been reported that examinations can be
performed on awake animals with training, see Collins et al (2003),
however this was not deemed suitable in this project.  Heart rate in a
conscious mouse is 500-700 bpm at rest.  Altering this rate will in turn
affect left ventricle function and fractional shortening in particular,
therefore it is important to maintain a physiological heart rate where
possible (Rottman et al., 2007).  In my study, mice were maintained at an
anaesthetic level that produced heart rates between 400-500 bpm, with the
whole examination lasting less than 20 minutes.  These parameters have
previously been shown to give good levels of data reproducibility (Wu et
al., 2010).  In line with best practice, mice were maintained in the supine
position, with limited pressure on the chest and core body temperature
maintained at 37.4°C using a homeothermic heated platform and rectal
probe.  Protective eye gel was used to prevent drying damage (Vicscotears,
Novartis).  The chest hair was removed of hair using hair removal cream
(Veet, Reckitt Benckiser, UK).  Heart and respiration rate were recorded,
along with electrocardiogram (ECG).  Heart images were taken with
warmed ultrasound gel.  These controls are necessary to give optimum
conditions for physiologically relevant measures.
Three main images were collected for analysis.  1) A parasternal long axis,
where the LV apex is at its maximum length and the aortic root is in full
view. M-mode is collected at the level of the papillary muscle for
consistently comparable cross-sections.  2) A clockwise, 90° rotation of the
transducer then also produced a short axis view, with another M-mode
taken between the two papillary muscles.  M-mode images were then
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analysed using the leading edge to leading edge method over 5 sinus beats,
and calculations made by the onboard software.  3) Each examination also
included an aortic pressure wave Doppler, giving an indication of systolic
function.  Mouse weight was collected at the start of the procedure and
measurements expressed as a ratio.  Previous studies have shown that there
are no statistical differences in heart size and function between genders of
CD1 mice (Stypmann et al., 2006).  However, this study did show that
heart size was not consistent until 12 weeks of age.  Therefore, to avoid
potential weight phenotype and age artefacts, all my data was expressed as
a ratio to body weight.  A full cardiac examination was collected on all
mice, producing a range of morphology and functional measures. See
figure 2.1 and 2.2.  The meaning of each one is described below;
Morphological measures
LV mass: Measures overall calculated mass of the left ventricle.  This is
the ultimate measure of heart tissue size used for the study of hypertrophy.
Left Ventricular Internal Diameter at diastole (LVIDd): Measures
diameter of the left ventricle when relaxed.  This gives a measure of
volume and is an indication of the hearts capacity to relax.  Hearts with
much hypertrophy may be bigger in mass but with less volume and
relaxation capacity due to fibrosis.
Left Ventricular Anterior Wall thickness at diastole (LVAWd):
Shows the measured thickness of the left ventricle anterior wall when
relaxed.
Left Ventricular Posterior Wall thickness at diastole (LVPWd):
Shows the measured thickness of the left ventricle posterior wall when
relaxed.
Interventricular Septum thickness at diastole (IVSd): Shows the
measured thickness of septal wall when relaxed.
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Functional Measures
Fractional shortening (FS%); Fractional shortening describes the
amount of diastolic space that is lost during systole. It is therefore a direct
measure of heart contractility.  It is the most common indice of left
ventricle function. As it is heart rate dependent, it is important to control
anaesthesia well.
Stroke Volume (SV μl); Stroke volume is a measure of the amount of
blood ejected from the heart each beat.  It is measured from the change in
left ventricle volume from diastole to systole.  It is a functional measure of
heart output.
Ejection Fraction (EF %); This indicates the percentage of blood of
blood ejected from the left ventricle, it is related to stroke volume and
fractional shortening.
Cardiac Output (CO ml/min); This is the most commonly used measure
of heart output, combining the stroke volume with the heart rate.
Peak Aortic Flow (mm/s); Peak outflow into the aortic arch is measured
by Doppler.  The echocardiograph does not measure pressure but the speed
out outflow is an indicator of systolic function and/or valve function.
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Figure 2.1; Relevant positions of cross sectional
measurements of heart size. These dimensions will be referred to in
the description of echocardiography data.  Diagram for representation only








Figure 2.2; Sample m-mode measurements from long axis (top)
and short axis (bottom) views. M-modes are collected from the level of the
papillary muscle where the heart can be seen at its fullest.  For the long
axis, this is where the aortic root and heart apex can be seen; the short axis
this is at 90̊ to this.  Views are representative and depict measurement
collection from the movement of the ventricle wall. ECG and breathing
rate is also shown along the base of the image, and experiences minimal
variation through the collection period.
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Cytokine MSD Multiplex ELISA
Plasma and culture medium cytokines were measured using a seven spot
multi-plex mouse pro-inflammatory assay kit (Meso-Scale Discovery,
Gaithersburg, MD, USA):  Levels of IL-6 and KC (the murine analogue of
IL-8) were measured from one sample well.  Standard manufacturer’s
instructions were followed and reagents supplied.  Results were expressed
as pg cytokine per ml of sample, calculated against a supplied standard
curve.  This assay employs a sandwich immunoassay format, where
specific cytokine capture antibodies are pre-fixed on the specific spots on
the base of the well. Cytokine levels can be quantified using a cytokine-
specific detection antibody labelled with a tag that emits light upon
electrochemical stimulation. All detection antibodies exhibit less than 1%
cross-reactivity with other analytes.
Plasma CGRP ELISA
Plasma CGRP levels were measured using an ELISA kit (Rat/Mouse,
Pheonix Pharmaceuticals Inc, USA).  This kit detects 0.16-100ng/ml
CGRP.  Plasma peptides were extracted using SEP-COLUMN’s (Pheonix
Pharmeaceuticals Inc, USA) before use in the ELISA kit.  All additional
reagents were purchased from Pheonic Pharmaceuticals.  In this assay, a
pre coated plate contained secondary antibodies to a CGRP primary
antibody. This antibody was competitively bound by CGRP in the
sample/standard or by biotinylated peptides.  Where biotinylated peptides
were bound, interaction with streptavidin-horseradish peroxidise allowed
production of a yellow product from substrate.  This yellow colour was
directly proportional to the amount of CGRP bound to the primary
antibody and thus the concentration found in the extracted plasma sample.
Cross-reactivity occurs with all CGRP forms and to some degree with
CGRP from other species, but not to closely related peptides such as
amylin, calcitonin or somatostatin.
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Reverse Transcription Quantitative PCR
Total ribonucleic acid (RNA) was extracted from tissues stored in RNA
later using a commercial kit (Qiagen® RNeasy Microarray tissue mini
Kit). 20-50mg pieces of tissue were used, as per manufacturer’s suggestion.
This kit extracts RNA of >200 nucleotides using spin columns and their
patented phenol-guandine-based QIAzol Lysis Reagent.  Tissues were
homogenised at 300Hz for 2 minutes using 5mm stainless steel beads
(Qiagen®) and Qiagen’s TissueLyser® LT.  The homogenate was then
treated with chloroform and the precipitated RNA sequentially purified and
eluted using the supplied reagents and spin columns.  RNA was eluted in
nucleotide free water and stored at -80°C.
RNA quality was assessed using a Nanodrop Spectrophotometer.  1μl of
sample was analysed for RNA quantity (ng/μl) and also for contamination,
with blank values removed.  260/280 and 260/230 values of around 2 are
considered to show pure RNA, a lower value indicates protein
contamination or ethanol contamination respectively.  Samples with values
unusually far from those expected were removed from the population.
500ng of RNA was used for the reverse transcription to cDNA.  This was
done using a High capacity RNA to cDNA, Reverse Transcription enzyme
kit with RNAase inhibitor (Applied Biosciences) and thermal cycler
(Applied Biosystems) set to temperatures recommended in the
manufacturer’s guidelines (37°C 60 minutes., 95°C 5 minutes, cool and
hold at 4°C >5minutes).  Stock cDNA was then diluted 1:40 for further
experiments.
A SYBR-green based PCR mix (Sensi-Mix®, SYBR-green No ROX,
Bioline) was made up to halve volumes of manufacturers specification,
resulting in 10μl reactions containing 2μl cDNA, 5μl SYBR-green, 1μl of
25μM forward and reverse primers with 2μl RNAse free water.  This was
prepared and added to 100 well gene discs (Qiagen®) by an automated
robot (CAS1200, Corbett Robotics®).  These discs then underwent PCR
(hold: 10 min at 95oC; cycling: 45 cycles: 10 s at 95oC, 15 s at 57oC and 5 s
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at 72oC; melt: 68-90oC) in a Corbett Rotorgene, which monitors copy
numbers via fluorescence.  SYBR-green is a dye which intercalates with
double stranded DNA, absorbing blue light and emitting fluorescent green
light during the amplification as an index of copy numbers.  Raw data was
analysed using the rotorgene 6000 series software and collected as an
output of copies/μl.  It was then standardised against three housekeeping
genes using GeNorm software (Vandesompele et al., 2002).  These were
murine Phospholipase A2 (mPLA2), Actin and Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH).  The GeNorm program calculates a
normalisation factor from the geometric mean of the three housekeeping
genes.  Housekeeping gene expression stability is ensured by a calculated
M value.  All genes showed M values in the usable range (<1.5), showing
they were not altered by experimental conditions, therefore represent good
housekeeping genes.
RT qPCR Primers
RT qPCR primers were desalted and unmodified, purchased from Sigma,
UK.  The sequences are shown in table 2.1.  They were re-suspended in
nucleotide free water for use.  These oligos were used with a pool of septic










































































































Table 2.1; Table Of Primer Sequences, Shows forward and reverse
primer sequences, in the 5’ to 3’ direction, the accession number and
amplicon size.
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Mesenteric Artery Wire Myography
First and second-order mesenteric artery branches (approx. 30-40μm
diameter at rest, approx. 100μm under tension) were isolated from mixed
gender TRPA1 WT and KO mice or CD1 mice, in ice cold Krebs (118mM
NaCl, 24mM NaHCO3, 1mM MgSO4, 4mM KCl, 0.5mM NaH2PO4,
5.5mM glucose, and 2.5mM CaCl2).  They were cleaned of fatty tissue,
mounted and normalized to normal peripheral artery tension (13.3kPa) on a
wire myograph (DMT 610M or 620) using 0.025 mm tungsten wire, under
a light microscope.  Vessels were maintained throughout the experiment in
37°C Krebs solution gassed with air/5% CO2.  This gas mixture was
chosen to produce a more physiological oxygen tension than obtained
when using oxygen only.  All salts were bought in their anhydrous forms
from Sigma UK, with the exception of NaCl from MP Biomedicals, UK.
Tissue viability was tested and peak contraction assessed using 2 minute
incubations in ‘high K’ solution (38mM NaCl, 24mM NaHCO3, 1mM
MgSO4, 80mM KCl, 0.5mM NaH2PO4, 5.5mM glucose, and 2.5mM
CaCl2).  Endothelial function was assessed using carbachol (10µM diluted
in water, Sigma, UK), where a relaxation of >60% over 2 minutes was used
as a positive threshold. This concentration of carbachol was selected as it
is commonly used to produce endothelial dependent relaxations of
mesenteric arteries, and particularly used for the determination of
endothelial function, for instance in Johns et al (2007) who similarly use
mouse mesenteric arteries in a wire myograph.   Average responses to
carbachol are included in figure 4.1, demonstrating clear differences in
responsiveness, consistent with their classification of holding functional or
non-functional endothelium. Tissues were sub-maximally pre-constricted
with U46619 (10nM in 5µl water, Biomol, UK).  This is a stable agonist of
the thromboxane A2 receptor.  Activation of this receptor on smooth
muscle cells leads to activation of Gq signalling, producing IP3 and DAG,
both of which lead to intracellular calcium concentration increases from a
combination of store release and extracellular influx (Dorn and Becker,
1993).  Relaxation to cinnamaldehyde (trans-cinnamaldehyde >95%,
Sigma, 3–300 µM in 5µl ethanol) was assessed from single concentrations,
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measured after 5 minutes, or from cumulative additions, measured for 3
minutes per concentration.  All drugs supplied as <100% purity had their
concentration adjusted accordingly.  Data was expressed as percentage
relaxation of pre-constriction.
For some experiments, additional pharmacological mediators were used.
These included further dilutions of U46619 (0.1-300nM in water),
phenylephrine (Sigma UK, 0.03-30µM in water), KCl (Sigma UK,
producing 10-300mM K+ in water), SP (Sigma UK, 10nM-1μM in 0.01%
BSA/water), CGRP (Sigma UK, 1-100nM in 0.01% BSA/water), the
peptide CGRP antagonists CGRP8-37 (Sigma, 3μM in 0.01% BSA/water)
and BIBN 4096 BS (Gift from Dr H Doods (See Doods et al., 2000),
Boehringer, 10μM in 5μl DMSO added 15 minutes before pre-
constriction), the larger conductance calcium activated potassium channel
(BKCa) blocker Paxilline (1μM in 5μl DMSO, added to bath 15 minutes
before pre-constriction), the TRPA1 antagonists HC-030031 (Pfizer UK,
30μM in 5μl or 10μM in 1.67μl DMSO) and TCS5861528 (Tocris, 30μM
in 5μl DMSO), both added 15 minutes before pre-constriction, and a
30mM potassium Krebs (90mM NaCl, 24mM NaHCO3, 1mM MgSO4,
30mM KCl, 0.5mM NaH2PO4, 5.5mM glucose, and 2.5mM CaCl2) used as
a 3 minute pre-constriction which blocks hyperpolarisation.  Vehicle
controls were used for each vessel.  Rational behind each concentration
choice are explained in the text.
Bronchial Ring Wire Myography
Major bronchi were dissected from the airway of CD1 mice under ice cold
Krebs solution (composition previously listed).  Rings of approximately
2mm were cut and mounted on the wire myograph, using the procedure
used for mesenteric arteries.  Following a 60 minute rest, baseline tension
was set to around 2mN (Manzini, 1992).  Several concentrations of
carbachol were investigated for contractile ability, with 1µM (in 5ul water)
giving a sub-maximal but strong and consistent pre-constriction.  This pre-
constriction is similar to that used by Manzini (1992) who also investigated
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neurogenic dilation of murine bronchi. Cinnamaldehyde shows selectivity
to the TRPA1 receptor at low to mid µM concentrations (Bandell et al,
2004), therefore several concentrations from 3-300µM were tested, with
60µM showing a sub-maximal but reproducible relaxation of bronchi rings
(about 40% over 3 minutes). No previous studies have investigated the
dilation effect of cinnamaldehyde on isolated mouse bronchi. In fact,
Andre et al., (2008) have previously shown 30µM cinnamaldehyde to
induce contraction of the guinea pig bronchi; however in the mouse model
I see no evidence of contractile effects. To further demonstrate the
presence of epithelium, 1µM SP (5ul in 0.01% BSA in water) was applied
for a 3 minutes following cinnamaldehyde application. Similar to that of
carbachol, this concentration is commonly found in similar studies in
published literature e.g. Szarek et al., (1998), where a relaxation response
indicates the presence of intact, functional epithelium.   In between each
contraction peak, tissues were washed three times with Krebs and allowed
to rest for at least 10 minutes.
For some experiments additional pharmacological antagonists were added
to the bath 15 minutes before pre-constriction.  These included HC-030031
(50 and 100µM in 0.05% DMSO in Krebs), AP-18 (100µM in 0.1%
DMSO in Krebs) and SR140333 (1µM in 5ul water).   These antagonists
are used at similar concentrations to published studies (Zhou et al (2011),
Yu and Ouyang (2008), Andre et al (2008) Cao et al, (2012), Nassini et al
(2012) Taylor-Clark et al (2008)), with 100µM HC-030031 being double
the concentration reported to inhibit TRPA1 induced bronchi contractions
(Andre et al, 2008).
Cerebral And Pulmonary Artery Wire Myography
Middle cerebral, cerebellar and pulmonary arteries were dissected from
male Wistar rats (300-400g) under ice cold Krebs solution (composition
previously listed). Sections were mounted on the wire myograph using the
procedure used for mesenteric arteries.  Following a 60 minute rest,
baseline tension was set using the normalisation module of the LabChart
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software so that it was similar to the pressure experienced in vivo (9 kPa
for cerebral arteries, 2 kPa for pulmonary arteries). Tissue viability and
peak contraction were assessed using three sets of 2 minute incubations in
‘high K’ solution (previously defined composition).  Cumulative
concentration curves to the contractile agents U46619 (0.1-1µM in 1-5µl
water) and phenylephrine (0.03-10nM in 1-5µl water) were than collected
with additions every 2 minutes, to establish optimal pre-constriction.
Change in tension was recorded as raw values (mN) or normalised to
maximal tension obtained during 2 minute incubations with 80mM
potassium Krebs.  Subsequently, 30nM and 100nM U46619 (for 5 minutes)
were used to pre-constrict cerebral and pulmonary arteries respectively.
Endothelial function was assessed using carbachol (10µM in 5µl water,
Sigma, UK), where a relaxation from pre-constriction of >60% over 2
minutes was used as a positive threshold.
Following U46619 pre-constriction, cumulative concentration curves to
cinnamaldehyde (3-300µM) and MO (1-100µM), with additions every 3
minutes, were used to reveal the effect of TRPA1 on these tissues.
Relaxation is presented as % of U46619 pre-constriction tension.  In some
studies, pre-constriction was followed by a single application of 300µM
cinnamaldehyde or vehicle (5µl ethanol), added for 3 minutes.  This was
also completed in the presence of HC-030031 (10-100µM in 0.05% DMSO
in Krebs) or vehicle, added 15 minutes before pre-constriction. The
concentrations of HC-030031 selected are in-keeping or above those using
similar tissues in published studies (Taylor-Clark et al (2008), Earley et al
(2009)).
Macrophage Cultures
Peritonitis was elicited by 1ml i.p injection of 1% oysterglycogen (Sigma,
UK) in TRPA1 WT and KO mice under isoflurane.  After 18 hours, mice
were terminated by careful cervical dislocation.  Cells were collected by
peritoneal lavage using a 22G needle (BD Biosciences) into cold D-PBS
(No Ca2+/Mg2+, Invitrogen).  Live cells diluted 1/5 in Trypan Blue (Sigma,
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UK) were counted using a Neubauer chamber at 20x magnification on a
microscope.  The remaining cells were centrifuged to a pellet (15min, 4°C,
2000 rpm) and re-suspended in culture medium in a culture hood, at a
concentration of 2 x 106 cells per ml.  Medium was Dulbecco's Modified
Eagle Medium (DMEM, No glutamine, PAA, Austria) with added 10%
fetal bovine serum, glutamine (2mM), 1x pencillin and streptomycin (all
PAA, Austria).  0.6 x 106 cells in 300μl of medium was plated in to 8 well
culture slides (BD Biosciences) and incubated in a cell culture incubator
for 2 hours to allow cells to adhere.  Finally, the culture slide was washed
twice with 300μl medium, leaving 100μl covering the slide and adherent
cells.
Wells were then treated with Ang II (1μM final bath concentration with
medium vehicle) or control vehicle addition, and left for 8,12,18 or 24
hours in the incubator.  At the end of this time, culture medium was
collected for cytokine analysis and the adherent cells stained on the slide
using QuickDiff (Gamidor, UK) a form of Romanowski stain.  Macrophage
phenotype was defined by imaging under oil immersion microscopy (100x).
Data Analysis
Data was analysed in Microsoft Excel and Graphpad Prism 5, expressed as
mean +/- the standard error of the mean where N>2. In the case of small N
numbers (3-5), the error of the mean is a predictive value to illustrate data
variation only.  All data sets were tested for normality using the Shapiro-
Wilks test. Where they conformed to a Gaussian distribution, data was
subsequently analysed with parametric tests. For two group data sets,
analysis by paired or unpaired t-test was used. This was paired where both
data sets were collected from the same mouse.  One-tailed analysis was
used where the hypothesis was to test for changes in a single direction.
Two-tailed analysis was used where potential for changes in either
direction existed. For data with multiple sets, one-way ANOVA with
Bonferroni’s post-test was chosen.  For time courses, two-way ANOVA
with Bonferroni’s post test was used.  Statistical significance was assumed
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where p<0.05. In some graphs with multiple data sets, clear trends were
not significant in ANOVA tests.  This was generally due to low N numbers
in one or more of the groups.  Where comparisons were important for data
interpretation, a single unpaired t-test was additionally used.  This was
generally in conditions of low numbers of control animals, comparing two
treated groups of higher N.
Where data showed divergence from Gaussian distribution, non-parametric
tests were used. ‘SEM’ is shown for these groups to allow illustration of
data variability in a similar manner throughout the thesis. For graphs of
two data sets the Mann-Whitney U test was used, for multiple data sets the
Kruskall-Wallis test with Dunn’s post test was used. Similarly, statistical
significance was assumed where p<0.05.  In practice, non-Gaussian data
was seen for measures of activity and the cytokines IL-6 and mIL-8 only.
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Chapter  3 – Investigating the role of TRPA1 in basal
cardiovascular hemodynamics
Introduction
The TRPA1 receptor was first identified and characterised over 10 years
ago (Jaquemar et al., 1999, Story et al., 2003).  It was quickly identified as
a potentially interesting cation channel, with publications linking it to
several sensory functions.  In 2006, two sets of KO mice were created and
published simultaneously.  One of these mice were from the Bautista group
(Bautista et al., 2006), the other by the Kwan group (Kwan et al., 2006).
Many groups have now used these mice to show an important role for
TRPA1 in pain and inflammation.  Few have investigated vascular
implications of TRPA1 activation.  Our group maintain a colony of TRPA1
WT and KO mice derived from those by Kwan KO (Kwan et al., 2006).
This is our preferred KO strain as expression of the remaining receptor
portion is limited by addition of an endoplasmic reticulum retention signal.
No fundamental differences between the KO strains have been reported,
however using these mice removes the unlikely possibility that a portion of
the receptor may remain to be expressed on the cell surface.  Although this
protein is unlikely to show signalling activity itself, it could still potentially
interact and modulate the activity of other membrane receptors and
components. I aim to use these mice to characterise the cardiovascular
phenotype associated with global TRPA1 deletion in vivo. Further
discussion of TRPA1 KO strains is provided in the introduction.
TRPA1 KO mouse lines and commercially developed antagonists clearly
demonstrate that TRPA1 is important for sensing noxious and potentially
noxious compounds.  Many noxious compounds have cardiovascular
effects.  TRPA1 is primarily expressed on sensory neurones, but has also
been found in other neuronal and non-neuronal locations, some of which
may be relevant to cardiovascular regulation control, for example vagal
neurones (Nassenstein et al., 2008) and endothelial cells (Earley et al.,
2009).  There is also evidence that TRPA1 is involved in the
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pathophysiology of a number of clinical diseases, particularly of the
airway, bladder and joint.  All of the identified diseases are linked to
sensory neurone activity, largely in relation to pain and inflammation.  If
TRPA1 antagonists are to be further developed for clinical use, it will be
important to investigate the role of TRPA1 in the cardiovascular system
and investigate the contribution of non-neuronal expression to
physiological processes.
Currently, several studies have investigated the vasodilatory properties of
proposed TRPA1 agonists.  These have been introduced in chapter 1 and
will be discussed further in chapter 4, however the mechanisms attributed
are often based upon neuropeptide release (see table 1.1).  The studies
support a role for TRPA1 in regulating local vascular tone, which could
lead to changes in blood pressure via a change in peripheral resistance.
Although very few studies have investigated the systemic cardiovascular
effects of TRPA1 activation, cinnamaldehyde is the most well used TRPA1
agonist in vivo. Similarly to the actions of intra-vascular capsaicin acting
on TRPV1 receptors; intra-luminally applied TRPA1 agonists can also
trigger central reflexes and alter blood pressure. Although these responses
have not been characterised to the degree of those to capsaicin, intra-
arterial cinnamaldehyde application to rats (Yuan et al., 1992) and guinea
pigs causes a drop in blood pressure via increases in peripheral blood
vessel diameter (Harada et al., 1975). This was shown to have a central
reflex component in a recent publication from our group, where i.v.
cinnamaldehyde caused a drop in blood pressure and heart rate, followed
by a pressor response and tachycardia, both of which were reduced in
TRPA1 KO mice.  Use of the pharmacological agents prazosin and
atropine, which are adrenergic and cholinergic antagonists respectively,
revealed that the TRPA1 mediated response to cinnamaldehyde comprised
an autonomic mediated vaso-vagal mechanism (Pozsgai et al., 2010).
Additionally, in isolated hearts cinnamaldehyde has shown positive
chronotropic and inotropic actions, leading to arrhythmias at high
concentrations (Harada et al., 1975).  This was shown to be mediated by
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catecholamine release acting on beta adrenergic receptors (Harada and
Saito, 1978).  The source of catecholamine release is thought to be the
adrenal gland (Harada and Saito, 1978).  Evidence of increased
sympathetic outflow following TRPA1 activation is also supported by a
recent study using genetically hypertensive rats, where sympathetic
mediated arrhythmias were observed on inhalation of diesel fumes, and
shown to be TRPA1 dependent (Hazari et al., 2011).
Summary Of The Background
TRPA1 KO mice have provided a valuable research tool to investigate
TRPA1 mediated responses.  To date, they have proven the importance of
neuronally expressed TRPA1 in inflammatory diseases linked to
neurogenic inflammation.  However, the role of non-neuronally expressed
TRPA1 has yet to be investigated.  Previous studies have shown the ability
of the TRPA1 agonist cinnamaldehyde, which is well characterised and can
be dosed in vivo, to influence the heart and alter cardiovascular regulatory
systems.  More recently, there have been an increasing number of papers
describing the vasodilatory nature of various TRPA1 agonists.  As there is
growing industrial interest in developing TRPA1 antagonists for clinical
use, it is now timely to investigate the potential role for TRPA1 to
influence cardiovascular regulation.  Therefore I have used WT and KO
mice to investigate the phenotype created when TRPA1 has been globally
deleted.
Aims
 To confirm the genotype of the TRPA1 WT and KO mouse colony
 To investigate basal characteristics of TRPA1 WT and KO mice in
terms of body weight, activity, heart weight, left ventricle size,




Confirming The Genotype Of The TRPA1 Mice
TRPA1 WT and KO mice were genotyped by ear punching before
weaning.  This was done according to the method stated in the materials
and methods section, using primers recommended in Kwan et al (2006).
Figure 3.1 shows a representative image, created using tail tip tissue,
showing how the genotype of mice can be determined.  In most cases, the
mice were bred from heterozygous matings, leading to litters containing a
range of genotypes.  This allowed littermate pairings to be created for the
majority of studies.
Investigating The Basal Characteristics Of TRPA1 WT And KO
Mouse Hearts Using Echocardiography
Mice aged 2.5 to 3 months were assessed for their body weight and left
ventricular size under light isoflurane anaesthesia.  Body weight was
similar between WT and KO mice, and did not vary significantly between
genders (WT F 22.5g, M 29g, KO F 26.6g, M 27.5g).  However there was
a tendency for males to be of larger mass.  They are presented as pooled
data in figure 3.2, with an average of 24-25g.  This graph provides a
snapshot of comparable animals, thus does not preclude against weight
differences at other ages.  However, it is important when comparing heart
sizes that the mice are as similar in size as possible.  With this in mind, all
echocardiographical measures are presented as a ratio to body weight,
eliminating it as a confounding variable.
Echocardiography is one of the most accurate methods of obtaining in vivo
left ventricular morphology and functional data from mice.   Method of
collection and parameters measured are explained in chapter 2.  A
complete examination was performed on 27 TRPA1 WT and 29 TRPA1
KO mice of 2.5-3 months of age.  Many of these mice were littermate
pairs.  Figure 3.3 shows average morphological characteristics of the left
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ventricle.  No differences were seen in any of the left ventricle wall
thicknesses, or in total left ventricle mass of either group.  These mice were
later used in a hypertrophy study (Chapter 5), therefore these measures
could not be confirmed by necropsy at this point.  However, previous
publications have demonstrated good correlations between necropsy heart
weight and left ventricle size calculated by echocardiography (Stypmann et
al., 2006).  Table 3.1 is a table showing the average values separated by
gender.
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Figure 3.1 Genotype Determination Of TRPA1 Colony Mice By
Endpoint PCR. Results show products of endpoint PCR from tail tip
samples extracted using the Sigma ExtractRED-N-Amp tissue PCR kit, run
on a 1.8% agarose gel with pBS/Hpa II ladder. Image is taken under UV
light.  The WT band runs at ~310 bp, whereas the KO band runs at about





Figure 3.2 Body Weight Of Paired, Littermate, TRPA1 WT And
KO Mice. Results show naive male and female pairs of mice, weighed at
2.5-3 months of age. N=27 pairs, 16 Female, 11 Male. Not significantly















Although there are no statistical differences between mice of the same
gender, but different genotypes; there are consistent differences seen
between same genotype mice of different genders.  Female mice of both
genotypes showed significantly larger hearts, with thicker walls, for all
measures, except for LVPW width, which did not reach significance.  This
may be due to slight differences in body weight between genders, as given
above.
Figure 3.4 shows heart function measured in the same WT and KO mice as
the morphological data.  As described in the materials and methods section,
fractional shortening is the most commonly used measure of left
ventricular contractility, and is related to both ejection fraction and stroke
volume.  All measures of left ventricular emptying showed similar heart
function in both genotypes.  Cardiac output is based on calculations of
heart ejection volume and heart rate, simultaneously measured by ECG.  In
this experiment, heart rates are controlled between 400 and 500 beats per
minute to provide comparable measurements of heart function.  Aortic
peak flow shows the velocity of blood leaving the aortic root, and is
therefore an indicator of systolic function. In line with the previously
presented data, heart contractility and output were similar in mixed gender
groups of paired TRPA1 WT and KO mice.
A table containing averages split by gender is shown in table 3.2.  No
statistical differences were seen between WT and KO averages collected
from mice of the same gender.  However, significant differences were seen
in measures of stroke volume, cardiac output and peak aortic flow between
male and female groups of the same genotype.  These may all be due to the
significant differences in stroke volume, which will in turn affect cardiac
output and peak aortic flow.  The data shows smaller stroke volume in
females, but as heart rate was controlled during the experiment, cardiac
output is also lower.  The reasons for this are not related to left ventricle
size differences, where my data shows females to have larger heart mass,
likely due to thicker heart walls, contradicting most data from humans and
animal models where male hearts are bigger with thicker walls (Baumann
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et al., 2008, Huxley, 2007). Larger hearts would be expected to produce
larger stroke volumes.  These findings also differs from those of Stypmann
et al (2006), who show left ventricle size and left ventricle function do not
change significantly with gender in CD1 mice.  These partially agree with
data presented in a review by Huxley (2007), showing human females to
have smaller stroke volume, but similar cardiac output due to a higher heart
rate.  However, female hearts were also of smaller mass.
Summary 1; Body Weight, Heart Size And Function In TRPA1
WT And KO Mice.
 Age matched TRPA1 WT and KO mice do not differ significantly
in terms of body weight.
 TRPA1 WT and KO mice do not significantly differ in terms of
heart size or function.
 Female mice displayed significantly bigger hearts with thicker
walls than male mice.  However, this corresponded with decreased
stroke volume, cardiac output and peak aortic flow.
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Figure 3.3 Baseline Left Ventricle Physical Parameters In
TRPA1 WT And KO Mice Measured By
Echocardiography. Result show A. calculated left ventricle
mass as a ratio to body weight (BW). B. left ventricular internal
diameter at diastole as a ratio to BW (LVIDd:BW).  C. left
ventricular anterior wall thickness at diastole, as a ratio to BW
(LVAWd:BW). D. left ventricular posterior wall thickness at
diastole, as a ratio to BW (LVPWd:BW) E. interventricular septum
thickness at diastole, as a ratio to BW (IVSd:BW).  All graphs show

























































































Table 3.1 Baseline Left Ventricle Physical Parameters In TRPA1
WT And KO Mice, Measured By Echocardiography and split by
gender. Results show A. calculated left ventricle mass as a ratio to body
weight (BW). B. left ventricular internal diameter at diastole as a ratio to
BW (LVIDd:BW).  C. left ventricular anterior wall thickness at diastole, as
a ratio to BW (LVAWd:BW). D. left ventricular posterior wall thickness at
diastole, as a ratio to BW (LVPWd:BW) E. interventricular septum
thickness at diastole, as a ratio to BW (IVSd:BW).  Table shows average
values from 11 male WT and 11 male KO mice, 16 WT female mice and
18 KO female mice.  Statistics are compared to female equivalent in an
unpaired, two tailed t-test.  *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
Mixed Male Female















































































































Figure 3.4 Baseline Heart Function In TRPA1 WT And KO Mice
Measured By Echocardiography And Aortic Arch Doppler.
Results show A. percentage fractional shortening. B. stroke volume in
microlitres.  C. percentage ejection fraction. D. cardiac output in millilitres
per minute. E. peak aortic flow rate in mm/seconds.  All graphs show male































































































Table 3.2 Baseline Heart Function In TRPA1 WT And KO Mice
Measured By Echocardiography And Aortic Arch Doppler, Split
By Gender. Results show A. percentage fractional shortening. B. stroke
volume in microlitres.  C. percentage ejection fraction. D. cardiac output in
millilitres per minute. E. peak aortic flow rate in mm/seconds. Table
shows average of 11 WT and 11 KO male mice and 16 WT and 18 KO
female mice. Statistics are compared to female equivalent in an unpaired,
two tailed t-test.  *p,0.05, **p<0.01.
Mixed Male Female















































































































Investigating The Basal Blood Pressure Of TRPA1 WT And KO
Mice Using Tail Cuff Plethysmography And Radiotelemetry
The basal blood pressure of WT and KO mice was initially established
using tail cuff plethysmography.  Several batches of mice were needed to
collect a large enough data set, however the process was kept as similar as
possible for each, as described in the materials and methods section.
Figure 3.5 shows average systolic, mean and diastolic for TRPA1 WT and
KO mice.  This figure also contains the data split by gender (3.5B/C).
Statistical analysis showed that KO mice had a significantly lower blood
pressure, in terms of all parameters, compared to WT mice.  This
significance remained in the female group when the data was split,
however the difference in the male group was smaller and did not reach
statistical significance.  Figure 3.6 shows the average mean blood pressure,
measured by tail cuff in young mice at different ages (8-14 weeks).  This
data is taken from daily training readings and shows that the KO mice
displayed a consistently hypotensive phenotype from a young age,
suggesting that it is an inherent part of their phenotype and not developed
with age.  The consistency of the reading over time also suggests that the
mice quickly became well trained using the method and gave reproducible
measurements.
Different sets of mice were fitted with radiotelemetry devices, measuring
central blood pressure and heart rate from the aortic arch. These have been
introduced in chapter 2. Use of telemetry devices in cardiovascular
research has been widely validated, particularly in reviews by Kramer
(Kramer et al., 2000, Kramer and Kinter, 2003, Kramer et al., 2001).
108
Figure 3.5 Average Baseline Blood Pressures In TRPA1 WT
And KO Mice Measured By Tail Cuff Plethysmography. Results
show A. average blood pressure in mixed gender mice. B. female only. C.
male only. N= number of mice.  Statistics are from an unpaired, two tailed
















































































Figure 3.6 Baseline Mean Blood Pressure Measured By Tail
Cuff Plethysmography Between 8 And 14 Weeks Of Age In
TRPA1 WT And KO Mice. Results show mixed gender mice. N=27 WT
and 31 KO mice.  Data presented as an average from N= 4-72 readings per
week. (N from from week 8 to 14, WT: 5, 41, 63, 56, 45, 22, 14, KO: 4, 25,
46, 72, 62, 35, 35). Average of all readings from the same mouse shown as
N=1 on previous graph.  Statistics are two way ANOVA with Bonferroni’s
post-test, **p<0.01, ***p<0.001.

























** ** *** ** **
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Figure 3.7 shows basal blood pressure, heart rate and activity levels for
mixed gender TRPA1 WT and KO mice, measured by telemetry and
plotted at half hourly intervals over one day.  This data was collected over
days’ 10-13 post implantation, and averaged to give a more accurate 24
hour profile.  Recovery from the procedure was measured by lack of pain
behaviours, good healing and increasing daily body mass measurements.
Seven to ten days post surgery is generally considered an adequate
recovery time from the experiences of other groups who do similar
telemetry surgery and is often used in publications.  TRPA1 WT and KO
mice displayed similar profiles of blood pressure.  This also applied to
heart rate and pulse pressure.  Through all these graphs, TRPA1 KO mice
appeared to have consistently higher readings.  These were never
statistically different at any time interval, but when the whole profile is
compared with a two-tailed unpaired t-test, TRPA1 WT and KO profiles
were significantly different in terms of systolic and mean blood pressure,
and pulse pressure.
Figure 3.9 F shows activity levels.  Again, the profile is similar between
the TRPA1 WT and KO mice; however there is a higher nocturnal activity
peak in KO mice.   This was not significant at any half hourly interval, but
showed significance in a Mann-Whitney U test, a non parametric form of t-
test comparing the whole 24 profile.  A non-parametric test was chosen as
TRPA1 KO data did not fit a Gaussian distribution.  Overall, there was a
general trend of increased activity in the KO mice.
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Figure 3.7 Baseline 24 Hour Hemodynamic And Activity Profiles
Of Mixed Gender TRPA1 WT And KO Mice, Measured By
Telemetry. Results show average profile of weekend days 10-13 after
implantation of telemetry probe PA-C10 with aortic arch placed catheter.
Mice experience a 12/12hr light/dark cycle, with the dark cycle shown in
the shaded area. Data shown as half hourly averages. A. Systolic blood
pressure. B. Mean blood pressure.  C. Diastolic blood pressure. D. Heart
rate. E. Pulse pressure.  F. Spontaneous activity. Graphs show data from
mixed gender mice. N=7 WT and 10 KO mice in A-D, N=9 WT and 10
KO for E-F.  Statistics in graphs A-E are from a two tailed unpaired t-test
of the whole profile, WT compared with KO. *p<0.05, ***p<0.001, or in
the case of activity (F), which has a non-Gaussian distribution, a two tailed
































































































































































































































































Figure 3.8 Baseline Day/Night Hemodynamic And Activity
Averages From Mixed Gender TRPA1 WT And KO Mice,
Measured By Telemetry. Results show averages of 12 hour day time
and 12 hour night time readings taken during weekend days 10-13 after
implantation of telemetry probe PA-C10, with aortic arch placed catheter.
24 hour profiles shown on previous graph. A. Systolic blood pressure. B.
Mean blood pressure. C. Diastolic blood pressure. D. Heart rate. E. Pulse
pressure.  F. Spontaneous activity. Graphs show data from mixed gender
mice. N=7 WT and 10 KO mice in A-D, N=9 WT and 10 KO for E-F.  One
way ANOVA with Bonferroni’s post test completed on A-E, day time
compared with daytime **p<0.01, ***p<0.001. Activity has a non
Gaussian distribution, so statistics are from a non parametric test, the































































































































The 24 hour profiles clearly show both sets of mice to express diurnal
variations in all parameters.  Mice were more active, with higher blood
pressures and heart rate during the night, consistent with them being
nocturnal mammals.  Figure 3.8 shows day time and night time averages
from each of the profiles shown in figure 3.7.  These graphs show the
magnitude of the diurnal variations is similar between WT and KO
animals. Increased nocturnal blood pressures and pulse pressures were
seen, mirroring that seen in the profiles, however these were not significant
in an ANOVA analysis.  On the other hand, both TRPA1 WT and KO mice
showed significant increases in heart rate during the night time. This was
in line with an increase in activity.
Activity levels were analysed with a non-parametric test, namely the
Kruskall-Wallis test with Dunn’s post-test, a non-parametric form of
ANOVA.  Increased nocturnal activity counts were seen in both groups,
increasing to 3-4 times daytime averages, which was significant in KO
mice.
As there is potential for differences to occur between gender, the baseline
telemetry profiles were also split to show females and males separately.
This is shown in figure 3.9 and 3.10 respectively.  Profiles accurately
reflect diurnal patterns seen when the data sets are combined.   Female
mice also reflected the outcome of mixed gender profiles, showing KO
mice to give significantly higher systolic and mean blood pressures, pulse
pressures and activity readings over the 24 hours, being statistically
different in a two-tailed unpaired t-test, or Mann-Whitney U test in the case
of activity.   Again, these values were not statistically significant at any
half hourly interval when tested by ANOVA.  When plotted alone, male
mice gave an opposing pattern, with WT mice giving significantly higher
systolic, mean and diastolic blood pressure readings, heart rate and pulse
pressure, when profiles are compared by two-tailed unpaired t-test.  This
may indicate sex specific characteristics, however, conclusions drawn from
this separated data should be considered with care due to low mice
numbers.
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Summary 2; Blood Pressure And Heart Rate Phenotype Of
TRPA1 WT And KO Mice Using Tail Cuff Plethysmography And
Telemetry.
 Tail cuff plethysmography gave consistent blood pressure readings
after mouse training.  Using this technique, TRPA1 KO mice
displayed a significant hypotensive phenotype compared to WT
mice, which was apparent from our first measurements at 8 weeks
of age and appeared consistently over the experimental period.
 Telemetered TRPA1 WT and KO mice produced similar diurnal
rhythms, but blood pressure parameters were significantly higher in
TRPA1 KO mice over 24 hours.  These were not significantly
different when averaged into daily and nightly readings.
Voluntary Wheel Running In TRPA1 WT And KO Mice
Telemetry data suggested a hyperactivity phenotype in telemetered TRPA1
KO mice.  Therefore, I compared daily wheel running distance in pairs of
TRPA1 WT and KO mice. See chapter 2 for measurement method. This is
shown in figure 3.11 where mice were trained for three weeks with a wheel
in their home cage, then measured in pairs for one week.  Adding wheels is
common for cage enrichment, but has also been used by several studies to
investigate the physiological and psychological effects of exercise.  For
example, a 4 week wheel placement is used by Eisele et al (2008) to show
that exercise increases mitochondria content in cardiomyocytes, but does
not alter left ventricle morphology.  This change may be beneficial for the
performance of the heart.  In my study, mice were naïve and were not used
for other measures in this thesis, therefore I did not measure their heart
size.  Results from wheel running measurements mirrored the findings
from telemetry, where KO mice ran significantly further each night than
WT pairs.  These findings were consistent as there was a similar magnitude
increase (around 60%), from single and combined 7 day readings.   Further
analysis of the data is presented in figure 3.12, showing speed of wheel
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turning as an index of preferred running speeds. The average turning
speeds from each pair is taken over the course of the 7 days. Panel A
shows a histogram of the frequency that specific turning speeds were
measured from each pair of mice. Analysis of the mode of this data, to
indicate most preferred speed, and area under the curve, to show distance
ran, is shown in panel B and C respectively.  Together, these graphs show
that in addition to KO pairs running significantly more distance than WT
pairs, they also show a preference for running faster.  The distance is
shown by a significantly bigger histogram, analysed by area under the
curve (3.12C).  The increased speed is shown by significant preferences for
faster running speeds in TRPA1 KO pairs, compared to WT pairs
(3.12A/B).  This narrowly missed significance when compared by modes
(3.12B).
Summary 3; TRPA1 KO Mice Are More Active And Conduct
More Voluntary Nocturnal Running
 Telemetered TRPA1 KO mice showed significantly higher
nocturnal spontaneous activity levels compared to WT mice.
 When given voluntary running wheels, TRPA1 KO mouse pairs ran
further each night and in total over 6 nights, compared to WT mice.
 This was shown to be due to both increased running speed
preferences and increased wheel distance ran.  Indicating a
increased preference for exercise in KO mice, compared to WT
mice.
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Figure 3.9 Baseline 24 Hour Hemodynamic And Activity Profiles
From Female TRPA1 WT And KO Mice, Measured By Telemetry.
Results show average profile of weekend days 10-13 after implantation of
telemetry probe PA-C10 with aortic arch placed catheter. Mice experience
a 12/12hr light/dark cycle, with the dark cycle shown in the shaded area.
Data shown as half hourly averages. A. Systolic blood pressure. B. Mean
blood pressure.  C. Diastolic blood pressure. D. Heart rate. E. Pulse
pressure.  F. Spontaneous activity. N=3 WT and 7 KO mice in A-D, N=4
WT and 7 KO for E-F. Statistics in graphs A-E are from a two tailed
unpaired t-test of the whole profile, WT compared with KO. ***p<0.001,
or in the case of activity (F), which has a non-Gaussian distribution, a two


























































































































































































































































Figure 3.10 Baseline 24 Hour Hemodynamic And Activity
Profiles From Male TRPA1 WT And KO Mice, Measured By
Telemetry. Results show average profile of weekend days 10-13 after
implantation of telemetry probe PA-C10 with aortic arch placed catheter.
Mice experience a 12/12hr light/dark cycle, with the dark cycle shown in
the shaded area. Data shown as half hourly averages. A. Systolic blood
pressure. B. Mean blood pressure.  C. Diastolic blood pressure. D. Heart
rate. E. Pulse pressure.  F. Spontaneous activity. N=5 WT and 3 KO mice
in A-D, N=5 WT and 3 KO for E-F. Statistics in graphs A-E are from a
two tailed unpaired t-test of the whole profile, WT compared with KO.
*p<0.05, ***p<0.001, or in the case of activity (F), which has a non-




























































































































































































































































































Figure 3.11 Voluntary Wheel Running Distance In Mixed Gender
TRPA1 WT And KO Mice. A. daily averages. B. Total over 6
nights/7days, measured in metres from pairs of mice with cage mounted
wheels. N= 6 WT pairs, 3 female, 3 male, 4 KO pairs, 2 female, 2 male.
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Figure 3.12 Preferred Wheel Speeds Of Voluntary Exercising
TRPA1 WT And KO Mice. Graph uses the same data as presented in
3.13. A. Histogram of the frequency of average wheel speeds measured
from each pair of mice over 7 days. B. Mode of data in A. C. AUC of data
in A. Statistics are from a two-way ANOVA in A, **** p<0.0001, **
p<0.01 compared to WT.  One tailed, unpaired t-test in C, compared with





This study has approached characterisation of TRPA1 WT and KO mice
from a novel angle, focusing on cardiovascular parameters. In this chapter,
I show that TRPA1 WT and KO littermates can be accurately genotyped
using small sections of tissue, and that they display similar characteristics
in terms of appearance, weight, heart morphology, heart function and basal
hemodynamic.  Small differences were displayed in some of the data
collected, for instance between methods of data collection, and when data
is split by gender.  However, the conflicting nature and mild magnitude of
these changes suggests that TRPA1 KO mice display only a mild
cardiovascular phenotype when compared to WT mice. In contrast,
TRPA1 KO mice displayed a striking increase in both spontaneous activity
and voluntary exercise compared to TRPA1 WT mice.
TRPA1 Littermates Show Similar Physical Characteristics
TRPA1 WT and KO mice bred in-house, display indistinguishable physical
characteristics and have similar weights at 2.5-3 months of age.  Data
presented here is for mixed gender mice, where at this time point mice did
not significantly vary in weight depending on gender.  However, as
expected, there were trends for increased body mass in males emerging.
As mice age, gender based differences in body weight occur in all strains
(See growth charts available from JAX mice
http://jaxmice.jax.org/support/weight/index.html).  Mice used in this study
were relatively young, therefore the lack of significant body weight
differences seen in the data is not entirely unexpected. Longer term
tracking of body weight in TRPA1 WT and KO mice would be a desirable
addition to the study; however no TRPA1 dependent basal body weight
differences have been reported by other groups.  TRPA1 has not been
directly linked to metabolism or body weight, however many of the
identified agonists do possess such links.  For example, MO and
cinnamaldehyde have been shown to delay gastric emptying (Doihara et
al., 2009), cinnamaldehyde reduces blood glucose and cholesterol levels
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(Subash Babu et al., 2007), and has insulinotropic effects (Anand et al.,
2010).  A potential improvement to this data would be a time course,
following the weight of a large cohort of TRPA1 WT and KO littermates.
To approach the problem of weight and gender differences in subsequently
presented data, heart morphology is shown as a ratio to body weight, and
results are also presented for separate genders.
TRPA1 WT And KO Mice Show Similar Heart Morphology And
Function, Measured By Echocardiography
Echocardiography was used to measure the dimensions of the left ventricle
in paired TRPA1 WT and KO mice. Many studies have investigated
gender related differences in heart size and function in humans, using
echocardiography.  A review by Huxley (2007) describes human females to
have smaller hearts, and thus stroke volume, but similar cardiac output due
to a higher heart rate.  The response to stress is also different between
genders, with males predominantly increasing TPR, whereas females
increase heart rate, to achieve higher cardiac output.  Stypmann et al
(2006) has provided echocardiographical reference values for 12 and 52
week old CD1 mice.  They show no significant differences in heart
morphological and functional parameters between different genders or over
time points, suggesting that heart size stays stable in these mice over time.
Conversely, Baumann et al (2008) have investigated gender differences in
echocardiographical heart measurements from two mouse strains.  They
show similarities to data from human studies, where female mice have
small left ventricular dimensions, thinner heart walls, but similar overall
functional measurements.  Differences were more prominent in C57/BL6
than in BalbC mice, again suggesting strain influences.  However, female
mice were also smaller in body weight, and significant gender differences
were lost when the results were normalised to body mass.  Therefore, to
eliminate weight related errors, my data is expressed as a ratio to body
weight, both as mixed and split gender.  Trends are similar between
genders, however absolute values differ.  Many of these observed
differences are in line with the publications presented above, showing
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female mice to have smaller stroke volume.  However, I also found female
mice to have thicker heart walls and overall larger heart mass, which
conflicts with reported data from humans and animal models.  The
explanation for this is not clear, but may represent a problem from
processing mice in single sex experimental groups where housing
conditions are not identical i.e. Groups of mice per cage.  These factors
could affect feeding and body weight.  Although gender body weight
differences were not significant, there were small differences apparent at
this time point. It may also be a result of small differences in heart rate
during the measurements, but this was not recorded.
When mixed gender groups are analysed, left ventricle mass as a ratio to
body weight is similar between TRPA1 WT and KO mice, as were the
internal dimensions and wall thicknesses.  This data suggests that TRPA1
deletion does not influence heart morphology.  Similar results are seen
when data is split by gender, suggesting that genders were similarly
affected by TRPA1 deletion.  Left ventricular function was assessed using
echocardiographical measurements and Doppler readings.  Mixed gender
TRPA1 WT and KO mice show similar left ventricular volumes,
contractility and systolic functioning.  Again, the data remained similar
when split by gender, suggesting that TRPA1 KO does not influence
cardiac function.
There are some differences in the absolute values of echocardiographical
data collected from males and females in disease models (Leinwand,
2003), thus many studies are conducted using one gender only.  My data
reflects potential differences in absolute values between genders.
However, most relevant clinical findings and strong phenotypes appear in a
non-gender specific manner, therefore it is potentially more relevant to
study mixed gender populations, best reflecting the patient population.
This is particularly important in this study, as it is a novel investigation of
the cardiovascular phenotype of TRPA1 KO mice.  Excluding a gender
from this study would potentially overlook valuable data. Using power
analysis to determine group sizes, I examined a relatively high number of
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mixed gender mice, enabling splitting of the data.  Although variability was
more than expected, enough mice were used to get accurate measures and
there were no observations of a strong phenotype, either gender or TRPA1
dependent.  TRPA1 has been suggested to be directly activated by ROS,
including H2O2 and products of oxidative stress (Bessac et al., 2008,
Andersson et al., 2008, Trevisani et al., 2007).  These ROS are thought to
contribute to protein damage and onset of age related diseases, including
those of the vasculature (Stadtman, 2001).  Therefore a longer term study
may be warranted, due to the potential for age related differences to occur.
This could be a topic for future study, measuring heart characteristics
serially, over the lifetime of the mice.
TRPA1 KO Mice Present A Hypotensive Phenotype When
Measured By Tail Cuff Plethysmography
Average blood pressures in mice are similar to that of humans; namely
around 120mmHg systolic pressure, 100mmHg mean pressure and
80mmHg diastolic pressure.  Significant deviations above or below these
levels indicate hypertensive or hypotensive phenotypes, respectively.  Tail
cuff plethysmography is a well validated method to collect serial
measurements of blood pressure from trained, conscious mice. It has been
previously used in our group to characterise three different genotypes of
mice. In my study, mixed gender TRPA1 WT mice produced stable and
reproducible blood pressures, around 120/80mmHg, similar to that
expected.  However, paired TRPA1 KO mice presented with significantly
lower blood pressures than WT mice, around 110/75 mmHg.  This is not
hypotension using clinical definitions (<90/60mmHg), but shows a
significantly lower blood pressure than TRPA1 WT mice.  Significant
efforts were made to ensure reproducibility of this data, using multiple
blinded sets of mice, and employing independent investigators.  This has
included several undergraduate students, trained under my supervision, and
another PhD student.  In total, similar measurements have been taken from
around 7 distinct sets of mice, by 4 investigators, with similar data patterns
in all cases.  When data was split by gender, similar trends occurred in both
male and female mice.  However, a generally lower blood pressure and
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increased variability was seen in male mice and prevented significance.
These factors may have been due to behavioural differences between
genders of mice, where male mice are harder to obtain measurements from
due to increased movement and vasoconstriction.  This results in lower
measurable values.  It is known that androgens are important mediators of
aggression, along with changes in 5-hydroxytryptamine (5HT) signalling
(Nelson and Chiavegatto, 2001).  Aggression and stress responses are
strongly linked. Therefore, further investigation of these responses may be
interesting, particularly as sensory neurones and TRPA1 have recently
been linked to aggression via pheromone receptors in drosophilia (Liu et
al., 2011).  The neuropeptide SP is also consistently linked to the formation
of aggressive behaviours, acting via NK receptors in the brain (Katsouni et
al., 2009).  Various blood borne markers and behavioural tests for stress
and aggression are available.
The literature describes various mechanisms of TRPA1 mediated
vasodilation in vivo (Bodkin and Brain, 2010).  Evidence thus far suggests
that TRPA1 deletion would remove a valuable peripheral artery dilation
mechanism, which may lead to an increased blood pressure via an increase
in total peripheral resistance. This suggestion is supported by my data
presented in chapter 4, showing the TRPA1 agonist cinnamaldehyde to
cause peripheral artery vasodilation. My findings of hypotension in TRPA1
KO mice opposes these suggestions, but may suggest TRPA1 has other
activities relevant to blood pressure control.  However, there are some
potential methodological considerations which may have contributed to
these findings.  Firstly, the generation of KO mice has potential side
effects.  Many KO strains, particularly global KO’s, show some evidence
of compensatory expression. To date, TRPA1 KO mice have been well
studied and have had no reported compensations.  However, this is the first
study to investigate systemic cardiovascular regulation in these mice,
therefore it is possible that deletion of TRPA1 and removal of its dilatory
signalling has been over-compensated in the KO mice, leading to a
hypotensive phenotype.  Another consideration is of the tail cuff method,
as it is associated with increased animal stress due to restraint, which could
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increase blood pressure and heart rate (Kramer and Kinter, 2003).  In this
study, extensive training was used to habitualise animals to the procedure,
in an effort to reduce the effects of stress.  The mice are also likely to be
warmed above ambient temperatures when inside the restraint tube.
Warming is an essential part of the technique, where the tail artery must be
dilated to gain good quality tail swelling measurements, which are used to
determine the blood pressure. Therefore the effect of heat stress and tail
dilation may also have a role in my findings. However, results from WT
mice show the expected blood pressure, indicating the training efforts were
successful and that confounding factors were avoided. Additionally, there
are also considerations of the effect of TRPA1 deletion on stress responses
in mice.  Lower blood pressure recordings could potentially be caused by
either a decrease or increase in stress responses, preventing acquisition of
accurate measurements.
Tail cuff plethysmography measures mainly systolic pressure (Mahoney
and Brody, 1978), from the tail large artery.  Although this has been shown
to give good correlation to central blood pressure, there are differences in
absolute measured pressures (Bunag and Riley, 1974).  At physiological
pressures (100-120mmHg) tail cuff plethysmography gives very similar
readings to telemetry probes, however at lower and higher pressures there
are slight under and over valuations, respectively (Mahoney and Brody,
1978).  These differences were only of a few mmHg but differences at the
extremities of normal blood pressure were also seen by Bunag and Riley,
(Bunag and Riley, 1974) who simultaneously measured blood pressure by
both methods in rats treated with hypertensive and hypotensive agents.
There are also considerations of pressure wave reflections in vessels
downstream of the aorta, which may alter measurements.  Differences in
blood pressure measurements and the effect of antihypertensive drugs have
been reported (McEniery, 2009) and the level of pressure wave deflection
can vary in disease settings, where measurement of this deflection
correlates with cardiovascular risk (Safar and Jankowski, 2009).  Therefore
126
both peripheral and central measurements of blood pressure can have value
as disease predictors.
A finding that TRPA1 is involved in the regulation of blood pressure
would be hugely influential, both in terms of drug development and
physiological understanding.  For all of the reasons outlined above, there
was therefore a great need to validate the findings using the gold standard
method of conscious mouse blood pressure recordings, which is
radiotelemetry.
TRPA1 WT And KO Mice Have A Similar Blood Pressure
Phenotype When Measured By Radiotelemetry
Radiotelemetry probes are an important and powerful tool for phenotyping
mouse blood pressure (Van Vliet et al., 2006).  Telemetry probes
measuring central blood pressure from the aortic arch, showed TRPA1 WT
and KO mice to have similar hemodynamic profiles and diurnal variations
at room temperature (around 21°C), unrestrained in their home cage.
Mixed gender mice showed clear daily patterns of blood pressure, heart
rate and activity; increasing sharply at the beginning of the night time and
coming down as the night progressed.  These profiles are also seen when
data is split by gender.  Day time pressures and activity were low and
relatively stable.  Measurements of home cage circadian rhythms are one of
the major advantages of using telemetry.  This is particularly important in
mice, as they are nocturnal and differences in blood pressure will be most
pronounced during times of activity.  My results showed an average blood
pressure of around 120/80mmHg during the day time, when mice were
resting and had low activity levels.  Blood pressure increased during
spontaneous nocturnal activity, rising to an average around 130/100mmHg.
Day time and night time averages were significantly different in terms of
heart rate and activity, with clear trends in other parameters.  Such
increases are consistent with those reported in Van Vleit et al (2006), who
worked on characterising the use of telemetry probes, suggest the value of
24 hour diurnal recordings and averaging these values to produce a more
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consistent blood pressure average.  Diurnal changes are likely to be as a
result of physical and thus sympathetic activity (Shepherd, 1987).
The most interesting and novel findings from the telemetered mice
concerned the increase in spontaneous activity counts during the night time
in TRPA1 KO mice, when compared to the WT mice.  This increase in
activity may partially explain the trends of increased blood pressure in the
female KO mice.  Activity is measured by an accelerometer feature of the
telemetry transmitter, fitted to the right flank of the animal.  This gives an
arbitrary number of activity counts.  The accuracy of these counts has been
questioned, with suggestions that the sensitivity of the count can be
affected by telemeter orientation and receiver position (Van Vliet et al.,
2006).  There is also no measure of the type of activity undertaken by the
telemetered mice, which would demand use of specialised activity cages or
night time video recordings.  Therefore, I cannot be certain that increased
counts truly demonstrate increased spontaneous activity, or the type of
movements. For this reason, further studies were undertaken measuring
voluntary wheel running in pairs of littermate TRPA1 WT and KO mice.
These were collected from a separate group of animals with running wheels
in their home cage and support the telemetry findings, showing that
TRPA1 KO mice participate in more voluntary exercise, consistently
running significantly further and faster than WT mice.  Future work will be
needed to investigate the reasons for the observed activity differences in
TRPA1 WT and KO mice.
The effect of activity in this study are in line with findings from Adlam et
al (2011) showing telemetered mice undergoing exercise to predominantly
increase their heart rate, not blood pressure, to reach the increase in cardiac
demand.  There are many investigations using wheel running training in the
literature, looking at a variety of adaptive changes.  My findings are similar
to those of Koteja et al (1999), who selectively bred for higher running
distance and show that this is due to an increased speed, not time spent
running. However, in their study, running distance was not correlated with
overall activity levels in the mice, using specialised activity measuring
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cages. Therefore wheel running may represent an independent measure of
activity to that of telemetry.  Together, the wheel running and telemetry
activity data strongly suggest a hyperactivity phenotype in TRPA1 KO
mice.  Long distance running is reported to be a heritable trait in many
studies (Swallow et al., 1998), although the exact genes responsible are not
clear. Therefor genetic manipulation has the potential to result in changes
in activity.  Additionally, high running mice have been shown to have
similar neurobiology to sufferers of Attention deficit hyperactivity disorder
(ADHD) (Rhodes et al., 2005).
Increased blood pressure variability over 24 hours, and from day to day, is
emerging as an important indicator of cardiovascular event risk as it is
suggested to be the cause of much end organ damage (Rothwell, 2011).
Heart rate variability is also a factor that could be extrapolated from the
data, giving a measure of autonomic function, with reduced variability also
linked to cardiovascular events and can be increased by exercise
(Routledge et al., 2010).  Alterations in activity level mean that analysis of
the data for blood pressure variability is not appropriate.  Therefore these
parameters were not measured in this study.
Findings from tail cuff plethysmography, showing hypotension in TRPA1
KO mice, were not confirmed using telemetry.  Earley et al, (2009) have
recently described intraluminal administration of the TRPA1 antagonist
HC-030031 in pressurised cerebral arteries to cause an increase in
myogenic tone in vivo.  This could potentially lead to increased blood
pressure through an increase in peripheral resistance, and suggests that
TRPA1 could potentially provide a tonic dilatory influence on vessel tone.
Based on this evidence, TRPA1 KO mice may be expected to show
increased blood pressure.  In my study, telemetry data from mixed gender
profiles showed a trend for consistently higher systolic and mean blood
pressures in TRPA1 KO mice.  This pattern of increased blood pressure
was retained in female data analysis, but was reversed in male analysis.
However, split gender data must be interpreted with caution due to the
increase in activity in TRPA1 KO mice and lower N numbers.  The small
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magnitude of blood pressure differences and incompatibility of this data
between measurement methods, suggests that there is no clear blood
pressure phenotype associated with TRPA1 deletion.  The differences
between measurement methods could be further investigated in this study
by concomitantly measuring blood pressure by tail cuff and telemetry.
This has been done in many other validation studies and shows good
correlations, particularly of basal systolic pressures (Feng et al., 2008,
Whitesall et al., 2004), but was logistically impossible to complete during
the time frame of this PhD.  These measurements would also allow us to
investigate the effects of wheel running exercise in the TRPA1 WT and
KO mice.  Such dramatic differences between tail cuff and telemetry
findings may be due to a physiological response to the tail cuff procedure,
which may differ in TRPA1 WT and KO mice.  This opens many potential
avenues of investigation, relating to stress responses and the TRPA1
receptor.
Conclusion
In this chapter, I have shown that TRPA1 KO mice do not display any
strong physical or hemodynamic phenotypes when compared to TRPA1
WT mice.  They share similar weights, heart morphology, heart function,
heart rate and blood pressure.  Measurements of blood pressure were
collected by both tail cuff plethysmography and telemetry, with differing
results.  However, this is likely to be due to methodological considerations.
Telemetry is the gold standard approach to mouse blood pressure
phenotyping and this data suggests there are no clear differences between
TRPA1 WT and KO mice.  The telemetry data also suggests hyperactivity
characteristics may be expressed in KO mice.  This data was backed up by
significant increases in voluntary wheel running distances and speeds, an
independent measure of activity. Therefore, I show the potential for
TRPA1 KO mice to display increased levels of physical activity which
warrant further investigation.
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Chapter 4 – Characterising Cinnamaldehyde Induced
Vasoreactivity In The Mouse Mesenteric Artery, Using
The Wire Myograph
Introduction
Mechanisms attributed to local blood flow control vary depending on tissue
type and can be modulated in vivo by central control mechanisms.  This is
often linked to the cell types involved and the tissue innervation.  Blood
pressure can be altered by changing the total peripheral resistance of the
vascular system; where increasing the resistance increases the pressure of
the system.  Therefore, the vascular tone experienced in large vascular
beds, such as mesenteric beds, can easily influence systemic blood
pressure.  Many antihypertensive drugs work by reducing peripheral
resistance.
An increasing number of studies are demonstrating that proposed TRPA1
agonists can modulate vascular tone in isolated arteries, causing
vasorelaxation (See table 1.1). This leads to the hypothesis that TRPA1
can have a role in peripheral resistance control both via both local and
central signalling. The main TRPA1 experimental agonists are currently
MO and cinnamaldehyde. We have recently used cinnamaldehyde to
investigate central reflexes initiated by intra-vascular TRPA1 agonism,
demonstrating induction of a vaso-vagal reflex.  We are now interested in
characterising the locally mediated component of TRPA1 induced
vasorelaxation, as this may play an important role in the response to locally
produced TRPA1 agonists. Several studies have used topically applied
cinnamaldehyde on the human forearm, showing it to cause physiologically
relevant increases in local blood flow (Namer et al., 2005, VanderEnde and
Morrow, 2001). Additionally, unpublished data from our group collected
by Aisah Aubdool, has shown topical application of cinnamaldehyde to the
mouse ear causes a robust increase in local blood flow which does not alter
flow in the vehicle treated contralateral ear.  Furthermore, this response is
almost completely lost in TRPA1 KO mice and in WT mice following
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treatment with TRPA1 antagonists.  Some of this data will be presented
later in this chapter.  Together, these studies suggest that topical application
of cinnamaldehyde induces TRPA1 mediated vasodilation of the local
vasculature, but does not allow enough agonist to reach the circulation to
activate reflex mechanisms, and does not release enough vasodilator agents
to leak in to the circulation and induce systemic changes in blood pressure.
When investigating the signalling pathways responsible, studies have
utilised a range of techniques to show the effect of TRPA1 agonist
application to localised vascular beds, including using various species and
techniques to propose a range of different mechanisms. These varying
findings may be due to methodological differences, as human and animal
in vivo studies demonstrate C-fibre and neuropeptide components, whereas
isolated animal vessels often show changes in calcium handling and
hyperpolarisation of the smooth muscle.  These mechanisms are not
incompatible but this suggests that non-neuronal tissues may react to the
agonists, modulating the vasorelaxant response, potentially via TRPA1.
Several studies suggest that sensory neurone derived peptides, such as
CGRP, may be important in TRPA1 mediated vasorelaxation.  Hikiji et al
(2000) and Louis et al (1989a) show MO in the cat tooth pulp and rat hind
paw respectively, causes C-fibre mediated dilation via neuropeptides.
Using Laser Doppler flowmetry, MO induced blood flow increases have
been shown to be modulated by SP and CGRP in the mouse ear (Grant et
al., 2005) and in our recently published study we also found that topically
applied cinnamaldehyde causes vasodilation that is TRPA1 mediated
(Pozsgai et al., 2010).
Several TRP channels have been shown to be expressed on endothelial
cells and cause endothelial dependent vasodilation (Yao and Garland,
2005). Earley et al (2009) recently used isolated rat cerebral arteries
treated with the TRPA1 antagonist HC-030031 (3μM) in the pressurised
myograph, to show MO induced vasorelaxation was dependent on TRPA1
expressed on endothelial cells.  They proposed a tissue specific mechanism
in which TRPA1 activation causes calcium activated calcium release from
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stores, opening calcium activated potassium channels (SKCa and KCa3.1)
and hyperpolarising the cell.  The hyperpolarisation is then passed to
vascular smooth muscle cells via myoendothelial gap junctions or by
creating areas of high extracellular potassium, which activates smooth
muscle KIR channels.   This study used a range of antagonists for the
potassium channels investigated, including apamin (for SKCa), TRAM34
(for KCa3.1) and BaCl2 (for KIR), and is currently one of the most highly
cited accounts of TRPA1 induced relaxation.  However, it is likely to be
specific to the cerebral artery, as similar arrangements of TRPA1 receptors
with potassium activated calcium channels has not been reported in other
vascular beds. Earley et al did not investigate the role of neuropeptides or
sensory neurones in their model.  The mechanism in the cerebral arteries
also differs from those identified in other tissues, which do not show
endothelial dependence, but do provide evidence of sensory
neurone/neuropeptide involvement.  For example, when using similar
concentrations of cinnamaldehyde on rat aortic rings, Xue et al, (2011) find
no effect of endothelial removal, L-NAME, ODQ or indomethacin addition
(inhibitors of NO, soluble guanylyl cyclase and prostaglandin production
respectively), whereas Yanaga et al (2006), using the same model, find a
partial endothelium dependent component which is NO mediated and
blocked by L-NAME.  Neither of these studies investigated dependence on
TRPA1.  Consequently, there is a need to characterise a complete pathway
in a tissue, before investigating how this differs between tissues, and in
different scenarios, using similar methodology.  I am particularly interested
in tissues relevant to blood pressure control.  We were the first group to
investigate in vivo blood flow changes in TRPA1 KO mice, showing local
application of cinnamaldehyde to the paw induces significant blood flow
increases in TRPA1 WT mice only (Pozsgai et al., 2010).  In this
publication we also showed that i.v. cinnamaldehyde application initiated a
TRPA1 mediated, neuropeptide independent vaso-vagal response, causing
an initial drop in blood pressure and heart rate followed by a more
sustained increase in both.  These findings suggest that TRPA1 activity is
relevant to the regulation of the cardiovascular system; however the
mechanisms at play are still unclear. The tone of small blood vessels in
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large vascular beds is important for total peripheral resistance and thus
blood pressure.  Determining the contribution of TRPA1 to local vascular
tone is therefore of value in investigating its potential role in blood
pressure control.
Aims
 To investigate cinnamaldehyde induced vasorelaxation in isolated
resistance vessels of the mesenteric vascular bed.
 To investigate the TRPA1 dependency of this relaxation
 To demonstrate that this is relevant in vivo by studying skin blood
flow in the anaesthetised mouse ear.
 To study the mechanism mediating TRPA1 induced vasorelaxation.
Results
Cinnamaldehyde Induced Vasorelaxation And Vasodilation
First order mesenteric arteries isolated from TRPA1 WT and KO mice
were investigated using a wire myograph.  These mice had been genotyped
as previously described.  In all experiments, arteries were rested before use,
allowing the tissue to stabilise.  The vessels were challenged three times
with high potassium solution (80mM), establishing maximum tissue
contraction, before endothelium function was assessed by the extent of
relaxation to carbachol (10μM, added for 2 minutes) after pre-constriction
using U46619 (10nM, 5 minutes), a TxA2 mimetic. Representative traces
of raw data collected from TRPA1 WT mesenteric arteries during high K+
challenges and carbachol treatment are shown in appendix figure 1.
U46619 was chosen as a pre-constriction agent due its long and consistent
contraction of the mesenteric arteries.  Other pre-constriction agents were
investigated, in particular phenylephrine, however this did not produce a
stable constriction over the test period.  A carbachol relaxation response of
more than 60% was used to define positive endothelium function.  In initial
studies, WT mouse mesenteric arteries were used to assess the
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concentration related effect of cinnamaldehyde, using single a
concentration treatment on each U46619 pre-constriction Representative
traces of raw data collected from TRPA1 WT and KO mesenteric arteries
treated with a single concentration of cinnamaldehyde following pre-
constriction are shown in appendix figure 2. Average percentage relaxation
is calculated and plotted on figure 4.1. This figure also shows the effect of
vehicle addition (0.01% ethanol, final bath concentration), with the total
relaxation shown as ‘vehicle or 0µM cinnamaldehyde’. The relaxation to
vehicle provides a useful control, showing the effect of both time and
vehicle on the level of pre-constriction. Panel A and B of figure 4.1 show
data split for vessels with and without functional endothelium respectively.
This is combined in panel C. These vessels were from animals of both
gender, and graphs showing data split by sex are shown in figure 4.2.
These graphs show similar response patterns to the combined data,
suggesting that gender is not an important modulator of the response to
cinnamaldehyde.  By grouping the data into mixed gender groups, I was
able to increase N and strengthen my statistical analysis.
In both TRPA1 WT and KO vessels, cinnamaldehyde causes a
concentration dependent vasorelaxation.  This suggests that
cinnamaldehyde has both TRPA1 dependent and independent vasodilatory
actions.  In the mouse mesenteric artery, with and without functioning
endothelium, TRPA1 KO mice displayed a concentration response curve
shifted to the right in comparison to WT mice, which was significant at
30μM cinnamaldehyde for vessels with and without functional
endothelium, demonstrating reduced potency.  This provides evidence that
TRPA1 is an important mediator of the cinnamaldehyde response, but is
not the exclusive mediator in this tissue.
Panel C of figure 4.1 shows combined data from vessels with and without
endothelial function.  This graph can be used to compare responses within
genotype, where differences show the extent of endothelial dependence in
the response. In figure 4.1, both WT and KO vessels show a very small
rightward shift in cinnamaldehyde concentration response when endothelial
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function is absent.  This shows that cinnamaldehyde does have some
vasodilatory action occurring via the endothelium. This is of bigger
magnitude in KO vessels compared to WT vessels, indicating that the
TRPA1 component is likely to be endothelium independent.  Moreover,
these changes cannot be attributed to differing levels of endothelium
function, as groups with and without functional endothelium in both
genotypes, show similar positive and negative responses to carbachol.
Figure 4.3 shows the EC50 calculated as an average for each treatment
group using each animal’s individual concentration response curve.  This
graph illustrates the decrease in the potency of cinnamaldehyde in TRPA1
KO vessels, increasing the EC50 value.  This reached significance only
between WT and KO vessels where functional endothelium was absent.
Additionally, data shows little endothelium dependency in WT mice.  Only
in KO mice does removal of the endothelium cause a significant decrease
in the potency of cinnamaldehyde.  Together with the previous figure, these
results suggest that cinnamaldehyde has TRPA1 dependent and
independent relaxation mechanisms in the mesentery, and that TRPA1 is
involved in the portion mediated by vascular smooth muscle cells, as only
the KO vessel response was affected by loss of endothelial function.
There have been no previous studies investigating differences in mesenteric
artery vasorelaxation between TRPA1 WT and KO mice. If TRPA1 KO
vessels were to have a different sensitivity to pre-constriction agents, this
may impact on their vasorelaxant ability. Here, data shows that TRPA1
WT and KO mesenteric arteries without functional endothelium are able to
produce similar levels of raw tension (mN) and % constriction compared to
the maximal tension produced by 80mM potassium Krebs, in response to
cumulative concentrations of the physiologically relevant contractile
agonist phenylephrine (mimicking sympathetic tone), depolarising levels of
KCl and U46619, the pre-constriction agent commonly used in this
chapter. This data is shown in figure 4.4. I therefore conclude that the
ability to produce tone is not influenced by a TRPA1 dependent
component.
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My data suggests that ex vivo cinnamaldehyde induced vasorelaxation is
likely to be partially dependent on the TRPA1 receptor.  Data produced by
my colleague Aisah Aubdool also shows the in vivo consequences of
topical cinnamaldehyde application by measuring cutaneous blood flow.
In figure 4.5, donated by Aisah, topical application of 10%
cinnamaldehyde to TRPA1 WT mouse ear causes a significant increase in
blood flow.  In TRPA1 KO mice, this response is significantly attenuated
(Figure 4.4A). Similarly, an attenuation of the response occurs in CD1
mice, after i.p. pre-treatment with the TRPA1 antagonist TCS5861528
(10mg/kg) (Figure 4.4B).  This concentration has previously been used to
reduce mechanical hypersensitivity in diabetic rats when given i.p. by Wei
et al (2009).
Several studies, including that of Earley et al (2009), have previously
investigated TRPA1 induced vasodilation using MO.  I have also used MO
on the mesenteric vessels from TRPA1 WT and KO mice, with and without
functional endothelium, presented in figure 4.6.  A representative trace of
raw data collected during a cumulative concentration response curve to
MO in a TRPA1 WT mesenteric artery, is shown in appendix figure 3.  The
effects of MO vehicle additions are also shown. In my hands, MO caused a
concentration dependent vasoconstriction, which was not influenced by
endothelium or TRPA1 presence.
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Figure 4.1 The Effect Of Cinnamaldehyde On TRPA1 WT And
KO Mouse Mesenteric Arteries With And Without Functional
Endothelium. Results are from vessels on a wire myograph pre-
constricted to U46619 (10nM, 5 minutes). The effect of single
concentrations of cinnamaldehyde are shown (CA, 3-300μM) and %
relaxation at 5 minutes measured.  Endothelium function is assessed using
carbachol (10μM) added for 2 minutes. The EC50 is calculated per animal
and expressed as group averages.  Graph shows combined data from mixed
gender mice. A. endothelial intact only N=10-11. B. No functional
endothelial N=14-15. C. Data from A and B combined. Statistics are one
way ANOVA with Bonferroni for carbachol, or two-way ANOVA with
Bonferroni for cinnamaldehyde additions ***p<0.001, compared to intact
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Figure 4.2 The Effect Of Cinnamaldehyde On TRPA1 WT And
KO Mouse Mesenteric Arteries With And Without Functional
Endothelium, Split By Gender. Results are from vessels on a wire
myograph pre-constricted to U46619 (10nM, 5 minutes). The effect of
single concentrations of cinnamaldehyde are shown (CA, 3-300μM) and %
relaxation at 5 minutes is measured. A) Female B) Male mesenteric
arteries. N numbers are as indicated. Statistics are from a two-way
ANOVA with Bonferroni’s post test, *p<0.05, **p<0.01 comparing WT


















































Figure 4.3 Potency Of Cinnamaldehyde Induced Vasorelaxation
In TRPA1 WT And KO Mouse Mesenteric arteries. Results show
vessels pre-constricted to U46619 (10nM, 5 minutes). EC50 is calculated
per animal and presented as an average.  Graph shows pooled data from
male and female paired mice. Statistics are from one way ANOVA with
Bonferroni’s post-test, ****p<0.0001, compared to WT without functional
endothelium (-endo).  ###p<0.001 KO endothelium (+endo) compared to
KO without endothelial function (-endo). N numbers are as indicated


























Figure 4.4 The contractile ability of mesenteric arteries from
TRPA1 WT and KO mice in response to phenylephrine, KCl and
U46619. Results show vessels without functional endothelium, pre-
constricted with cumulative concentrations of phenylephrine (0.03-30µM
A-B), KCl (K+ 10-300mM C and D) or U46619 (0.1-300nM E-F) at 3
minute intervals. Panel A, C and E show raw tension, whereas panels B,D
and F show tension as a % of the maximal tension recorded in response to
3, 2 minute challenges with 80mM K+ Krebs. EC50 is calculated per
animal and presented as an average.  Graph shows pooled data from male
and female paired mice.
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Figure 4.5 The Effect Of Cinnamaldehyde On Blood Flow In The
Anaesthetised TRPA1 WT And KO Mouse Ear, Measured By
Laser Doppler Flowmetry. Results show blood flow measured for 30
minutes after topically applied cinnamaldehyde (CA, 10% in ethanol) or
vehicle, total flow is calculated as area under the curve. A. TRPA1 WT and
KO female mice.  N=4 B. Male CD1 mice pre-treated for 30 minutes with
TRPA1 antagonist (TCS5861528 (TCS), 10mg/kg i.p.) or vehicle (20%
DMSO in saline). N=5. Statistics are from a one way ANOVA with
Bonferroni’s post test, *p<0.05, ***p<0.001 compared to respective
vehicle, #p<0.05 compared to control CA treated ear.  Graph is of



















































Effect of TRPA1 antagonists on cinnamaldehyde induced
vasorelaxation
To further confirm the TRPA1 component of cinnamaldehyde induced
vasorelaxation, I pre-treated tissues from CD1 mice (TRPA1 WT) with two
concentrations of the TRPA1 antagonist HC-030031, 10 and 30μM.  This
concentration range is used in other publications, with both 10 and 30μM
significantly reducing cinnamaldehyde (300μM) induced contraction on
isolated bladder smooth muscle (Andrade et al., 2011).  The peak of my
cinnamaldehyde concentration response curve is also 300 μM.   Figure 4.7
shows that neither concentration of HC-030031 had an effect on
cumulative cinnamaldehyde concentration response curves in vessels with
and without functional endothelium.  In panel C, where all data is overlaid,
the graph shows a small non-significant difference between vessel with and
without functional endothelium. A representative trace showing the effect
of vehicle (ethanol) additions rather than cinnamaldehyde, over the same
time course of a cumulative concentration curve is shown in appendix
figure 4, where no effects of vehicle are seen. Representative traces of the
raw data collected from a cumulative concentration curve to
cinnamaldehyde, conducted in a CD1 mouse mesenteric artery, pre-treated
with HC-030031 (30μM) or its vehicle (0.01% DMSO) are shown in
appendix figure 5.
Studies presented in this chapter commonly use mesenteric arteries from
CD1 mice, which are WT with respect to the TRPA1 receptor. These mice
hold a different genetic strain background from that of TRPA1 WT and KO
mice, which have a mixed C57/BL6 and B6129P1/F2J background. In
order to address the possibility that strain differences may account for my
inability to block cinnamaldehyde responses with HC-030031, a separate
series of studies used mesenteric arteries from CD1 and C57/BL6 mice pre-
treated with either vehicle (0.05% DMSO in Krebs), or 10, 30, 50 or
100µM HC-033031, prior to application of cumulative cinnamaldehyde
concentrations. None of these antagonist concentrations reduced the
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vasorelaxation response to cinnamaldehyde, although higher concentrations
were conversely associated with an increased relaxation response (figure
4.8), which may be due to detrimental effects on tissue viability. In figure
4.9, these findings are built upon using mesenteric arteries from TRPA1
WT mice pre-treated with 50µM HC-030031 or its vehicle (0.05% DMSO
in Krebs), before accumulating concentrations of cinnamaldehyde. 50µM
HC-030031 was chosen as the highest concentration which did not show
detrimental effects on tissue viability in previous figures. As seen in
arteries from CD1 and C57/BL6 mice, HC-033031 was ineffective at
inhibiting vasorelaxation to cinnamaldehyde in TRPA1 WT arteries.
Figure 4.9 also shows raw tension from TRPA1 WT arteries where 50µM
HC-030031 pre-treatment results in a reduction in arterial tone throughout
the cinnamaldehyde concentration response curve. The experiments
presented in figure 4.8 and 4.9 were collected over several months and a
difference in cinnamaldehyde EC50 values is observed compared to some
previously and subsequently presented data. As previously presented data
showed similar contractile ability in TRPA1 WT and KO mesenteric
vessels, it is likely that high concentrations of HC-030031 act to inhibit
smooth muscle contraction. This is similar to the finding of Capasso et al
(2011) who showed 10µM HC-030031 to be ineffective at blocking MO
induced contraction of the murine intestine in an organ bath, but that higher
concentrations of antagonist are anti-spasmodic, inhibiting contraction to
acetylcholine.
The contractile abilities of mesenteric vessels from the different strain
backgrounds I have used in this chapter was also characterised, in a similar
manner to that previous described for TRPA1 WT and KO mice. This is
presented in figure 4.10, where contractile responses to phenylephrine and
U46619 were indistinguishable in CD1, C57/BL6 and TRPA1 WT
mesenteric arteries. These findings suggest that strain is not a key factor
influencing the response to cinnamaldehyde, therefore CD1 vessels are
commonly used as WT vessels in further work for enhanced economic ease
and availability, along with vessels from genetically modified C57/BL6
mice. This allowed further investigation of mechanistic elements.
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Preliminary studies conducted in mesenteric arteries from CD1 mice
utilised another TRPA1 receptor antagonist, TCS5861528, which is an
analogue of HC-030031, but reportedly with increased solubility.
Similarly to HC-030031, a representative trace of the raw data is shown in
appendix figure 6. A concentration of 30µM shows no significant effect
on cinnamaldehyde induced vasorelaxation in vessels without functional
endothelium (figure 4.11).  This concentration has previously been shown
to completely inhibit inward current from rat TRPA1 expressed in HEK
cells (Wei et al., 2010).    In this chapter, TCS5861528 has previously been
shown to inhibit topical cinnamaldehyde induced vasodilation (figure 4.5)
suggesting it does block TRPA1 responses at higher concentrations. For
both antagonists, higher concentrations of antagonist were attempted but
were found unsuitable due to solubility problems.  Therefore, although
vessels from our TRPA1 KO mice suggest partial dependence of
cinnamaldehyde induced vasoreactivity on TRPA1 activity, these findings
cannot be confirmed using the selected TRPA1 antagonists.
Summary 1; The TRPA1 Component In Cinnamaldehyde
Induced Vasorelaxation.
 Cinnamaldehyde causes concentration dependent vasorelaxation of
mouse mesenteric arteries.
 This occurs in both TRPA1 WT and KO vessels, with and without
functional endothelium.  However, in TRPA1 KO vessel there a
decrease in potency, shown by a significant increase in EC50. This
demonstrates a TRPA1 dependent component in the response.
 This response is relevant in vivo, where topical cinnamaldehyde
causes an increase in blood flow which is significantly reduced in
TRPA1 KO and mice pre-treated with a TRPA1 antagonist.
 TRPA1 WT and KO mice do not differ in their ability to produce
contractile tone. Additionally, contractile abilities do not differ
between TRPA1 WT, CD1 or C57/BL6 mesenteric vessels.
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 MO causes concentration dependent vasoconstriction of mesenteric
arteries; a response which did not show TRPA1 dependence.
 TRPA1 antagonists are unable to alter the cinnamaldehyde response
at a range of concentrations, up to a level where they interfere with
tissue contraction. This occurs similarly in CD1, C57/BL6 and
TRPA1 WT arteries.
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Figure 4.6 The Effect Of MO On Vascular Tone Of TRPA1 WT
And KO Mesenteric Arteries. Results show vessels mounted on a wire
myograph, pre-constricted to U46619 (10nM, 5 minutes). The effect of
single concentrations of MO are shown (MO, 3-30μM) and % change in
tension at 5 minutes measured.  Endothelium function is assessed by %
response to carbachol (10μM) added for 2 minutes.  Average relaxation is
shown, for vessels with functional endothelium (+) and without (-). Graph
shows mixed gender mice. Statistics are from a one way ANOVA with
Bonferroni’s post test, comparing vessels with and without endothelium
from the same genotype.  ***p<0.001.  N numbers are as indicated.  No
significant differences are seen in a two way ANOVA.


































Figure 4.7 The Effect Of Cinnamaldehyde On Vascular Tone In
CD1 Mouse Mesenteric Arteries, With And Without Functional
Endothelium And Addition Of The TRPA1 Antagonist HC-
030031. Results show vessels on a wire myograph, pre-constricted to
U46619 (10nM, 5 minutes). The effect of cumulative concentrations of
cinnamaldehyde are shown (CA, 3-300μM in ethanol), using % change in
tension at 3 minutes.  HC-030031 (HC, 10 or 30μM in DMSO vehicle), a
TRPA1 receptor antagonist, was added to the bath 15 minutes before pre-
constriction. Graph shows mixed gender mice. A. Vessels with functional
endothelium (+endo) B and without (-endo). C. Combined. N numbers are

































Figure 4.8 The Effect Of Cinnamaldehyde On Vascular Tone In
CD1 And C57/BL6 Mouse Mesenteric Arteries Without
Functional Endothelium, With And Without Addition Of
Increasing Concentrations Of The TRPA1 Antagonist HC-
030031. Results show vessels from CD1 (A) or C57/BL6 (B) mice on a
wire myograph, pre-constricted to U46619 (10nM, 5 minutes). The effect
of cumulative concentrations of cinnamaldehyde are shown (CA, 3-300 or
1000μM in ethanol) as % change in tension at 3 minutes.  HC-030031 (HC,
10, 30, 50 or 100μM in DMSO vehicle), a TRPA1 receptor antagonist, was
added to the bath 15 minutes before pre-constriction. Graph shows mixed
gender mice. N numbers are as indicated.
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Figure 4.9 The Effect Of Cinnamaldehyde On Vascular Tone In
TRPA1 WT Mouse Mesenteric Arteries Without Functional
Endothelium, With And Without Addition Of The TRPA1
Antagonist HC-030031. Results show vessels from TRPA1 WT mice on
a wire myograph, pre-constricted to U46619 (10nM, 5 minutes). The effect
of cumulative concentrations of cinnamaldehyde are shown (CA, 3-
1000μM in ethanol), using raw tension (A) or % change in tension at 3
minutes (B).  HC-030031 (HC, 10 or 30μM in 0.05% DMSO vehicle), a
TRPA1 receptor antagonist, was added to the bath 15 minutes before pre-
constriction. Graph shows mixed gender mice. N numbers are as indicated.
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Figure 4.10 The contractile ability of mesenteric arteries from
TRPA1 WT, CD1 and C57/BL6 mice in response to
phenylephrine and U46619. Results show vessels without functional
endothelium, pre-constricted with cumulative concentrations of
phenylephrine (0.03-30µM A) or U46619 (0.1-300nM B) at 3 minute
intervals.   Data shown as a % of the maximal tension recorded in response
to 3, 2 minute challenges with 80mM K+ Krebs. Graph shows pooled data
from male and female paired mice. Statistically, potency of phenylephrine
and U46619 are not different in TRPA1 WT and KO vessels.
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Figure 4.11 The Effect Of Cinnamaldehyde On Vascular Tone In
CD1 Mouse Mesenteric Arteries Without Functional
Endothelium, With And Without Addition Of The TRPA1
Antagonist TCS5861528. Results show vessels on a wire myograph,
pre-constricted to U46619 (10nM, 5 minutes). The effect of cumulative
concentrations of cinnamaldehyde are shown (CA, 3-300μM in ethanol)
using % relaxation at 3 minutes. TCS5861528 (30μM in DMSO vehicle
(TCS 30)), a TRPA1 receptor antagonist, was added to the bath 15 minutes
before pre-constriction. Graph shows equal numbers of mixed gender mice.










Investigating the effect of TRPA1 antagonist HC-030031 in
rodent tissues
In this chapter I have shown cinnamaldehyde to cause concentration
dependent relaxation of murine mesenteric arteries, in a manner that is
significantly inhibited by genetic deletion of TRPA1 but not by addition of
the TRPA1 antagonist HC-033031, or structurally related antagonist
TCS5861528. I have also shown that cinnamaldehyde induces vasodilation
in vivo, which can be significantly inhibited by TCS5861528. Several other
studies have utilised HC-030031 to investigate the role of TRPA1 in
isolated tissues, although none have demonstrated activity in wire
myograph or on the mouse mesenteric artery. A summary of previous
findings using HC-030031 in isolated tissues is shown in table 4.1. To
investigate the activity of HC-030031 in whole tissue preparations in the
wire myograph, several of the tissues used in this table were revisited.
The rodent airway has been used in several studies investigating TRPA1
function. Zhou et al (2011) and Yu and Ouyang (2008) used preparations
of rat and guinea pig respiratory system in an organ bath.  In both studies,
neurones expressing TRPA1 were isolated from the tissue for the direct
recording of neural activity.  Neural responses to TRPA1 agonists could be
inhibited by pre-incubation with HC-030031 at a concentration of 30µM
and 10µM respectively.  In another study, isolated bronchial rings from
guinea pigs were maintained in an organ bath and contracted in response to
the TRPA1 agonist’s acreolin, crotonaldehyde, cinnamaldehyde (30µM)
and those within cigarette smoke (Andre et al., 2008).  These responses
were significantly inhibited by 50µM HC-030031.  Contraction and
relaxation of murine bronchi rings can be measured in the wire myograph
and this formed the basis of the first preliminary investigation. Bronchi
rings (2mm thickness) from one CD1 mouse were mounted on the wire
myograph and held under approximately 2mN tension. The protocol was
similar to that described by Manzini (1992) to investigate capsaicin
induced relaxation of murine bronchi rings and the protocol was devised in
collaboration with Dr Dom Spina. Rings contracted in response to 1µM
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carbachol and relaxed to further addition of 1µM SP, an indication of the
presence of the NK1 receptor on the epithelium.  This was later confirmed
by use of an NK1 receptor antagonist. After initial concentration response
trials, 60µM cinnamaldehyde was chosen as a concentration producing
submaximal relaxation of bronchi rings from carbachol pre-constriction
(average 5.71 mN following 5 minute pre-constriction, dropping to
4.69mN after 3 minute cinnamaldehyde application). This is in contrast to
the contraction response to 30µM cinnamaldehyde seen by Andre et al
(2008) in isolated guinea pig bronchi rings. Upon further addition of SP
(1µM), tension returned to baseline (average of 1.64mN).  To investigate
the role of TRPA1 in this response, bronchi were incubated with 50 and
100µM HC-030031 for 15 minutes before pre-constriction.  This did not
significantly influence the relaxation to cinnamaldehyde (figure 4.12) or
later applied SP. The effect of the structurally distinct TRPA1 antagonist
AP-18 (100µM) was also investigated in similar manner, however it failed
to inhibit the response to cinnamaldehyde and SP, despite this
concentration being identical to that recently used to inhibit TRPA1
dependent insulin secretion from whole pancreatic islets (Cao et al, 2012)
and ten times higher than that recently used in a recent study investigating
TRPA1 activities in the mouse airway (Nassini et al., 2012).
Representative traces of the raw data can be found in appendix figure 7.
Inability to block cinnamaldehyde induced vasorelaxation of the murine
airway with TRPA1 antagonists indicates that TRPA1 may not be involved
in the response. I also present preliminary data investigating the role of SP
in cinnamaldehyde induced bronchi relaxation, as this is likely to represent
a neuropeptide mediating relaxation following sensory neuron activation.
Application of SR140333, a NK1 antagonist, blocked the relaxation
response to both cinnamaldehyde and exogenous SP.  This data is included
in figure 4.12 and in representative traces of the raw data in appendix
figure 8. This concentration of NK1 antagonist was previously used by
Taylor-Clark et al (2008) to block substance P dependent contraction of the
guinea pig bronchus in response to TRPA1 activation by 4-ONE.
Together, this data presents a complex picture where SP appears to be
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mediating the cinnamaldehyde response in the airway, suggesting a
neurogenic mechanism, but where the role of TRPA1 cannot be confirmed
by blockade using either HC-030031 or AP-18.
Preliminary findings suggested that bronchi rings would not yield a
positive confirmation of HC-030031 antagonist ability. Further studies
moved to a new tissue; namely the cerebral artery. Due to the size of this
vessel, this could not be conducted using mice, therefore arteries were
collected from albino Wistar rats. Earley et al (2009) have previously
shown rat cerebral arteries to dilate in response to MO in the pressure
myograph; a response which is blocked by just 3µM HC-030031.
Therefore I attempted to reproduce this data in the wire myograph. Figure
4.13 shows the contractile ability of cerebral arteries challenged with
cumulative concentrations of U46619 (0.1nM-1µM, additions every 2
minutes) or phenylephrine (0.03nM – 0.1µM additions every 2 minutes).
Cerebral arteries contracted in response to U46619 with an EC50 of 1.7µM
when calculated from raw tension data and 40.5nM when data is
normalised to maximal response to high potassium depolarisation.
Cerebral arteries were insensitive to phenylephrine. Representative traces
of a cerebral artery cumulative concentration curve to U46619 are shown in
appendix figure 9. Subsequently, 30nM U46619 (5 minutes) was used as a
pre-constriction agent to investigate the effect of TRPA1 agonists.  This
concentration produced consistent and clear sub-maximal contractions
which can be seen in the raw data trace in appendix figure 10, also showing
the cumulative concentration curve in response to cinnamaldehyde (3-
300µM, A). Results from the complete data-set are presented in figure
4.14., which also shows the observed relaxation response to MO (1-30µM,
B).  Both of these plots would benefit from further extension of the
concentration response curve, but clearly demonstrate a concentration
related relaxation response to TRPA1 agonists can be achieved in the rat
cerebral artery.  To investigate the TRPA1 dependency of this response, a
single application of 300µM cinnamaldehyde was given following U46619
pre-constriction, producing an average relaxation of 80% over 3 minutes.
Pre-treatment of the same vessels with HC-030031 (10µM, 15 minutes
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before pre-constriction), at a concentration three times that used to block
MO-induced vasodilation in the cerebral artery by Earley et al (2009), did
not significantly alter this response (88% relaxation from pre-constriction).
Addition of vehicle (0.05% DMSO in Krebs) in place of HC-030031 and
vehicle (5ul ethanol) in place of cinnamaldehyde resulted in an average
constriction over 3 minutes of 8%. A representative trace of the raw data
can be seen in appendix figure 11. Therefore I conclude that HC-030031 is
ineffective at blocking cinnamaldehyde induced vasorelaxation in rat
cerebral arteries.
Nassini et al (2011) have recently described MO-induced vasorelaxation of
guinea pig pulmonary arteries, which can be blocked with HC-030031
(10µM) or the CGRP receptor antagonist BIBN 4096 BS (BIBN) (10µM).
Using a similar approach to that used for cerebral arteries, I investigated
cinnamaldehyde induced vasorelaxation of rat pulmonary arteries.  Figure
4.15 shows contraction of arterial rings to cumulative concentrations of
U46619 (0.1nM-0.3µM) and phenylephrine (0.03-10nM), as previously
described for cerebral arteries. Concentration dependent contraction to both
stimuli was observed, however the response to phenylephrine was biphasic,
with contraction turning to dilation at higher concentrations. U46619
application produced consistent contractions, with an EC50 of 47nM based
on raw tension data and 46nM when tension is normalised to maximal
depolarisation induced contraction. 100nM was selected as an appropriate
concentration for pre-constriction, producing clear and consistent sub-
maximal tension over 5 minutes. Representative tension traces showing
cumulative concentration curves to U46619 in pulmonary arteries is
presented in appendix figure 12. Cumulative concentration response
curves to cinnamaldehyde (10-300µM) and MO (1-100µM) were
conducted from U46619 pre-constriction. As shown in figure 4.16 A and
B, concentration dependent relaxation was seen in response to
cinnamaldehyde, however MO produced an incremental contraction on top
of pre-constriction tone.   Representative raw data traces of the dose
dependent response to cinnamaldehyde can be seen in appendix figure 13.
Similar to experiments previously presented in the cerebral artery, a single
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cinnamaldehyde concentration was used to test the ability of HC-030031
(10µM) to inhibit the relaxation response to cinnamaldehyde.  300µM
cinnamaldehyde produced an average vasorelaxation from U46619 pre-
constriction of 72%.  Following pre-treatment with HC-030031, at the
concentration shown by Nassini et al (2011) to inhibit MO induced
relaxation (10µM), a similar average relaxation was seen (74%). This
demonstrates that HC-030031 does not inhibit cinnamaldehyde induced
relaxation in the pulmonary artery (panel C).  Additions of vehicle in place
of HC-030031 (0.05% DMSO in Krebs) and in place of cinnamaldehyde
(5ul ethanol), resulted in an average contraction of 9% over 3 minutes.  A
representative trace of the raw data can be seen in appendix figure 14.
Andrade et al (2011) have recently shown contraction in rat bladder strips
treated with cinnamaldehyde. Contraction induced by 300µM
cinnamaldehyde could be blocked with 60 and 100µM HC-030031,
suggesting a TRPA1 dependent mechanism.  Therefore I attempted to
demonstrate the antagonistic ability of HC-030031 against cinnamaldehyde
actions in the mouse bladder, using rings of tissue mounted in the wire
myograph. Clear contraction was produced in response to 1µM carbachol,
but no response was seen upon application of up to 600µM
cinnamaldehyde.  Tension in response to carbachol was not maintained
sufficiently enough to study any potential relaxation effects of
cinnamaldehyde.  Therefore this data is not included.
My previously presented findings show cinnamaldehyde induced
vasorelaxation of the mouse mesenteric artery to be slightly but
significantly reduced in TRPA1 KO mice. No differences in the contractile
ability of TRPA1 WT and KO mesenteric were found, suggesting a role for
TRPA1 in this vasodilative response. I then attempted to confirm these
findings using pharmacological antagonists of the TRPA1 receptor. HC-
030031 is the most commonly used TRPA1 agonist to date, often used in
isolated cell and neurone studies.  HC-030031 was ineffective at reducing
the relaxation response induced by cinnamaldehyde at several
concentrations, in WT mesenteric arteries from several strains.  This was
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also the case for the related antagonist TCS5861528. Several attempts
were made to ascertain if HC-030031 could block cinnamaldehyde
responses in isolated tissues mounted in the wire myograph, which is
important as a positive control. As described in Table 4.1, several tissues
have been used to study TRPA1 and utilised HC-030031. In the rodent
bronchi, cerebral artery and pulmonary artery I was able to demonstrate
cinnamaldehyde induced relaxation responses.  However none of these
responses were affected by HC-030031 at concentrations similar and above
those used in similar published studies. My findings are summarised in
summary 2.  It is hard to conclude whether this data demonstrates a lack of
function of this antagonist in the wire myograph preparation, or if the
response in not mediated by TRPA1. Several extensions to this data are
possible, including collection of full cinnamaldehyde concentration
response curves under a range of HC-030031 concentrations and the testing
of HC-030031’s ability to block other TRPA1 agonist responses in these
tissues. Despite this, several lines of evidence suggest that the mechanism
of cinnamaldehyde induced relaxation may be sensory neurone and TRPA1
mediated, and there is little evidence to eliminate this option.  The
remainder of this chapter discusses the investigation of the mechanism
driving cinnamaldehyde induced vasorelaxation of the mouse mesenteric
artery.
Summary 2; Investigating the effect of TRPA1 antagonist HC-
030031 in rodent tissues
 Cinnamaldehyde causes relaxation responses in rodent bronchi
rings, cerebral arteries and pulmonary arteries.
 In murine bronchi this response is not affected by the TRPA1
antagonists HC-030031 or AP-18, but is almost abolished by NK1
antagonism, suggesting a SP mediated mechanism.
 HC-030031 also does not alter this response in rat cerebral and
pulmonary arteries. Rat cerebral arteries also relax in response to
MO.
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 A positive confirmation of HC-030031 activity in the wire
myography tissue mount was not obtained.  This does not allow us
to conclude if our previous results suggest a lack of TRPA1 activity
















segments in an organ bath.
No reduction in tissue contraction to mustard oil
(10-4-10-7M).  They find that higher concentrations
of HC-030031 are antispasmodic, inhibiting








Isolated lung and bronchi in an
organ bath, with vagal nerve trunk
isolated and activity of fine branches
recorded by suction electrode.
Inhibition of cinnamaldehyde (1mM) induced
afferent vagal nerve activity.  No reduction in cold










Contraction of bladder strips (10mm
by 4mm) from sham mice or
following spinal cord injury in an
organ bath.
Estimated IC50 values against cinnamaldehyde
(300µM) was 46.3µM in sham treated mice and
31.2µM in bladder strips following spinal cord
injury.  In sham mice, only 60 and 100µM HC-









Measured secretory responses to









Mounted in a pressure myograph. Luminally applied HC-030031 significantly inhibits









Vagal nerves (Jugular and nodose)
are isolated within tissue maintained
in an organ bath.  Neural activity is
recorded during oesophageal
pressure distension.












Measurement of bronchial ring
(2mm) contractions in an organ
bath.
HC-030031 significantly inhibits contraction to
cigarette smoke extract, crotonaldehyde,






Measurement of arterial contraction
in an organ bath
HC-030031, BIBN and capsaicin desensitisation
significantly reduces arterial relaxation in
response to MO (10µM).
Table 4.1 The use of HC-030031 as a TRPA1 antagonist in isolated tissue studies. Describing the concentration, solvent, tissue
and species, experimental set-up and findings from a range of published studies using the TRPA1 antagonist HC-030031.
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Figure 4.12 The Effect Of Cinnamaldehyde On CD1 Mouse
Bronchi Rings Arteries Treated with TRPA1 Or SP Antagonists.
Results show using % relaxation at 3 minutes of bronchi mounted on a wire
myograph, pre-constricted to carbachol (1µM, 5 minutes). The effect of
60µM cinnamaldehyde (CA in 5µl ethanol) is shown in the open bar, with
shaded bars showing the effect of 15 minute pre-treatment with HC-
030031 (50 or 100µM in 0.05% DMSO in Krebs), AP-18 (100µM in 5ul
DMSO) or SR140333 (1µM in 0.01% BSA in water). Graph shows
bronchi with intact epithelium from one male mouse, N for bronchi rings is
3 for CA alone, plus pretreatments of AP-18 and SR140333.  N is two
rings for other treatments. As N is low and from one animal only, SEM is
indicative of variation only.
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Figure 4.13 The Contractile Response Of Rat Cerebral Arteries
To U46619 And Phenylephrine. Results show raw tension
measurements (A/B) and tension as a % of maximal response to Krebs
containing 80mM potassium (C/D) in response to U46619 (0.1nM-1µM in
water A/C) and phenylephrine (0.03nM-0.1µM in water B/D).  Cumulative
concentration curves were constructed with additions every 2 minutes to
segments of rat cerebral artery mounted on a wire myograph. Graph shows





Figure 4.14 The Effect of TRPA1 Agonists On Rat Cerebral
Arteries With and Without Treatment With TRPA1 Antagonists.
Results show % relaxation from U46619 (30nM, 5 minutes) pre-
constriction of rat cerebral arteries subject to cumulative concentration
additions of cinnamaldehyde (CA 3-300µM every 3 minutes, A) or MO (1-
30µM every 3 minutes, B). The effect of a single concentration of
cinnamaldehyde (300µM in 5ul ethanol) or vehicle following pre-
constriction is shown in C, where 15 minute pre-treatment with HC-030031
(10µM in 0.05% DMSO in Krebs) does not affect % relaxation. Graph
shows a total of 4 rats with 7 vessels in A, 1 in B and 7 in each bar in C, all




Figure 4.15 The Contractile Response Of Rat Pulmonary
Arteries To U46619 And Phenylephrine. Results show raw tension
measurements (A/B) and tension as a % of maximal response to Krebs
containing 80mM potassium (C/D) in response to U46619 (0.1nM-0.3µM
in water A/C) and phenylephrine (0.03nM-10nM in water B/D).
Cumulative concentration curves were constructed with additions every 2
minutes to segments of rat pulmonary artery mounted on a wire myograph.
Graph shows a total of 4 rats with 12 vessels in A, 3 in B, 9 in C and 3 in
D, with and without intact endothelium.
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Figure 4.16 The Effect of TRPA1 Agonists On Rat Pulmonary
Arteries With and Without Treatment With TRPA1 Antagonists.
Results show % relaxation from U46619 (100nM, 5 minutes) pre-
constriction of rat pulmonary arteries subject to cumulative concentration
additions of cinnamaldehyde (CA 10-300µM every 3 minutes, A) or MO
(1-100µM every 3 minutes, B). The effect of a single concentration of
cinnamaldehyde (300µM in 5ul ethanol) or vehicle following pre-
constriction is shown in C, where 15 minute pre-treatment with HC-030031
(10µM in 0.05% DMSO in Krebs) does not affect % relaxation. Graph
shows a total of 4 rats with 6 vessels in A, 3 in B and 7-8 in each bar in C,




Figure 4.17 The Effect Of SP On Vascular Tone In CD1 Mouse
Mesenteric Arteries. Results show vessels mounted on a wire
myograph, pre-constricted to U46619 (10nM, 5 minutes). The effects of
cumulative concentrations of substance P are shown (10-1000nM in 0.01%
BSA in water) using % relaxation at 3 minutes.  Time controls show
natural relaxation of the tissue over the same time of pre-constriction.
Graph shows mixed gender mice. N numbers are as indicated. Not









Figure 4.18 The Effect Of Cinnamaldehyde And αCGRP On
Vascular Tone Of αCGRP WT And KO Mesenteric Arteries.
Results show endothelial intact vessels mounted on a wire myograph, pre-
constricted to U46619 (10nM, 5 minutes). A) The effect of cumulative
concentrations of cinnamaldehyde (CA, 3-300μM in ethanol) or B)
cumulative concentrations of αCGRP (1-30nM), measured as % relaxation
at 3 minutes is shown. Graph shows female vessels with functional
endothelium. Statistics are from two way ANOVA with Bonferroni’s post
test. *p<0.05, ****p<0.0001 WT+ compared to KO+. EC50 shown for
cinnamaldehyde only, statistics are from a two-way unpaired t-test,











Investigating The Mechanism Of Cinnamaldehyde Induced
Vasorelaxation
Several investigations of TRPA1 agonist induced vasorelaxation have
demonstrated C-fibre and neuropeptide involvement.  Therefore I
examined the contribution of the neuropeptides substance P and CGRP to
the cinnamaldehyde vasorelaxation response. Figure 4.17, shows
cumulative concentration response curves to substance P (1-1000nM), in
CD1 WT mice, with and without functional endothelium.  CD1 mice were
used in these experiments as a substitute for TRPA1 WT mice, which were
the ideal choice but not available at the time these studies were conducted.
CD1 mice have a different genetic background to that of TRPA1 WT and
KO mice, but show similar responses to contractile agents and
cinnamaldehyde application, suggesting that the effect of TRPA1
activation may be similar.  Time control relaxation from pre-constriction is
also shown.  Representative traces of raw data collected from cumulative
concentration response curves to CGRP and SP, in vessels without
functional endothelium, are shown in appendix figure 15.  The
concentration range was similar to that used by Ahluwalia and Vallance
(1997), who constricted rat mesenteric veins to 1-10000nM substance P.  In
my model, substance P treated vessels relaxed to a maximum of about 30%
from pre-constriction.  This is in line with that of the natural relaxation of
the tissue over time and shows no significant differences from time
controls.  These differences suggest that substance P does not relax small
diameter mesenteric arteries of the mouse. A similar lack of effect was seen
by Berthiaume et al (1997), who saw no effect of 0.5nM substance P
applied to the mouse mesenteric circuit (arteries and veins) pre-constricted
with U46619.
CGRP is one of the most potent microvasculature vasodilators identified to
date (Brain and Grant, 2004).  It is released from sensory neurones and is
implicated in TRPA1 induced vasodilation through studies that use a range
of agonists, as discussed previously.  Here, I used αCGRP KO mice to
investigate its contribution to cinnamaldehyde induced vasorelaxation
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(Figure 4.18). These mice have a C57/BL6 background, something
partially shared with TRPA1 WT and KO mice, and display identical
pharmacological responses to contractile agents. Cinnamaldehyde caused a
concentration dependent relaxation of both αCGRP WT and KO arteries
(Figure 4.18A). Cinnamaldehyde displayed significantly decreased
potency in αCGRP KO vessels, shown by a significantly increased EC50.
Additionally, there was significantly less relaxation of U46619 pre-
constricted vessels to 10μM cinnamaldehyde where αCGRP was deleted.
Therefore, this suggests that αCGRP plays an important role in
cinnamaldehyde induced vasorelaxation.  I additionally investigated the
ability of αCGRP to relax pre-constricted αCGRP WT and KO mesenteric
arteries.  I found vessels from both genotypes to be very sensitive to
αCGRP; however αCGRP KO arteries were significantly more reactive to
1nM αCGRP than αCGRP WT vessels.  This is expected from previous
studies using αCGRP KO mice, showing them to be more responsive to
exogenously applied αCGRP than αCGRP WT mice (Gangula et al., 2000).
This is likely to be via an increase in receptor mediated sensitivity when
endogenous αCGRP is removed (Smillie and Brain, 2011).  Representative
traces of raw data collected from CGRP WT and KO mesenteric arteries
treated with cumulative concentrations of cinnamaldehyde and αCGRP are
shown in appendix figure 16.
I aimed to confirm my findings using CGRP8-37, a peptide antagonist of the
CGRP receptor.  A range of concentrations are used in studies that involve
mesenteric vessels (generally ranging from 1µM to 10μM).  However, this
compound is expensive and thus I aimed to find the lowest effective
concentration.  I have characterised my chosen concentration.  In figure
4.19 I illustrate the effect of CGRP8-37 (3μM), on αCGRP cumulative
concentration response curves (1-100nM).  This concentration of
antagonist is well within its expected activity range as seen in other
publications. Similarly, αCGRP is a potent vasodilator and has previously
been used at these concentrations and below, to relax mesenteric arteries in
a wire myograph (Meens et al., 2009).   Panel A and B, shows that αCGRP
causes a concentration dependent vasorelaxation in vessels with and
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without functional endothelium. In both cases, the concentration response
curve is shifted to the right on pre-incubation with 3μM CGRP8-37, which is
significant in places, indicating decreased αCGRP potency (For EC50, see
later).  This confirms that the antagonist is effective.  When all of the data
is overlaid in panel C, vehicle treated vessels with and without functional
endothelial cells showed comparable reductions in αCGRP mediated
relaxation.  However, in both groups, addition of the CGRP receptor
antagonist causes a statistically significant reduction in αCGRP induced
relaxation. The EC50 for αCGRP on each animals’ mesenteric arteries are
calculated, in the presence and absence of CGRP8-37.  The results of this are
shown in more detail in figure 4.20.  Reflecting conclusions from the
concentration response curves, the potency of αCGRP on vessels with and
without functional endothelium is similar.  Incubation with CGRP8-37
increases the EC50 in both groups, however the increase is only significant
in vessels with functioning endothelium suggesting that the endothelium
may play a role in αCGRP induced vasorelaxation.  Endothelium
dependent and independent vasodilatory roles of CGRP have been shown
in the literature (Brain and Grant, 2004).
Having established an effective concentration of peptide CGRP receptor
antagonist, I used it to further investigate the involvement of CGRP in the
cinnamaldehyde response.  The concentration chosen was effective at a
range of tissue relevant concentrations of exogenous αCGRP, thus I was
confident it would be appropriate for antagonism of stimulus released
endogenous αCGRP.  Figure 4.21 shows cumulative cinnamaldehyde
concentration response curves in CD1 TRPA1 WT vessels, with and
without functional endothelium and with and without application of peptide
CGRP receptor antagonist.  Results show no significant changes in
cinnamaldehyde responses with addition of the peptide CGRP antagonist.
Representative traces of the raw data are shown in appendix figure 17.
Panel A shows the antagonistic effect of CGRP8-37 on the cumulative
concentration response to αCGRP, whereas panel B shows no effect of
CGRP8-37 on the cumulative concentration response to cinnamaldehyde.
These findings conflict with data from αCGRP KO mice and may represent
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an inability for this concentration of CGRP8-37 to effectively access and
block the CGRP receptor in these tissues.  Despite efforts to validate this
concentration of CGRP8-37, higher concentrations may be needed to be to
block the endogenously released CGRP. Again, there was a small and non
significant decrease in relaxation to cinnamaldehyde was seen when
endothelium was removed.
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Figure 4.19 The Effect Of Peptide CGRP Receptor Antagonist
On αCGRP Induced Vasorelaxation Of CD1 Mouse Mesenteric
Arteries With And Without Functional Endothelium. Results show
vessels on a wire myograph, pre-constricted to U46619 (10nM, 5 minutes).
The effect of cumulative concentrations of αCGRP are shown (1-100nM)
as % change in tension at 3 minutes.  CGRP8-37 (3μM), a CGRP receptor
antagonist, was added to the bath 15 minutes before pre-constriction.
Graph shows mixed gender mice. A. Without functional endothelium N=12
for points 1-30nM, N=5-9 100nM. Statistics are from two way ANOVA
with Bonferroni’s post test, **p<0.01, *p<0.05 comparing CGRP8-37 and
vehicle. B. With functional endothelium N=13-15 for 1-30nM, N=5-9 for




















Figure 4.20 Potency Of αCGRP Induced Vasorelaxation In CD1
Mouse Mesenteric Arteries, With And Without Functional
Endothelium And With And Without Addition Of Peptide CGRP
Receptor Antagonist. Results show vessels on a wire myograph, pre-
constricted to U46619 (10nM, 5 minutes). EC50 calculated from αCGRP
cumulative concentration response, as seen in previous figures. CGRP8-37
(3μM), a CGRP receptor antagonist, was added to the bath 15 minutes
before pre-constriction.  Graph shows mixed gender mice. N=11-12.
Statistics are from one way ANOVA with Bonferroni’s post test.  **p<0.01






















Figure 4.21 The Effect Of Cinnamaldehyde Induced
Vasorelaxation In CD1 Mouse Mesenteric Arteries, With And
Without Addition Of Peptide CGRP Receptor Antagonist. Results
show vessels mounted on a wire myograph and pre-constricted to U46619
(10nM for 5 minutes). The effect of cumulative concentrations of
cinnamaldehyde are shown (CA, 3-300μM in ethanol) using % change in
tension at 3 minutes.  CGRP8-37 (3μM in 0.01% BSA in water) a CGRP
receptor antagonist, is added to the bath 15 minutes before pre-constriction.
A)  Vessels with functional endothelium (+endo) B) Vessels without
functional endothelium (-endo), C) combined data. Graph shows mixed
gender mice. N numbers are as indicated.  No significant differences in a
two way ANOVA.
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The previously presented data using αCGRP KO mice suggested a CGRP
component was present in the vasorelaxation model.  This was not
supported by the use of the peptide CGRP receptor antagonist CGRP8-37.
To clarify the findings, I used another CGRP receptor antagonist BIBN.
This is a well characterised non-peptide antagonist, developed by
Boehringer for use in migraine and first characterised by Doods et al
(2000).  This molecular antagonist is more stable and 200x more potent
than CGRP8-37 at the human CGRP receptor, being 150x less potent at the
rat CGRP receptor (Doods et al., 2000, Verheggen et al., 2002). I used a
concentration of 10μM, as this has been previously used effectively in
mouse aortic ring relaxation within this group, where it blocked the action
of up to 10nM αCGRP (Grant et al., 2004). Use of multiple concentrations
of this antagonist would have been preferable in this study, however this
drug is not commercial available and the company is not currently
providing it for academic studies.  Therefore, I chose a concentration of
this compound previously validated in our laboratory. At this
concentration, the slow kinetics of the antagonist mean that receptor block
is almost insurmountable, resembling that of a non-competitive antagonist
(Hay and Poyner, 2005).  In figure 4.22, BIBN is shown to significantly
inhibit cinnamaldehyde induced vasorelaxation in vessels with functional
endothelium. Representative raw data traces showing cumulative
concentrations curves to cinnamaldehyde in the presence of BIBN or its
vehicle, are shown in appendix figure 18.
The data collected using BIBN and vessels from αCGRP KO mice suggest
a strong involvement of CGRP in the cinnamaldehyde response.  This
conflicts with data using the peptide antagonist CGRP8-37 , likely due to the
concentration selected only producing a small inhibition of endogenous
CGRP vasorelaxation. The effect of BIBN seems to be more pronounced
than that observed in the αCGRP KO mice.  The reasons for this are not
clear, but may be related to the different mechanisms of CGRP antagonism.
In αCGRP KO mice, the αCGRP protein is lost, which may cause
compensation from other dilator peptides such as β-CGRP. αCGRP KO
mice were additionally shown to be more sensitive to CGRP receptor
176
agonism. Together, this data shows that the CGRP receptor and the
αCGRP protein are both involved in the vasorelaxation response to
cinnamaldehyde.
Recent investigations using MO and cinnamaldehyde have identified
hyperpolarisation of the vascular smooth muscle as a potential mechanism
of action (Earley et al., 2009)(See table 1.1). The results presented in this
chapter have shown cinnamaldehyde induced vasorelaxation ex vivo, to be
partially TRPA1 dependent and largely endothelial independent (Figure
4.1/4.3).  Data collected using αCGRP KO mice and the non peptide CGRP
receptor antagonist BIBN, have also suggested that there is a CGRP
mediated component to cinnamaldehyde induced vasorelaxation.  To
investigate the mechanism further, I used vessels without functional
endothelium pre-constricted with 30mM K+ Kreb’s. Normal Kreb’s has
only 4mM K+.  Increases in extracellular potassium can hyperpolarise
smooth muscle cells via several mechanisms.  At low levels such as 10mM,
increases in Na+/K+ and KIR channel activation cause hyperpolarisation of
the tissue due to increased K+ permeability, pushing the membrane
potential towards the K+ equilibrium potential, as described by the Nernst
equation.  At concentrations such as the 30mM used in my Krebs, there is a
diminished transmembrane K+ gradient, along with additional Na+/K+ and
KIR channel activation, increasing the resting potential and causing a small
amount of depolarisation of the membrane, whilst blocking further K+
efflux and hyperpolarisation.  Therefore, pre-constriction using 30mM K+
Kreb’s is often used as a method of pre-constriction which can also
determine if a dilatory response is being mediated by hyperpolarisation.
Depolarisation by increasing extracellular K+ has previously been used in
the priming stages of the experiment, where I use an 80mM K+ Kreb’s
solution to fully depolarise the tissue and gain an understanding of the
maximum constriction that can be achieved for each vessel.  This
concentration greatly reduces the potassium gradient across the membrane
and opens KIR channels by releasing their rectification, allowing the
membrane potential to depolarise to the new resting membrane potential
which is much more positive than that in normal extracellular conditions,
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which increases the opening probability of voltage operated sodium
channels. Resultant further depolarisation due to sodium entry will activate
voltage operated calcium channels, leading to calcium influx and tissue
contraction.   However, high levels of K+ such as 80mM, are damaging to
tissues over a period of more than a few minutes due to cell swelling and
the depletion of ATP by saturation of the sodium potassium exchanger.
Figure 4.23 shows that cumulative applications of cinnamaldehyde are
unable to fully relax vessels which are constricted with 30mM K+ Kreb’s.
This is likely to be due to the inability of the tissue to hyperpolarise,
therefore blocking cinnamaldehyde signalling and vasorelaxation via this
mechanism. The potency and efficacy of cinnamaldehyde is greatly
decreased in comparison to vessels in normal Kreb’s (see previous graphs),
with relaxation in 30mM K+ Kreb’s not reaching 50% even at the peak of
the concentration response curve.  However, these higher concentrations of
cinnamaldehyde, did significantly relax the vessels compared to that of the
time relaxed control.  This suggests that mechanisms other than
hyperpolarisation are also occurring in the cinnamaldehyde induced
vasorelaxation response.  Representative traces of the raw data in appendix
figure 19 show the cumulative concentration curve to cinnamaldehyde is
strongly inhibited during pre-constriction using 30nM K+.
TRPA1 is a non-selective cation channel, with a preference for calcium and
sodium permeation.  In rat mesenteric artery smooth muscle, the BKCa
channel is highly expressed (Hilgers et al., 2006) and activated by calcium
influx.  Therefore, calcium influx from the opened TRPA1 channel could
potentially activate BKCa channels in the mouse mesenteric artery, causing
vessel relaxation.  To investigate this as a potential link between TRPA1
and hyperpolarisation, vessels without functional endothelium were treated
with the BKCa channel blocker paxilline (1μM).  This concentration is
widely used and has been shown by Tammaro et al (2004) to greatly
reduce channel activity.  Figure 4.24 shows no significant shifts in the
cinnamaldehyde cumulative concentration response curve when vessels are
incubated with paxilline, compared to vehicle incubated control.  This
suggests TRPA1 is not causing vasorelaxation via a direct activation of
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receptors expressed on vascular smooth muscle cells. Representative raw
data traces showing the cumulative concentration response curve to
cinnamaldehyde in the presence of paxilline or its vehicle are shown in
appendix figure 20.
Summary 3; The Mechanism Of Cinnamaldehyde Induced
Vasorelaxation
 Cinnamaldehyde induced vasorelaxation was significantly reduced
in αCGRP KO vessels, along with those treated with the non-
peptide CGRP receptor antagonist BIBN.  However, it was not
affected by a concentration of the peptide CGRP antagonist CGRP8-
37 that reduced exogenous CGRP induced vasorelaxation.
 SP does not cause vasorelaxation of mesenteric arteries, therefore is
not involved in the cinnamaldehyde response.
 Blocking hyperpolarisation significantly blunts cinnamaldehyde
induced vasorelaxation, therefore is likely to be a key mediator.
However, this is not occurring via the BKCa channel, strengthening
conclusions of a CGRP and sensory neurone dependent mechanism.
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Figure 4.22; The Effect Of Cinnamaldehyde Induced
Vasorelaxation In CD1 Mouse Mesenteric Arteries, With And
Without Addition Of Non-Peptide CGRP Receptor Antagonist
Results show endothelial intact vessels mounted on a wire myograph, pre-
constricted to U46619 (10nM, 5 minutes). 10μM BIBN4096BS (BIBN)
was added 15 minutes before pre-constriction and cumulative
concentrations of cinnamaldehyde (CA, 3-300μM in ethanol). Graph shows
male mice. Statistics are from two-way ANOVA with Bonferroni’s post
test. **p<0.01, ***p<0.001 compared to DMSO control.  N numbers as
indicated.
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Figure 4.23 The Effect Of Cinnamaldehyde On The Vascular
Tone Of CD1 Mesenteric Arteries, Pre-constricted With 30mM
K+ Kreb’s. Results show vessels without functional endothelium mounted
on a wire myograph, pre-constricted to 30mM K+ Kreb’s for 3 minutes,
preventing hyperpolarisation of the smooth muscle. The effect of
cumulative concentrations of cinnamaldehyde are shown (CA, 3-300μM)
using % change in tension at 3 minutes. Time control line shows natural
relaxation of the tissue over the time of the pre-constriction.  Graph shows
data from mixed gender mice. Statistics are from two-way ANOVA with
Bonferroni’s post test. ****p<0.0001, **p<0.01, *p<0.05, comparing CA
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Figure 4.24 The Effect Of Cinnamaldehyde On Vascular Tone Of
CD1 Mesenteric Arteries, With And Without Antagonism Of The
BkCa Channel. Results show vessels without functional endothelium
mounted on a wire myograph, pre-constricted to U46619 (10nM, 5
minutes). Paxilline (BKCa channel antagonist, 1μM in DMSO) or vehicle
was added 15 minutes before pre-constriction. The effect of cumulative
concentrations of cinnamaldehyde are shown (CA, 3-300μM) as % change
in tension at 3 minutes. Graph shows data from mixed gender mice. N




In this chapter, I have demonstrated that the TRPA1 agonist
cinnamaldehyde, but not MO, causes concentration dependent
vasorelaxation of murine mesenteric arteries.  This was found to be largely
endothelial independent, thus vascular smooth muscle derived, with a
TRPA1 component defined by genetic but not pharmacological
interventions. I also show data demonstrating that the ability of mesenteric
arteries to constrict in the presence of the contractile agents phenylephrine
and U46619, is not affected by genetic TRPA1 deletion and is not
significantly altered in mice from different strain backgrounds. Data from
my colleague Aisah Aubdool was shown, demonstrating that this is dilation
is relevant in vivo at a peripheral site, where increases in blood flow
following topical application of cinnamaldehyde to the mouse ear were
reduced in mice pre-treated with TRPA1 antagonist and in TRPA1 KO
mice. I also show data from several rodent tissue types where inhibitory
activity of the TRPA1 antagonist HC-030031 against cinnamaldehyde
relaxation could not be demonstrated in the wire myograph. Investigations
into the underlying mechanism used CD1 WT mice with pharmacological
inhibitors and genetically altered C57/BL6 mice.  The results demonstrate
that there is no involvement of the neuropeptide SP, but that αCGRP
peptide, the CGRP receptor and hyperpolarisation of the smooth muscle are
all important parts of the vasodilation mechanism.  Together, the identified
mechanisms support a conclusion of cinnamaldehyde induced activation of
sensory neurones, causing CGRP release and hyperpolarisation of the
smooth muscle cells, leading to vasorelaxation.
Cinnamaldehyde Causes Concentration Dependent
Vasorelaxation Which Is Partially TRPA1 Mediated And Largely
Endothelium Independent.
Several published studies have investigated TRPA1 agonists for
vasoreactivity.  The most commonly used agonist are cinnamaldehyde and
MO, which induce relaxation and vasodilation. Methodology and findings
differ greatly among published papers (See table 1.1), suggesting that there
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are concentration and tissue specific effects.  While others have shown
dependence on TRPA1 using receptor antagonists (Earley et al., 2009,
Kunkler et al., 2011), we were the first to do this using vessels from
TRPA1 KO mice (Pozsgai et al., 2010). Data presented in this chapter has
shown that TRPA1 KO mouse vessels have reduced vasorelaxation
responses to cinnamaldehyde.  The tissue is still able to respond to
cinnamaldehyde but with reduced potency, suggesting the presence of
TRPA1 dependent and independent mechanisms.  The contribution of the
endothelium to this response was investigated using arteries without
functional endothelial responses.  These showed only a very small
reduction in relaxation in WT vessels, with slightly more in the KO
vessels, suggesting that the endothelium has only a minor role in the
TRPA1 mediated component of cinnamaldehyde induced vasorelaxation.
Indeed, the finding that endothelial loss has a significant effect on the EC50
only in KO mice, potentially suggests that the endothelium has taken on a
stronger relaxant role when TRPA1 is genetically deleted. This implies that
some compensatory changes may have occurred in the TRPA1 KO vessels.
Further investigation is warranted, as these compensations could impact on
our findings and others who use this mouse strain. This is particularly
important as the TRPA1 KO colony is maintained on a mixed strain
background, which may mean that results cannot be extrapolated easily to
other mouse strains. Compensatory changes in relaxation mechanisms are
common in many research settings and would not be unexpected if TRPA1
was part of a physiologically relevant dilation pathway.
In order to examine whether TRPA1 WT and KO mesenteric arteries
responded differently to contractile agents, their contraction in response to
phenylephrine, depolarising concentrations of potassium (via KCl
additions) and U46619 was characterised.  This was presented in terms of
raw vessel tension and also normalised to maximal tension produced in
response to a depolarising solution (80mM K+ Krebs). Phenylephrine and
KCl were used in addition to U46619, which is used commonly for pre-
constriction in this chapter, to demonstrate that our findings are not
stimulus specific. Phenylephrine is chosen as it mimics the in vivo setting,
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where sympathetic nervous activation plays a role in vascular tone via
receptor signalling.  Additions of KCl demonstrate the ability of
depolarisation to induce vascular contraction.  No significant differences
were seen in the contractile ability of mesenteric arteries from TRPA1 WT
or KO mice to any stimuli. These valuable findings suggest that
differences in contractile responses do not contribute towards the
significantly blunted vasodilation response to cinnamaldehyde in TRPA1
KO vessels. Additionally, data in this chapter shows that contractile
abilities to these stimuli does not differ between TRPA1 WT, CD1 and
C57/BL6 mouse mesenteric arteries, which is important where later studies
have utilised CD1 vessels for pharmacological studies and C57/BL6
vessels from genetically modified mice.
I further investigated cinnamaldehyde induced vasorelaxation using the
TRPA1 antagonists HC-030031 and TCS5861528.  These are related
antagonists, based on a common core structure.  TCS5861528 is a new
derivative of HC-030031, suggested to be more potent and soluble (Wei et
al., 2009).  However, neither of these antagonists were able to reduce
cinnamaldehyde induced vasorelaxation.  This data conflicts with my
findings from TRPA1 KO mice, suggesting that the receptor may not be
involved in the cinnamaldehyde response.  However, the in vivo studies by
Aisah Aubdool show TCS5861528 was able to reduce cinnamaldehyde
induced increases in blood flow in an in vivo situation. Significant efforts
were presented in this chapter to demonstrate the activity of TRPA1
antagonists in the wire myograph preparation.  This particularly focussed
on HC-030031 as it is the most commonly used TRPA1 antagonist,
however inhibition of cinnamaldehyde-induced relaxation could not be
achieved using several relevant antagonist concentrations in rodent
bronchi, cerebral artery and pulmonary artery. The bronchi did show
evidence of neurogenic activation as cinnamaldehyde induced relaxation
was almost abolished by a NK1 antagonist.  Further investigations of
TRPA1 antagonists could be made, using structurally different alternatives
or by investigating inhibition of responses induced by other TRPA1
agonists; MO responses for example.  However responses to MO were
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inconsistent in the rodent tissues studied, producing a mixture of relaxation
and contractile responses which do not align with those expected following
sensory neurone activation.  Therefore this study has concentrated on
cinnamaldehyde, which produces consistent relaxation responses in a range
of rodent tissues.  However, TRPA1 activity on non-neuronal cells and
TRPA1 independent actions of cinnamaldehyde are likely to also
contributing towards the observed relaxations, as shown by the remaining
relaxation response seen in TRPA1 KO mice.
The use of indomethacin and L-NAME as inhibitors of endothelial
mediated vasorelaxation was not utilised in this study.  These would be
potentially valuable additions to the investigation of TRPA1 WT and KO
vessel vasorelaxation as this would remove the main endothelial derived
mediators whilst leaving the myoendothelial gap junctions intact and
allowing electrical coupling.  However, there are also a number of
disadvantages with this approach.  For example, the use of these inhibitors
also removes the potential contribution of smooth muscle or sensory
neurone derived NO and COX products.  Also, retaining electrical coupling
of endothelial and smooth muscle cells does not allow us to completely
dissect the roles of the endothelium vs. the smooth muscle layer in the
vasodilating response. Although in this experiment I cannot prove that the
endothelial cell layer has been completely removed using carbachol
responses, I assume that endothelium removal has occurred as I have not
inhibited its action and vessels respond similarly to smooth muscle and
nerve stimuli, suggesting vessels are in good condition, while having lost
their responses to carbachol, an endothelial specific vasodilator.
My findings show only a small role for the endothelium in mediating
cinnamaldehyde induced vasorelaxation. This agrees with investigations
using rat aortic rings from Yanaga et al (2006), who show partial
endothelial dependence, and Xue et al (2011) who find no role for the
endothelium in the same model.  However, Earley et al (2009) have found
the MO induced dilation mechanism in rat cerebral arteries to be dependent
on TRPA1 mediated endothelial hyperpolarisation.  Mechanisms may
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therefore be location specific, with differences arising from vessel
components.  Species and regional differences in the reactivity of arteries
to both extracellular potassium and hyperosmolarity have been described,
particularly in relation to cerebral and mesenteric arteries (Ryman et al.,
1989).
Cinnamaldehyde Induced Vasorelaxation Is Relevant In Vivo
Our group has previously published studies showing cinnamaldehyde
injected into the mouse hind paw to cause vasodilation and increases in
blood flow (Pozsgai et al., 2010).  In this chapter, I additionally present
unpublished data showing topically applied cinnamaldehyde causes an
increase in blood flow in the mouse ear which is TRPA1 mediated.  In this
chapter, data from Aisah Aubdool, shows 10% cinnamaldehyde to induce
an increase in cutaneous blood flow measured by Laser Doppler.  This
shows similarities to studies on human forearm skin by Namer et al (2005)
and VanderEnde at al (2001), who have measured increased blood flow
and erythema respectively, in response to topically applied
cinnamaldehyde. Together, these studies show that cinnamaldehyde
reliably causes increased blood flow in vivo.  However, my colleague
Aisah Aubdool built on these findings in the literature by using genetic and
pharmacological alterations to show reduction of the cinnamaldehyde
response in TRPA1 KO and TRPA1 antagonist treated mice, demonstrating
a heavy dependence on TRPA1 activity.  We have further evidence to
support an endothelial independent mechanism in the mouse ear, as pre-
treatment with indomethacin and L-NAME have no effect on the
responses.  As the response is not completely blocked in TRPA1 KO mice,
this data mirrors the findings from isolated vessels, where some of the
relaxation induced by cinnamaldehyde is TRPA1 independent.
In the previous chapter I investigated whether TRPA1 KO mice had altered
basal characteristics in terms of blood pressure.  No striking phenotype was
observed in the TRPA1 KO mouse.  Similarly, when using Laser Doppler
we can compare basal levels of blood flow in peripheral tissues,
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investigating whether TRPA1 mediated vasodilation is an important
mediator of tissue perfusion.  In figure 4.4 there were no differences in
basal blood flow, indicating that TRPA1 is not needed to control basal
tissue perfusion.  However, it has the clear potential to be involved in
reactive changes in perfusion.
Evaluating the potential role of TRPA1 in myogenic constriction
The myogenic response, also termed the Bayliss effect, is particularly
important for the control of blood flow through peripheral arterioles.
Increases blood pressure cause additional stretch of the smooth muscle
cells lining the arterioles.  This activates the release of intracellular calcium
stores and surface channels, inducing a contractile response.  This process
does not require external signals, occurring on a cell by cell basis.
However the collective result will be a constriction of the arteriole and a
normalisation of blood flow. The myogenic response has a role in
essential hypertension, where the response is enhanced.  Mixed conclusions
have been draw as to whether this represents a protective function against
organ damage or part of the pathophysiology of hypertension (See Review
by Hughes and Bund, 2002).
Scotland et al., (2004) have described a role for C-fibres and TRPV1
induced SP release in the rat mesenteric artery myogenic response.  In the
pressure myograph, spontaneous myogenic constriction was seen from
around 60-100mmHg, in line with the pressure these vessels would
experience in vivo.  This constriction was endothelium independent but
dependent on calcium influx and could be virtually abolished by ablation of
sensory neurones or by antagonism of the TRPV1 receptor. Similar
reductions were seen with NK1 receptor antagonism or in vessels from
mice which lacked the NK1 receptor, suggesting a SP dependent
mechanism. 20-HETE is an eicosanoid produced by vascular smooth
muscle cells under luminal stretch, with a clearly defined role in the
myogenic response (Miyata and Roman, 2005). Scotland et al., also
demonstrated that 20-HETE can activate TRPV1 expressed in CHO cells.
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Therefore they suggest that 20-HETE produced under stretch activates C-
fibre TRPV1, leading to SP release and arteriole constriction via NK1.
However, 20-HETE can also directly depolarise smooth muscle cells
(Miyata and Roman, 2005). Potentially supporting these findings, Kannan
and Seip (1986) show SP inhibits relaxations induced by field stimulation
in rat mesenteric arteries under myogenic tone, but does not cause
contraction of the tissue.  The latter of these findings are similar to my own
data presented within this chapter, showing no changes in mouse
mesenteric artery tone on SP application.  My vessels are subject to
physiological tension and produce myogenic tone, although this is
distinctly different to the type of pressure experienced in vivo or in a
pressurised myograph.  Despite these findings, several reports concerning
NK1 activation on the vasculature demonstrate a dilation response,
suggesting anatomically distinct vessel beds may utilise different
mechanisms.  In humans, infusion of SP in to the brachial artery or
superficial vein of the hand induces an increase in blood flow (McEwan et
al, 1988), indicative of a dilation response.
In my study the mechanisms controlling myogenic tone were not directly
investigated.  Similar contractile abilities to a range of agents were
observed in both TRPA1 WT and KO vessels (See figure 4.4), suggesting
that sensitivity to contraction is not altered by genetic deletion of TRPA1.
In a recent study by Earley et al (2009) using cerebral arteries in a pressure
myograph, application of the TRPA1 antagonist HC-030031 was
associated with a small increase in myogenic tone, suggesting that tonic
activation of TRPA1 was associated with a vasodilatory influence. In this
study TRPA1 expression is shown to occur on the endothelial cells. This
study contrasts with the findings of Scotland et al (2004), where tonic
TRPV1 activity on C-fibres exerts a constricting influence via SP release.
This data suggests TRPA1 does not show a similar relationship with
myogenic tone as TRPV1.
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MO Mediates Vasoconstriction In Mesenteric Arteries
One of the most commonly used experimental TRPA1 agonists is MO.  It
has been used by several groups, including ours, to demonstrate TRPA1
mediated vasorelaxation both in vivo and ex vivo.  We have previously
shown that topically applied MO increases cutaneous blood flow, which is
greatly reduced in TRPA1 KO mice (Pozsgai et al., 2010).  Earley et al
(2009) have shown relaxation of isolated cerebral arteries in the perfusion
myograph induced by MO (3-100μM) is reduced by 3μM of the TRPA1
antagonist HC-030031.  Therefore, I applied similar concentrations of MO
to the mesenteric arteries (3-30μM).  These concentrations are below those
reported to activate TRPV1 (1mM) (Everaerts et al., 2011).  I found that
instead of relaxing the vessels, MO caused concentration dependent
vasoconstriction, which occurred at a similar magnitude irrespective of
tissue genotype or endothelial function.  TRPA1 activity has previously
been shown to cause smooth muscle contraction in other locations, such as
the airway (Andrè et al., 2008) and bladder (Andrade et al., 2006).
However, the action applies to all agonists of the receptor and does not
explain why differential effects are found with cinnamaldehyde and MO in
our model.  As MO is less selective than cinnamaldehyde, and shows
similar effects in TRPA1 WT and KO mice, I assume that this constriction
is occurring independently of TRPA1 activity in our model.  I have
therefore not investigated this agonist further and suggest caution to other
groups where MO is used as a TRPA1 agonist.  Where our group has
previously shown TRPA1 dependent vasodilation induced by MO applied
topically to mouse skin (Pozsgai et al., 2010), we may need to investigate
the contribution of TRPA1 expression in cell types outside the vessel wall,
in particular sensory neurones and keratinocytes which may be involved.
CGRP, But Not SP, May Mediate Cinnamaldehyde Induced
Vasorelaxation
Several studies using TRPA1 agonists suggest a mechanism where C-fibres
are activated, causing release of vasodilator neuropeptides such as CGRP
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and SP.  Most studies that have investigated this with pharmacological or
genetic manipulations use MO (See figure 1.6).  In the mesenteric vessels
used in this study, SP does not cause vasorelaxation.  Therefore, it cannot
be contributing to the cinnamaldehyde induced vasorelaxation. I used
αCGRP KO mice to show that cinnamaldehyde induced vasorelaxation is
partially dependent on CGRP release.  I then attempted to use two CGRP
receptor antagonists to strengthen the findings.
I validated a concentration of the peptide CGRP antagonist CGRP8-37
against exogenous αCGRP, showing it to significantly reduce the
magnitude of vasorelaxation.  However, at this concentration it showed no
inhibition of cinnamaldehyde induced vasorelaxation.  Although the
concentration of CGRP antagonist was validated, it is possible that receptor
blockade was not strong enough to significantly alter the vasorelaxation of
endogenously released CGRP following cinnamaldehyde application.  This
study would benefit from increasing the concentration of antagonist.
The non peptide CGRP receptor antagonist BIBN was also used in this
study.  A similar concentration (3μM) has previously been used within our
group to significantly reduce vasorelaxation of up 30nM exogenous CGRP
(Tam et al., 2006), and the 10μM concentration I have used in this chapter
was previously published by Grant et al (2004), both in isolated mouse
aortic rings.  This antagonist is more potent and binds with more affinity
than CGRP8-37, likely producing a non-surmountable receptor block at the
concentration used (Hay and Poyner, 2005).  This antagonist revealed a
strong role for the CGRP receptor in the vasorelaxation induced by
cinnamaldehyde.
Although the strength of the conclusions would be enhanced with
consistent results from genetic and pharmacological manipulations, it is
likely that the αCGRP KO mice give us the best idea of αCGRP peptide
involvement, whilst BIBN gives the best idea about CGRP receptor
involvement.  Together, they provide strong evidence for the involvement
of CGRP release and signalling in cinnamaldehyde induced vasorelaxation.
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The endogenous CGRP in our model is likely to be held in sensory
neurones, released when they are stimulated with cinnamaldehyde, via
TRPA1 receptor activation.  The sensory neurones in our mesenteric vessel
tissues are severed and could potentially become depleted in the model. To
test this, I applied sequential and varying concentrations of capsaicin to our
endothelium intact and denuded vessels.  Capsaicin application to
mesenteric arteries has previously been shown to induce CGRP release and
cause vasodilation (Fujimori et al., 1990).  At a concentration of 10μM,
relaxation of around 60% is obtained in WT vessels and is repeatable in
four sequential capsaicin additions.  This suggests that sensory neurones
are present in the vessels, and are not easily neuropeptide depleted.  This
could be further tested by using repeated capsaicin dosing in vivo to deplete
the sensory neurones of neuropeptides. Consequently, this data supports the
previous conclusions that cinnamaldehyde induced vasorelaxation of the
mouse mesenteric artery is partially mediated by CGRP.
Cinnamaldehyde Induced Vasorelaxation Is Largely
Hyperpolarisation Mediated
A previous study using MO, published by Earley et al (2009), has shown
TRPA1 dependent vasodilation to be mediated by endothelial
hyperpolarisation, which is then passed to the underlying smooth muscle
by myo-endothelial gap junctions and increases in local extracellular
potassium. This particular mechanism shows specificity to the cerebral
vasculature; however other studies have also suggested hyperpolarisation
to be an important mediator of cinnamaldehyde induced vasorelaxation
(See table 1.1).  To investigate the role of hyperpolarisation in the response
to cinnamaldehyde, I have used arteries without functional endothelium, as
previous findings have not shown endothelial cells to be important in the
TRPA1 dependent portion of the relaxation.  This also allows isolation of
the smooth muscle mediated mechanisms.  Vessels were bathed in raised
extracellular potassium, constricting the smooth muscle and preventing
hyperpolarisation.  In this setting, cinnamaldehyde induced vasorelaxation
was strikingly blunted, more than seen in TRPA1 KO mice.  Therefore I
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can conclude that hyperpolarisation is important in the TRPA1 dependent
and independent portions of the cinnamaldehyde response. This could
ideally be confirmed in parallel studies where the smooth muscle
membrane potential is measured with an electrode.  However this is a
challenging technique for which we lack the equipment and expertise
necessary.
CGRP receptors are known to be expressed on vascular smooth muscle
cells and CGRP itself causes smooth muscle hyperpolarisation via the
activation of KATP channels and endothelial derived NO (Wimalawansa,
1996).  TRPA1 expression itself has not been previously described in
vascular smooth muscle tissue.  Data presented in the next chapter show
TRPA1 expression to be very low in all levels of the vasculature, but at
higher levels in DRG.  This strengthens conclusions that TRPA1 expressed
on sensory neurones is mediating the CGRP release, which in turn causes
vasorelaxation via hyperpolarisation of the vascular smooth muscle layer.
Sensory neurones also contain a number of neuropeptides other than CGRP
and SP.  Therefore, these could also play a role in the vascular
consequences of TRPA1 activation.
TRPA1 is a non-selective cation channel and if it was directly expressed on
smooth muscle cells, it has the potential to activate calcium dependent
mechanisms without the need for further mediators.  This mechanism may
also be involved in cinnamaldehyde induced vasorelaxation.  The major
calcium activated potassium channel in smooth muscle cells is the BKCa
channel.  This channel is activated by calcium, such as that potentially
entering the cell following TRPA1 activation, causing a large efflux of
potassium from the smooth muscle cell and causing hyperpolarisation.  In
smooth muscle cells this will lead to relaxation.  Endothelial derived
epoxyeicosatrienoic acids (Zhang et al., 2001) have been shown to dilate
vessels via BKCa channels, and are thought to be a potential EDHF
mechanism in some tissues.  I tested the potential for the BKCa channel to
mediate cinnamaldehyde induced vasodilation by using a channel blocker
called paxilline, in vessels without functional endothelium.  This
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compound has been used extensively by other groups at a concentration of
1μM, which I have replicated.  Fountain et al (2010) have previously
shown mouse mesenteric arteries to express BKCa, and the channel has
been shown to be blocked by with 1μM paxilline in mouse cutaneous
sensory neurones (Zhang et al., 2010).  Paxilline works by binding to the
alpha subunit of the BKCa channel, common to all isoforms.  In this study,
blocking BKCa had no effect on cinnamaldehyde induced vasorelaxation,
thus it has proven not to be a key channel in this response.
This study suggests that TRPA1 activity can lead to hyperpolarisation
mediated vasorelaxation. Data has further suggested a role for CGRP
induced hyperpolarisation in cinnamaldehyde induced vasorelaxation,
without the need for functional endothelium.  CGRP can act directly on
vascular smooth muscle cells to increase cAMP levels.  This leads to
several mechanisms of vasodilation, including activation of potassium
channels and hyperpolarisation of the cell.  These channels are not BKCa,
but via ATP sensitive potassium channels (KATP) (Nelson et al., 1990).
This has been demonstrated in rabbit mesenteric arteries (Nelson et al.,
1990), human placental blood vessels by Dong et al (2004) and is
discussed in Brain and Grant (2004). However, as recently described for
Gs signalling downstream of beta-adrenergic receptors in the rat mesenteric
artery, KATP activity is not required for PKA mediated vasodilation, but
facilitates the spreading of this dilation response through the artery
(Garland et al., 2011). In my study, pre-constriction is gained using
U46619.  I thought to use the KATP channel antagonist glibenclamide to
investigate the component mediated by KATP channels in the relaxation to
cinnamaldehyde.  However, it has been reported that glibenclamide itself
antagonises U46619 induced constriction with some evidence of tissue and
species specificity (Cocks et al, 1990, Kemp and McPherson, 1998)
Within our group we have preliminary evidence to demonstrate this is also
the case in mesenteric arteries. CGRP also causes relaxation of smooth
muscle cells via hyperpolarisation independent mechanisms, such as PKA
stimulated increase in sarco/endoplasmic reticulum Ca2+-ATPase (SERCA)
activity.  These alternative pathways may account for the hyperpolarisation
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independent relaxation observed at higher concentrations of
cinnamaldehyde in our experiments; however these are unlikely to be
TRPA1 dependent. An alternative method of studying signalling
downstream of CGRP receptors is to pharmacologically block cAMP
increases or PKA activity, however it must be remembered that these
signalling components are common to many pathways. CGRP can also
cause endothelial dependent vasorelaxation, via the stimulation of NO
production and hyperpolarisation of underlying smooth muscle via
activation of BKCa, downstream of PKA and PKG.  In this study, I have
shown cinnamaldehyde to cause largely endothelial independent
vasorelaxation and suggest sensory neurones mediate this action. This
conclusion is in line with the data showing lack of BKCa involvement in
cinnamaldehyde induced vasorelaxation when endothelial cells are
removed.  The exact contribution of each potassium channel involved in
TRPA1 agonist induced vasorelaxation has not yet been investigated, thus
the evidence is novel and is of value to the field. In my model, further use
of potassium channel inhibitors or other signalling manipulations will be
needed to elucidate a clear mechanism.  These could include alternative
KATP blockers or inhibitors of PKA to investigate the links with CGRP.
The dependence of this on TRPA1 activity can then be assessed using
TRPA1 WT and KO mice.
A recent study by Xue et al (2011), using lower concentrations of
cinnamaldehyde in rat aortic rings, did not show direct involvement of
potassium channels. They instead suggest relaxation is due to effects on
calcium handling, reducing smooth muscle calcium influx and store
release.  A similar mechanism, at concentrations of cinnamaldehyde similar
to mine, was identified by Yanaga et al (2006), also in rat aortic rings.
However, hyperpolarisation could be playing a role in these findings as it
inhibits voltage operated calcium channels, the main channel responsible
for calcium influx.  Inhibition of calcium influx and store release was not
investigated in this chapter.  Several remaining questions could be better
answered if the hyperpolarisation study was repeated in TRPA1 WT and
KO mice.   Additionally, as in Xue et al (2011), I could apply
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cinnamaldehyde before the pre-constriction, or measure cytoplasmic
calcium levels, assessing its ability to block calcium increases.
Yanaga et al (2006) also identified an endothelial dependent component in
cinnamaldehyde induced vasorelaxation in rat aortic tissue which was NO
mediated.  These concentrations are similar to those used in this chapter,
which also shows a TRPA1 independent endothelial component,
suggesting that this portion could be NO mediated.
Differences in mechanism between studies may be due to location as
differential expression of potassium channels has been demonstrated across
the vascular system.  For example, lower messenger RNA (mRNA) copy
numbers of BKCa channel components are found in aortic tissue compared
to mesenteric tissue (Fountain et al., 2004).  Also, KIR channels, which are
important for amplifying smooth muscle hyperpolarisation, are poorly
expressed in mesenteric arteries when compared with coronary and
cerebral arteries (Smith et al., 2008).  Therefore, the mechanism operating
in each tissue may differ.  Differences may also be found with agonist
concentration.  In this study, I did not measure the potassium channel
components in the tissue.  However this would be a valuable addition to the
data.
In my model, cinnamaldehyde induces both TRPA1 dependent and
independent relaxation processes, the later becoming predominant at high
concentrations.  As our interests are not in cinnamaldehyde per se, but of
TRPA1 induced vasorelaxation, it will be important for future studies to
identify a more selective agonist.  This could include a recently identified
non electrophilic TRPA1 agonist that our group have played a role in
characterising (Ryckmans et al., 2011).  This will eliminate many of the
problems experienced in this research field, where agonist activity cannot
always be fully attributed to the receptor of study.
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Conclusion
In this chapter, I have investigated the vasodilation induced by the TRPA1
agonist cinnamaldehyde. Several other groups have shown that TRPA1
agonists can cause vasorelaxation of isolated vessels, and cause increases
in blood flow in vivo, but clear mechanisms have not been established. We
were the first group to use TRPA1 KO mice to demonstrate TRPA1
dependent components in cinnamaldehyde induced vascular responses both
ex vivo and in vivo (Pozsgai et al., 2010). I have now studied a range of
channels and mediators, using both genetic and pharmacological
interventions, to identify the pathway involved in this response in murine
mesenteric arteries. This is important in the context of the investigation
into the role of TRPA1 in cardiovascular regulation.  In isolated mesenteric
arteries, cinnamaldehyde induces vasorelaxation which is largely
endothelium independent, with a TRPA1 component likely to be
originating from expression on sensory neurones. The potency of
cinnamaldehyde was reduced in TRPA1 KO mice; however the presence of
a TRPA1 component could not be confirmed using TRPA1 antagonists,
which also did not block cinnamaldehyde responses in a number of rodent
tissues. These studies did not rule out a neurogenic mechanism and I
further hypothesised that activation of TRPA1 may lead to CGRP release.
The response to cinnamaldehyde was found to be reduced in αCGRP KO
mice and with the use of a non peptide CGRP receptor antagonist.  I have
additionally used pharmacological manipulations to show the neuropeptide
SP is not involved in the response of the mesenteric artery. CGRP release
is thought to lead to hyperpolarisation of the vascular smooth muscle layer.
In my model, blocking hyperpolarisation in the tissue significantly blunted
cinnamaldehyde induced smooth muscle dilation.  I also investigated the
involvement of the BKCa channel, the most likely candidate channel to be
mediating a direct TRPA1 induced relaxation of vascular smooth muscle.
Use of an antagonist of the BKCa channel did not affect the
cinnamaldehyde response.  This conclusion strengthens the findings that
CGRP is mediating the TRPA1 dependent component via sensory neurone
activation.  Further work will be needed to investigate other mediators of
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cinnamaldehyde induced smooth muscle hyperpolarisation and to
investigate the calcium handling changes suggested in other publications.
However, future studies should look to use more selective TRPA1 agonists
and antagonists when isolating the receptor dependent pathways.
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Chapter 5 – Investigating The Role Of TRPA1 In
Experimental Hypertension
Introduction
In the previous chapter, I showed a TRPA1 agonist to cause vasorelaxation
of the murine mesenteric artery, an example of a resistance vessel.
Resistance vessels are small arteries and arterioles, important in the control
of total peripheral resistance in the vascular system.  They are highly
innervated by sensory neurones, terminating at the media/adventitia border
and reaching into the smooth muscle layer.   Several neuropeptides can be
released from these nerves and have been suggested to inhibit increases in
blood pressure (Watson et al., 2002).  Neuropeptides have several
suggested roles in hypertension.  SP acts on its major vascular receptor,
NK1.  Previous studies using NK1 receptor antagonists have demonstrated
increases in blood pressure in acute experimental hypertension models.
These findings suggest that SP may be able to counter-act blood pressure
increases (Watson et al., 2002).  However, in the previous chapter I have
shown that SP does not mediate mesenteric artery relaxation.  Furthermore,
CGRP is a potent vasodilator acting via endothelial dependent and
independent mechanisms.  Blood pressure in CGRP KO mice has been
characterised by several groups, some showing spontaneous hypertension
(Li et al., 2004, Deng and Li, 2005), whilst others could not find any
changes (Lu et al., 1999).  This may be due to the method used to create
the KO strain, as Li et al have also removed the calcitonin gene.  Both
groups measured central blood pressure.  CGRP release has also been
described as a key compensatory mechanism against rising blood pressure
(Watson et al., 2002, Li and Wang, 2005, Deng and Li, 2005, Smillie and
Brain, 2011).  In our group, there are ongoing investigations showing that
CGRP is protective against the onset of Ang II induced hypertension, and
reduces the emergence of hypertensive markers (Smillie, Unpublished
data).  In chapter 4, data is presented suggesting that TRPA1 activation in
the vasculature leads to vasorelaxation via CGRP release.  This is highly
indicative of a protective role for TRPA1 in hypertension.
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Ang II is a key modulator of basal blood pressure in humans and has a role
in the development of essential hypertension.  It has various actions on
many cell types, causing vasoconstriction, increasing blood volume,
oxidative stress and inflammatory mediator transcription (Rosendorff,
1996, Gavras and Gavras, 2002, Mehta and Griendling, 2007).  The mouse
Ang II infusion model of hypertension, originally used by Byrne et al
(Byrne et al., 2003), is well characterised in our laboratory. An osmotic
minipump containing Ang II is implanted subcutaneously in to the mouse,
infusing the drug over 14 days and creating significant hypertension (Liang
et al., 2009).  This model produces quick onset, moderately severity
hypertension and mimics some of the pathology found in human
hypertension but occurs over a shorter time span than that found clinically.
This includes hypertrophy of large blood vessels and heart, along with
induction of associated inflammatory biomarkers (Monassier et al., 2006).
In normal conditions, ROS producing enzymes have important intracellular
signalling roles, contributing to cellular activities such as growth,
differentiation, migration and apoptosis.  The likely signalling molecular is
H2O2.  In pathological conditions, the redox homeostasis is shifted in
favour of oxidative stress by an increase in the production of ROS and a
depletion of antioxidant defences.  Many of the changes seen in the Ang II
model are linked to the induction of oxidative stress (Hitomi, et al., 2007),
showing clear parallels with the clinical situation, where ROS are closely
associated with essential hypertension and the resultant hypertrophy (Zalba
et al., 2001).  The resultant oxidative stress leads to activation of
inflammatory gene transcription, such as Interleukin-6 (IL-6) and
Monocyte chemotactic protein 1 (MCP-1).  This systemic inflammation
has destructive effects; in terms of hypertension this can lead to
vasoconstriction, endothelial dysfunction and vascular remodelling.
There are currently no studies which investigate the pathophysiological
relevance of TRPA1 in cardiovascular disease, but the likeliness of such a
role has been suggested (Bodkin and Brain, 2010).  As the TRPA1 receptor
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has been shown to be activated by oxidative stress (Andersson et al., 2008,
Trevisani et al., 2007) and upregulated by inflammatory mediators (Hatano
et al, 2012), there is potential for in vivo activation during hypertension.
Therefore use of the Ang II infusion, which is associated with oxidative
stress production (Hitomi et al., 2007), is an appropriate model for
investigating our hypothesis of TRPA1 mediated vascular protection.  In
line with my hypothesis, I have conducted this novel study investigating
the development and endpoints of experimental hypertension in TRPA1
WT and KO mice.  Blood pressure and hypertension endpoints are
evaluated, including measures of hypertrophy and inflammatory mediators.
ROS are produced by a range of enzymes, including the NADPH oxidase
(NOX) family.  Several, differentially regulated isoforms of NADPH
oxidase are expressed in vascular tissues, in different cellular locations.
NOX2 and NOX4 are both associated with ROS production, and show
increases in activity on Ang II stimulation in the rat (Wang et al., 2007).
NOX2 is particularly implicated in hypertension, where its over-expression
in mouse endothelial cells worsens oxidative stress and hypertension
(Bendall et al., 2007) during Ang II infusion, and NOX2 KO mice are
protected against hypertrophy in a similar model (Johar et al., 2006).  The
role of NOX4 is currently less clear, likely due to its intracellular location,
however it has also been implicated in Ang II receptor dependent
hypertension and hypertrophy (Wang et al., 2007).  Both NOX2 and NOX4
are measured in this chapter as pro-oxidative markers.
The tissue ROS level is balanced by the scavenging activity of antioxidant
systems, such as superoxide dismutase (SOD).  SOD is an antioxidant gene
which converts superoxide to hydrogen peroxide, in order for its
degradation.  ROS induce additional anti-oxidative genes, such as heme-
oxygenase (HO-1), which can be used as both an indicator of ROS
production and as a level of mounted anti-oxidant defence. The protective
effects of HO-1 activity are multifold, producing both vasodilator and anti-
oxidant compounds (Turkseven et al., 2005). The levels of SOD and HO-1
are measured as antioxidant defence genes. Their expression has also been
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shown to increase during Ang II infusion, reducing pathology (Chen et al.,
2003, Peterson et al., 2009, Gongora et al., 2006).
Hypertension is a disease of systemic inflammation, associated with the
expression of cytokines and chemokines.  The levels of some of these are
investigated during this chapter as a measure of inflammation severity
(Yao et al., 2006).  This will include MCP-1, IL-6 and KC (the murine
analogue of IL-8), which are all associated with Ang II stimulation and
cellular inflammation, an important step in the progression of
cardiovascular disease towards vascular events (Fisman and Tenenbaum,
2010).    In particular, these biomarkers are positively associated with
hypertensive remodelling and poor disease outcome (Behr et al., 2004,
Kolattukudy et al., 1998, Manhiani et al., 2007, Collier et al., 2011).
The results of this thesis so far indicate that TRPA1 is involved in a
dilatory pathway ex vivo, with more complex effects in vivo, I hypothesise
that TRPA1 is activated in vivo during Ang II induced hypertension,
leading to the release of CGRP which compensates against blood pressure
rises and pathological changes.  The loss of these pathways in global
genetic TRPA1 deletion, although not important basally, might therefore be
damaging in a disease setting associated with vasoconstriction and
oxidative stress.
Aims;
 Use tail cuff plethysmography to initially characterise the profile of
hypertension onset in TRPA1 WT and KO mice using the Ang II
infusion model.
 Collect in depth pressure, heart rate and activity readings over the
infusion period using telemetered TRPA1 WT and KO mice,
ascertaining if TRPA1 has a role in the hypertension induced in this
model.
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 Investigate the influence of TRPA1 on cardiac remodelling. Use
echocardiography to assess cardiac hypertrophy, confirming these
findings at necropsy.
 Study the expression of TRPA1 in the vasculature and on DRG
neurones, comparing this with TRPV1 and CGRP expression or
release.
 Investigate the influence of TRPA1 on the markers and mediators
of inflammation associated with Ang II induced hypertension.  Use
quantitative RTPCR and multiplex ELISA to measure the levels of
transcribed and circulating biomarkers as described above.
Results
Ang II Induced Hypertension Is Evaluated In TRPA1 WT And KO
Mice Using Tail Cuff Plethysmography
In chapter 3, TRPA1 WT and KO mice were trained for blood pressure
measurement by tail cuff plethysmography.  After ascertaining their basal
blood pressure, they underwent mild surgery to implant an osmotic
minipump subcutaneously. Ang II was delivered at a rate of 1.1mg/kg/day
under the skin of the animal for 14 days.  Control mice were also used,
carrying an empty pump.  After the first 3 days, blood pressure was
measured daily using tail cuff plethysmography.  This model was
previously used effectively in our group (Liang et al., 2009).  Figure 5.1 A,
shows the mean blood pressure of mixed gender mice for days 3-14 post
implantation.  As seen in previously presented data, TRPA1 KO mice have
a lower blood pressure than WT mice.  This difference is reflected over the
14 day period, in both control and Ang II treated mice.  Control mice of
both genotypes maintain a stable blood pressure throughout the
experimental period.  This can be seen more clearly in figure 5.3, which
additionally shows readings collected during the training period. Ang II
treated mice of both genotypes display a steady increase in blood pressure.
Blood pressure was never statistically different between WT and KO mice
in either treatment groups, however, WT mice showed earlier significant
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blood pressure increases in Ang II treated animals, when compared to their
respective controls.  By day 11, Ang II treated mice of both genotypes
showed significantly elevated blood pressure compared to their control
groups.
As blood pressure can vary depending on gender, panels B and C of figure
5.1 show the data split into female and male mice respectively.  Although
the sample size is relatively small, and shows large variations, slight
differences in onset profile between genders may be apparent.   However,
this is not significant and is likely to be due to variability between males in
particular.  In further analysis it is assumed that gender does not have a
large influence on basal blood pressure, or the response to experimental
hypertension model, in keeping with previously presented data.  Further
data is presented from mixed gender groups.
Figure 5.2 shows alternative analysis of blood pressure during the
experimental period, as shown as a profile in figure 5.1.  Analysis by area
under the curve, as shown in figure 5.2A, illustrates the increase in blood
pressure over the 14 day treatment period.  Percent change between day 0
and day 14 (5.2B), describes the magnitude of change from the beginning
of the experimental protocol, as a measure of hypertension severity.  This
measure takes into account the differences in basal blood pressure.
Similarly, average blood pressure from the final 3 days (12-14) (5.2C)
describes the average absolute hypertensive pressures experienced by each
group.   All measures demonstrated that the Ang II infusion robustly causes
hypertension.  Significant hypertension was gained by analysis using
percentage change and average of final 3 days blood pressure.  No
significant changes in blood pressure were seen in control mice, as shown
in figure 5.3. Ang II treated TRPA1 WT and KO mice both became
significantly hypertensive, showing an average mean blood pressure of
150-180 mmHg (figure 5.2C.  As systolic blood pressure is always higher,
this demonstrates that the model induces a quick onset, severe
hypertension.  None of the panels suggest significant differences in the
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magnitude of Ang II response between TRPA1 WT and KO mice,
considering the difference in baseline blood pressure.
In figure 5.3, additionally showing the extended training period for control
mice, there are significant differences in the blood pressure of TRPA1 WT
and KO control mice at training days -3 to implantation day (day 0).  This
reflects previously presented data in chapter 1, where KO mice appear to
have a hypotensive phenotype when blood pressure is measured by tail cuff
plethysmography.
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Figure 5.1 Blood Pressure Measured By Tail Cuff
Plethysmography During 14 Days Of Ang II Infusion Or
Following Operation Control, In TRPA1 WT And KO mice. Mean
blood pressure measured daily (around 4pm) in Ang II infused
(1.1mg/kg/day) or control operated animals.  Averaged readings are taken
from each mouse, then given as a group average.  N=8-9. A. Shows mixed
gender mice B. Shows only female mice N=4-5. C. Shows only male mice.
N=4-5.  Statistics are from two way ANOVA with Bonferroni’s post-test.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 comparing WT control to
WT Ang II treated animals.  # #p<0.01, # # #p<0.001, comparing KO
Control to KO Ang II treated animals. N numbers as indicated.
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Figure 5.2 Change In Blood Pressure Over 14 days Of Ang II
Infusion Or Control Operation, In TRPA1 WT And KO Mice,
Measured By Tail Cuff Plethysmography. Mean blood pressure
readings are taken from mixed gender mice, then given as a group average.
A. Area under the 14 day mean blood pressure curve for mixed gender
mice. Profile in previous graph. B. Percentage increase in mean blood
pressure from day 0 to day 14 average reading. C. Average mean blood
pressure during day 12, 13 and 14 of the infusion. Statistics are from one
way ANOVA with Bonferroni’s post-test. ***p<0.001, compared to





































































































































































Figure 5.3 Serial Blood Pressure Readings Obtained By Tail
Cuff Plethysmography From Control TRPA1 WT And KO Mice.
Averaged readings are taken from each mouse, then given as a group
average.  N=2-27 mice per day. (from -17 to 14 in order; WT;
3,5,21,17,2,6,19,18,23,22,18,3,5,18,22,24,23,20,6,6,6,6,6,6,6,6,6,6,6,6,4,4,
4, KO; 4,4,19,19,2,6,21,20,25,27,20,4,5,21,24,24,25,21,8,8,8,8,8,8,8,8,8,8,
8,6,6,6). Statistics are from two way ANOVA with Bonferroni’s post-test.
*p<0.05, **p<0.01, ***p<0.001, WT Control to KO Control animals.



































Effect Of Ang II Induced Hypertension Measured By Telemetry
In TRPA1 WT And KO mice
Using telemetry allows us to collect the best quality of data from conscious
and unstressed animals.  Although the tail cuff plethysmography study did
not suggest striking differences between TRPA1 WT and KO mice,
previous data presented in chapter 1 showed that outcomes may differ
between data collection methods.  In the telemetry study, baseline data was
collected before treatment with Ang II, therefore each mouse is able to
serve as its own control, reducing the numbers of mice needed for this
experiment. This also allows data to be analysed more robustly for
statistical evaluation.
Figure 5.4 shows blood pressure parameters measured from Ang II infused
TRPA1 WT and KO mice, presented as 4 hour averages.  These graphs
comprise mice which completed the entire experimental period.  A
summary of the hypertension results are described in figure 5.5.  In both
genotypes, Ang II infusion causes significant and severe hypertension by
day 13, the final complete measurement day.  Severe hypertension is
clinically defined as a systolic blood pressure above 180mmHg or a
diastolic blood pressure above 110mmHg (Carretero and Oparil, 2000).
No statistical significance is seen between genotypes for average daytime
and night time blood pressures; however these are significantly elevated
from daytime measures, in line with increased activity.  TRPA1 WT and
KO mice treated with Ang II show similar levels of blood pressure increase
both nocturnally and during amgiotensin II induced hypertension. The
combination of telemetry and Ang II induced hypertension is associated
with approximately 25% premature deaths (KO, 2x Females day 5, 1x
Male day 10, WT 2x Male day 6).  This affected the original power
calculations for this study and meant that for many experiments, a lower N
number was collected than had been originally planned, reducing the
ability to achieve statistical significance. These losses were not associated
with the telemetry surgery itself, as the few deaths that occurred this way
were replaced before the start of the experimental period.  Loss also seems
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not to be gender related and slightly higher than the 10% associated with
tail cuff measurements, suggesting a negative effect of having two
implants.  The reason for the death of these animals is not clear, as all
occurred at night.  However they occurred several days after the minipump
surgery, after the blood pressure had risen, suggesting a relationship with
the establishing hypertension.  Data including that from mice which were
lost during the protocol is presented later.  Strikingly, and in contrast with
data collected by tail cuff plethysmography (figure 5.1), the hypertension
measured by telemetry is of very rapid onset.  Hypertension is established
within the first day, levelling off to a mean blood pressure of around
150mmHg at day 2 in Ang II treated TRPA1 KO mice and day 5 in Ang II
treated WT mice (figure 5.4).  This pattern is again in contrast with that
seen in tail cuff plethysmography data, where WT mice established the
hypertension more rapidly and increases continue until day 11.
Hypertension is maintained in both genotypes of mice over the rest of the
experimental period when measured by telemetry, with no significant
blood pressure differences seen between groups for any parameter.
The telemetry probe also allows us to collect measurements of other
parameters such as heart rate, pulse pressure and activity levels of the
TRPA1 WT and KO mice.  This data is presented as 4 hour averages in
figure 5.6, and summarised in figure 5.7.   Heart rate and pulse pressure are
similar between TRPA1 WT and KO mice and are stable over the 14 days
infusion (figure 5.6).  Heart rate shows clear diurnal rhythms, being
increased at night time, in line with increased activity levels.  There are no
differences in heart rate or pulse pressure seen after 13 days of Ang II
treatment, the last full day of recording, compared to baseline
measurements (5.7 A/B).
Previous data presented in chapter 1 indicates that TRPA1 KO mice
display a basal hyperactivity phenotype.  In figure 5.6C, this is clearly
exacerbated during the Ang II infusion period.  Each subsequent day the
mice show an increased nocturnal activity peak, returning to an elevated
baseline level during the day.  Figure 5.7C shows average daytime and
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night time activity, again reflecting the suggested hyperactivity phenotype
of TRPA1 KO mice, which is exacerbated during Ang II infusion albeit
with some individual variation.  The trend is further analysed in figure 5.8,
investigating activity counts at 4 hour intervals at baseline and on the last
day of Ang II infusion.  Statistical differences between genotype are not
found, despite a clear increase in activity in KO mice (figure 5.8 A and B).
The data is also analysed as activity counts over days 1-7 and 8-14 by area
under the curve (Figure 5.8 C). This allows comparison of the first half of
the experiment (1-7), where mice are less active, with that of the later half
(8-14), where mice were most active The activity data is routinely tested
for normality using the Shapiro-Wilk normality test but does not fit a
Gaussian distribution, thus is analysed using non-parametric tests.  In the
case of figure 5.8C, I am most interested in if there are significantly higher
activity levels in TRPA1 KO mice, compared to TRPA1 WT mice, at the
end of the Ang II infusion period.  Therefore a Mann-Whitney U test is
used to compare these two data sets. Interestingly, Ang II infused TRPA1
WT mice show a similar level of nocturnal activity throughout the 14 day
infusion, whereas TRPA1 KO mice show increasing levels of activity as
the infusion progresses.  Analysed in this way, there is a statistical increase
in activity in Ang II treated TRPA1 KO mice, compared to the comparable
WT group, during the later stages of Ang II infusion (days 8-14). As
activity levels vary greatly between individuals, the measures proposed
here may need more animals to reach further significance.
Figures 5.9 and 5.10 show the same data as presented in figures 5.4 and
5.6, additionally including data from mice that died before the end of the
protocol.  Although increasing the sample size increases the statistical
power of the data, it also causes the results to show skewed trends in later
stages where more hypertensive mice may have died, leading to a drop in
average blood pressure readings around day 6-9 of recording.  This could
represent some compensation in the remaining mice.  The time of first
death is shown on each graph as a black dashed line.  Almost all deaths
occurred around day 5/6, corresponding to the peak of developing
hypertension.  This is several days after mini-pump implantation, and some
211
time since the telemetry surgery (approx. 2 weeks).  Therefore the
formation of hypertension is likely to have played a role in these deaths,
perhaps via increased risk of thrombosis.  They did not show signs of
discomfort during daily inspections (activity, alertness, posture etc.) prior
to death, therefore I believe they suffered an acute event.  Inclusion of this
data has little effect on patterns of heart rate, pulse pressure and activity,
compared to those previously described (figure 5.10).  However,
differences in blood pressure are seen.  This further suggests an acute event
as a result of hypertension, as longer term discomfort would have resulted
in reduced night time activity scores.  When data from mice which
prematurely died are included, the onset of hypertension occurs similarly in
both TRPA1 WT and KO mice.  I believe this to be a true representation of
the pathophysiological situation.  Both groups steadily increase their mean
blood pressure to around 150mmHg at day 6.  This is the point where the
first death occurred; further suggesting cardiovascular events were
causative.
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Summary 1 – Hemodynamic Parameters And Activity Levels In
Ang II Infused TRPA1 WT And KO Mice.
 Ang II infusion causes severe hypertension measured by tail cuff
plethysmography and telemetry.  This was of faster onset when
measured by telemetry, occurring directly after initation of infusion.
 There were no significant differences between the magnitude of
hypertension in TRPA1 WT and KO mice when measured by tail
cuff plethysmography, both groups of mice showed an approximate
70mmHg increase in mean blood pressure.  However, significant
hypertension became established earlier in TRPA1 WT mice,
occurring from day 6, whereas TRPA1 KO mice showed significant
hypertension from day 11.
 There were no significant differences between the magnitude of
hypertension in TRPA1 WT and KO mice when measured by
telemetry from the aortic arch, where both genotypes demonstrated
around 160mmHg systolic blood pressure at the end of the infusion
period. Onset patterns were similar between genotypes.
 In line with previous findings, TRPA1 KO mice were more active
throughout the protocol.   Their activity levels increased with each
day of Ang II infusion, which did not occur in WT mice. By the
end of the infusion period, TRPA1 KO mice showed around twice
the average peak activity count of that seen in the WT group.
Significantly increased levels of activity were recorded from KO
mice, compared to WT mice, during days 8-14 of the Ang II
infusion, when hypertension was established.
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Figure 5.4 Blood Pressure Measurements In Ang II Treated
TRPA1 WT And KO Mice Which Completed The Protocol,
Collected By Telemetry. Results show measurements taken every 15
minutes from the aortic arch during 14 day Ang II infusion (1.1mg/kg.day)
expressed as 4 hour averages. Data is from mixed gender mice. Dark
stripes indicate nocturnal period.  Graph includes only mice that completed
the whole 14 day treatment. No significant differences are seen in a two-
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Figure 5.5 Changes In Blood Pressure In TRPA1 WT And KO
Mice Which Completed The Protocol, Measured By Telemetry
At Baseline And Day 13 Of Ang II Infusion. Results include basal
data previously analysed separately in chapter 3. Ang II infused at a rate of
1.1mg/kg/day by osmotic minipump, blood pressure measured from aortic
arch. Daytime readings are average from 7am-7pm. Night time is average
of 7pm-7am readings.  All graphs show mixed gender mice, paired baseline
and day 13 readings N=6-10.  Statistics are from a one-way ANOVA with
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Figure 5.6 Heart Rate, Pulse Pressure And Activity
Measurements In Ang II Treated TRPA1 WT And KO Mice
Completing The Protocol, Collected By Telemetry. Results show
measurements taken every 15 minutes from the aortic arch during 14 day
Ang II infusion (1.1mg/kg.day) expressed as 4 hour averages. Data
includes mixed gender mice. Dark stripes indicate nocturnal period.  Graph
includes only mice which completed the whole 14 day treatment. No
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Figure 5.7 Changes In Heart Rate, Pulse Pressure And Activity
In TRPA1 WT And KO Mice Completing The Protocol, Measured
Using Telemetry At Baseline And Day 13 Of Ang II Infusion.
Results include basal data previously analysed separately in chapter 3. Ang
II infused (1.1mg/kg/day) by osmotic minipump, pressures measured from
aortic arch. Daytime readings are average from 7am-7pm, Night time is
average of 7pm-7am readings.  All graphs show mixed gender mice, paired
baseline and day 13 readings N=6-10. No significance seen in a one way
ANOVA for heart rate and pulse pressure, or Kruskall-Wallis test in the
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Figure 5.8 Activity Levels In TRPA1 WT And KO Mice Measured
Using Telemetry At Baseline And After Ang II Infusion. Results
show A) baseline data plotted at 4 hourly intervals. Basal data previously
analysed separately in chapter 3. B) Day 13 of Ang II infusion at a rate of
1.1mg/kg/day by osmotic minipump. C) Activity counts over days 1-7 or 8-
14 of Ang II infusion measured by area under the curve, grouped by
genotype. N=9 for WT, 7 for KO.  Statistics are from a one tailed, Mann-
Whitney U test comparing WT and KO days 8-14, * p<0.05. All graphs




Figure 5.9 Blood Pressure Measurements From All Ang II
Treated TRPA1 WT And KO Mice Entering The Protocol,
Collected By Telemetry. Results show measurements taken every 15
minutes from the aortic arch during 14 day Ang II infusion (1.1mg/kg.day)
expressed as 4 hours averages. Data includes mixed gender mice. Dark
stripes indicate nocturnal period.  Graph includes all mice entering the
protocol, including those who died prematurely. Time of first death is
shown as dashed line, WT loss 2x day 5, 1x day 10, KO loss 2x day 6).







































































Figure 5.10 Heart Rate, Pulse Pressure And Activity
Measurements From All Ang II Treated TRPA1 WT And KO Mice
Entering The Protocol, Collected By Telemetry. Results show
measurements taken every 15 minutes from the aortic arch during 14 day
Ang II infusion (1.1mg/kg/day) expressed as 4 hour averages. Data
includes mixed gender mice. Dark stripes indicate nocturnal period.  Graph
all mice entering the protocol, including those who died prematurely. Time
of first death is shown as dashed line (WT loss 2x day 5, 1x day 10, KO


























































Measuring Hypertrophy In Hypertensive TRPA1 WT And KO
Mice
Ang II in the brain is associated with increased sympathetic outflow and
energy expenditure, along with appetite suppression (McKinley et al.,
2003). As body weight is frequently used as a ratio base in this study, it
was important to determine the effect of the treatment protocol on body
mass.  This data is presented in figure 5.11.  Figure 5.11 A shows absolute
body weights are similar between TRPA1 WT and KO mice in all
treatment groups, at the start and end of the treatment period.  However, if
this is examined as % of start weight, a clear trend for a decrease in body
weight during Ang II treatment is seen in both genotypes. Control mice
maintain a similar body weight to that at the start of the protocol (Figure
5.11 B).  Although the decrease seen in Ang II treated groups is slight,
averaging to less than a 5% body weight loss and not causing significant
weight changes over the infusion period, this should be a consideration
when analysing body weight ratio results.
As the rate of blood pressure increase and final blood pressure levels are
similar in TRPA1 WT and KO mice, hypertrophy can be freely compared
between genotypes without pressure considerations.  Due to the non-
significant trends for body weight changes during Ang II infusion,
hypertrophy is measured as a ratio to body weight.  This data is collected
from paired mice which underwent blood pressure measurement by tail
cuff plethysmography or telemetry to increase numbers. Heart mass was
measured at or after necropsy as it has been suggested that Ang II induced
hypertrophy is due to both myocyte hypertrophy and fibrosis (Schnee and
Hsueh, 2000).  This hypertrophy can contribute towards diastolic
dysfunction and heart failure.  Heart mass is shown in figure 5.12,
expressed as a ratio to body weight, and also to tibia length.  Both methods
can be used to show hypertrophy, however the latter method is reported to
be the more accurate ratio based on the slow change in bone size in healthy
adults, contrasted with the relative flexibility of body weight.  Here, similar
trends are seen using both ratios, with Ang II treated animals having larger
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heart mass than control animals. Significant differences are only seen
between TRPA1 KO control and Ang II treated hearts using the ratio to
body weight.  The differences between Ang II treated TRPA1 WT and KO
mice were investigated using t-test, showing significantly larger hearts in
hypertensive TRPA1 KO mice than in hypertensive TRPA1 WT mice,
using both measures of heart mass. Therefore, although Ang II causes an
increase of mass in both WT and KO hearts, but this is significantly more
in TRPA1 KO mice.
Heart morphology was also investigated in vivo using echocardiography.
This is a more detailed measurement and allows investigation of
hypertrophy localisation around the left ventricle.     Figure 5.13 shows left
ventricle mass compared to body weight, measured by echocardiography.
As expected from previous figures, there are trends for increased left
ventricle mass in Ang II treated animals. Hypertrophy is only significant in
TRPA1 KO mice when all groups are compared with ANOVA.  In line
with previously presented data, trends in this graph also suggest that
TRPA1 KO mice are more susceptible to cardiac hypertrophy.
Echocardiography also allows measurement of left ventricular wall
thicknesses in the working heart, expressed as a ratio to body weight.
Measurements taken at the end of the infusion protocol are presented in
figure 5.14.  Changes seen in this graph show that the majority of left
ventricle hypertrophy is derived from the septum and anterior wall, where
there are non-significant increases in thickness compared to control
animals.
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Summary 2 – Hypertrophy In Ang II Treated TRPA1 WT And KO
Mice.
 Body weight was not significantly altered by Ang II infusion,
despite a trend for decreases in body mass in Ang II treated mice,
which was not seen in control mice.  This was not genotype
dependent.
 Significant cardiac hypertrophy occurs in both TRPA1 WT and KO
mice treated with Ang II.  Several measures show TRPA1 KO mice
have similar basal heart mass but KO mice develop significantly
larger hearts than WT mice during Ang II induced hypertension.
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Figure 5.11 Body Weight Of TRPA1 WT And KO Mice Following
14 Day Ang II Infusion Or Control Operation. Results show body
weight A. Measured after 14 days infusion (1.1mg/kg/day Ang II by
osmotic minipump) or in operation control animals. B. Necropsy weight
presented as a % of start weight. All graphs show mixed gender mice. No
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Figure 5.12 Heart Mass Measured At Necropsy Following Ang II
Infusion For 14 Days Or Control Operation. Results show mixed
gender mice terminated after 14 days treatment Ang II by osmotic
minipump (1.1mg/kg/day), or after operation control. A. Shows heart
weight as a ratio to BW. B. Shows heart weight as a ratio to tibia length.
Statistics are from one way ANOVA with Bonferroni’s post-test.
***p<0.001, compared to respective control operated animals, or from a



















































Figure 5.13 Heart Mass Measured By Echocardiography,
Following 14 Days Ang II Infusion Or Control Operation. Results
show A. Left ventricle mass as a ratio to body weight (BW). Graph shows
mixed gender mice.  Statistics are from a one way ANOVA with
Bonferroni’s post-test.  *p<0.05 compared to control. One tailed, unpaired





















Figure 5.14 Heart morphology Measured By Echocardiography
In Ang II Or Control Operated TRPA1 WT And KO Mice. Results
show thicknesses measured after 14 days infusion of Ang II (1.1mg/kg/day
by osmotic minipump), or in operation control mice. A. Left venticular
internal diameter at diastole as a ratio to BW (LVIDd:BW).  B. Left
ventricular anterior wall thickness at diastole, as a ratio to BW
(LVAWd:BW). C. Left ventricular posterior wall thickness at diastole, as a
ratio to BW (LVPWd:BW) D. Interventricular septum thickness at diastole,
as a ratio to BW (IVSd:BW).  All graphs show mixed gender mice. No
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Investigating The Inflammatory Endpoints Of Ang II
Induced Hypertension In TRPA1 WT And KO Mice.
Measuring The Expression Of TRPA1 By RT qPCR And
Comparing This With Expression Of TRPV1 And TRPC5, In
Control And Hypertensive TRPA1 WT And KO Mice
In chapter 1, the genotype of the TRPA1 WT and KO mice was confirmed
by endpoint PCR.  Using RT qPCR, I have also determined the level of
TRPA1 mRNA expression in a variety of tissues and investigated the
influence of Ang II infusion.  For all experiments, results are normalised
against 3 housekeeping genes and a template free sample is also included
to check for cross-contamination.  The housekeeping genes are GAPDH,
mPLA2 and actin.  They have been chosen for their stable expression
patterns in all treatment groups and are used as an index of mRNA
expression for each sample.  As described in chapter 2, their suitability for
this purpose has been tested using the GeNorm software.  Data presented in
figure 5.15 shows TRPA1 expression levels in DRG, aorta, heart and
mesenteric vessels.  These tissues have been chosen as key areas of interest
in the vasculature, which have the potential to be influenced by TRPA1
activity.  The heart and aorta are of direct interest to hemodynamics and
hypertrophy results, whilst the mesentery is of interest to link with my
myography data in chapter 4.  DRG’s have been investigated as the main
reported site of TRPA1 expression, where they mediate the majority of the
receptors effects.
All WT tissues investigated expressed some TRPA1 mRNA, however no
copies were found in TRPA1 KO tissues.  Results shown in figure 5.15
indicate that low expression levels of TRPA1 mRNA are present in
vascular tissues. I am not currently able to comment on the localisation of
TRPA1 expression in this tissue, but this could potentially be a result to
sensory neurone innervation. I am also unable to comment on the levels of
translated TRPA1 protein.  Western blots or immunohistochemistry would
be needed to confirm expression, however the poor availability of selective
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TRPA1 antibodies is an ongoing problem in the field. Ang II is known to
activate many nuclear factors, inducing changes in mRNA expression
(Mehta and Griendling, 2007).   Data in figure 5.15 shows that Ang II
infusion over 14 days significantly increases the level of TRPA1 mRNA
transcription in the DRG, which also expresses high levels of TRPA1
basally.  This data suggests that the main site of TRPA1 mRNA expression
is the DRG, and that it is upregulated in Ang II induced hypertension.
TRPA1 is co-localised with TRPV1 in many locations, including in around
67% of TRPV1 expressing DRG neurones (Kobayashi et al., 2005).  It has
also been suggested to have regulatory effects on TRPA1 activity and
protein levels.  Therefore, I have investigated the TRPV1 mRNA transcript
levels in a variety of tissues, namely DRG, aorta and heart and mesenteric
vessels (Figure 5.16).  Unlike TRPA1, TRPV1 is found to be highly
expressed in all tissues. This demonstrates that TRPA1 mRNA is
expressed at far lower levels than TRPV1 in the vasculature.  Therefore the
effects of activating each population are likely to differ.  In line with this,
TRPV1 mRNA shows some evidence of non-significant upregulation in
TRPA1 WT and KO aortas from Ang II treated mice.  It is unknown if this
is sensory neurone derived expression.  Confirmation of this expression at
the protein level and localisation studies such as immunohistochemistry,
would be of additional value.
Due to the increases in physical activity seen in TRPA1 KO mice, I also
conducted a preliminary study to investigate TRPA1 mRNA expression in
different areas of the mouse brain, and if this was affected by Ang II
induced hypertension.  Several areas and systems in the brain have been
shown to influence physical activity levels and behaviour phenotypes
(Jordan et al., 2008). Levels of TRPA1 expression were measured by RT
qPCR in the medulla, cortex, and striatum, shown in figure 5.17.  In WT
mice, low levels of TRPA1 mRNA are found in all brain regions and this is
unaffected by Ang II induced hypertension.  A TRPA1 KO mouse shows
no TRPA1 mRNA copies.  These findings are in line with the expression of
TRPA1 found in other tissues, suggesting TRPA1 is predominantly
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expressed in the DRG and only sparsely in whole tissues.  Small areas of
the brain may express TRPA1 mRNA but be diluted by the inclusion of
other brain areas, furthermore the nature of this expression is not clear as
low level expression occurred in all brain areas.  Low levels of expression
were not related to poor RNA quality, as the same samples yielded high
levels of TRPC5, another TRP channel expressed highly in the brain
(Okada et al., 1998).  TRPC5 expression was also not altered during
hypertension (5.17B).
Investigating The Levels Of Plasma CGRP In TRPA1 WT And
KO Mice With Ang II Induced Hypertension.
Several studies have suggested that CGRP plays a compensatory role in
hypertension.  This has recently been reviewed by Smillie and Brain
(2011), with some studies showing lower levels of plasma CGRP in
hypertension, and others showing increased levels.  My data also shows
that neuronal TRPA1 mRNA expression is increased in Ang II infused
TRPA1 WT mice, while results presented in chapter 4 show that TRPA1
mediated vasorelaxation occurs via CGRP.  I have not found a difference in
blood pressure between TRPA1 WT and KO mice either basally, or during
Ang II infusion.  However, increased TRPA1 expression levels in the DRG
suggest it could have a role in hypertension, which may be masked by
other factors.  My original hypothesis was that TRPA1 would act to
compensate against hypertension via the release of CGRP.  Therefore I
measured the plasma levels of α/βCGRP using ELISA.  This will be
referred to as CGRP collectively.  As shown in figure 5.18, the results are
in line with results from human essential hypertension patients, measured
in a similar manner by Portaluppi et al (1992).  No significant changes in
plasma CGRP are seen between genotypes, or during experimental
hypertension.  However, there is a trend for decreased CGRP levels in
hypertensive mice.
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Summary 3 – Expression Of TRP Channel Receptors And
Plasma CGRP Levels In Ang II Treated And Control TRPA1 WT
And KO Mice.
 TRPA1 mRNA is not highly expressed at any level of the
vasculature.  This is demonstrated by comparing the findings of
high TRPV1 expression in the vasculature and high TRPC5
expression in the brain, measured from the same samples.  The
responses of these other TRP channels are both largely unaffected
by Ang II induced hypertension.
 TRPA1 mRNA is predominantly expressed in DRG neurones, and
this expression significantly increases during Ang II infusion.
 Basal plasma CGRP levels are not affected by genotype and show a
trend for reduction during Ang II induced hypertension.  This
suggests a lack of effect of TRPA1 activity on basal plasma CGRP
and after 14 days Ang II infusion.
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Figure 5.15 TRPA1 Gene Expression In TRPA1 WT And KO
Mice After 14 Day Ang II Infusion Or Control Operation. Results
show mRNA expression measured by RT qPCR after 14 days infusion of
Ang II (1.1mg/kg/day by osmotic minipump), or operation control. A.
DRG B. Aorta  C.  Heart  D. Mesenteric vessels.  All graphs show mixed
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Figure 5.16 TRPV1 Gene Expression, Measured By RT qPCR, In
14 Day Ang II Or Control Treated TRPA1 WT And KO Mice.
Results show mRNA expression measured by RT qPCR following 14 day
Ang II infusion at 1.1mg/kg/day by osmotic minipump, or operation
control. A. DRG.  B. Aorta.  C) Heart. D) Mesenteric Vessels. All graphs







N=3 N=7 N=3 N=9


















N=3 N=8 N=3 N=9



















N=3 N=8 N=3 N=9


























N=3 N=8 N=3 N=9


















Figure 5.17 TRPA1 And TRPC5 Gene Expression In TRPA1 WT
And KO Mice Following 14 Day Ang II Infusion Or Control
Operation. Results show mRNA expression measured by RT qPCR from
the medulla, cortex and striatum after 14 days infusion of Ang II
(1.1mg/kg/day by osmotic minipump), or operation control. A) TRPA1 B)
TRPC5 (not including TRPA1 KO). Graph shows mixed gender mice. No
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Figure 5.18 Plasma CGRP In TRPA1 WT And KO Mice Following
14 Day Ang II Infusion Or Control Operation. Results show plasma
CGRP measured by ELISA from plasma samples collected after 14 days
infusion of Ang II (1.1mg/kg/day by osmotic minipump), or operation
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Measuring The Expression Of Inflammatory Biomarkers In
Control And Hypertensive Mice, TRPA1 WT And KO Mice
Following the completion of 14 days Ang II infusion, tissues were
collected for RT qPCR.  The expression of pro and anti oxidant proteins
and inflammatory mediators were measured.  The mRNA expression levels
of mediators were investigated in the heart and aorta, as these tissues
showed significantly increased hypertensive hypertrophy in TRPA1 KO
mice compared to WT mice, in the Ang II induced hypertension model.
Pro-Oxidative Markers
Figure 5.19 shows expression levels of NOX2 and NOX4 in the aorta and
heart of control or Ang II treated TRPA1 WT and KO mice.  These
locations were chosen as there are direct links between Ang II activation of
NOX and hypertrophy.  TRPA1 WT and KO control mice display high
copy numbers of NOX2 mRNA in the aorta and heart (5.19A and B), with
a non-significant trend for decreased levels in KO mice.  When analysed
using unpaired t-test, Ang II induced hypertension significantly increases
the levels of NOX2 mRNA expression in aortas of the TRPA1 KO mice,
compared to that of the WT mice.  In the heart there is a strong trend for
increased NOX2 mRNA in both Ang II treated groups. Further N numbers
will be needed to expand on the significance of these findings.
Both the aorta and heart show lower copy numbers of NOX4 (5.19C and
D) than NOX2. Similar to that of NOX2, there is non significant trend for
decreased expression of NOX4 in TRPA1 KO mice aortas, compared to
those of WT mice. Using ANOVA analysis, NOX4 mRNA expression
significantly increases in both WT and KO Ang II treated mouse hearts.
This is of significantly smaller magnitude in TRPA1 WT mice when tested
by t-test, following our interests in phenotype differences between TRPA1
WT and KO mice.  In the aorta, NOX4 expression was not upregulated in
TRPA1 WT mice during hypertension, but analysis by t-test shows
significant upregulation in TRPA1 KO mice treated with Ang II, compared
to their controls.  However, a higher basal level of NOX4 mRNA
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expression means that Ang II treated TRPA1 WT and KO aortas do not
show significant differences. Together, differing regulation mechanisms of
NOX isoforms expression is indicated in the heart and aorta.
Anti-Oxidative Markers
The expression studies on pro-oxidant genes suggest the increased
hypertrophy in KO mice could be due to increased NOX expression and
ROS levels.  To avoid damaging oxidative stress levels, increased levels of
ROS must be met by increased anti-oxidant defences, such as SOD and
HO-1.  Both the aorta and heart show high basal copy numbers of HO-1
and SOD1 mRNA (figure 5.20).  These are not significantly different
between genotypes. Ang II induced hypertension increases mRNA
expression of HO-1 mRNA in both genotypes, however this seems more
prominent in the aorta of TRPA1 KO hypertensive mice and the heart of
TRPA1 WT hypertensive mice (figure 5.20A and B).  This finding
suggests differential regulation in each tissue.  In a t-test, Ang II treated
TRPA1 KO mice show significantly more HO-1 mRNA expression in the
aorta, but significantly less in the heart, compared to Ang II treated WT
mice.
SOD1 expression showed no significant differences in TRPA1 WT and KO
control mice, however Ang II induced hypertension causes non-significant
trends for an increase in SOD1 expression in hearts from both genotypes,
and a decrease in expression in the aorta of TRPA1 KO mice.  When Ang
II treated groups are analysed by t-test, TRPA1 KO mice show a
significantly decreased level of SOD1 mRNA in the aorta, but an increased
expression level in the heart, compared to TRPA1 WT mice.
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Summary 4 – Oxidative Markers In Ang II Induced Hypertensive
Or Control TRPA1 WT And KO Mice
 NOX 4 expression significantly increases in the heart of both
TRPA1 WT and KO mice during Ang II induced hypertension.
Significantly more NOX2 and NOX4 mRNA are found in
hypertensive TRPA1 KO mice, compared to that of hypertensive
TRPA1 WT mice, in the heart and aorta of respectively.  This
suggests there may be increased ROS production in Ang II treated
TRPA1 KO mouse vasculature.
 Anti-oxidative markers HO-1 and SOD1 show trends for
upregulation in Ang II induced hypertension, except for SOD1 in
the aorta. Ang II treated TRPA1 KO mice show significantly
higher levels of HO-1 in the aorta but lower levels of SOD1
compared to Ang II treated TRPA1 WT mice. In the heart they also
show significantly lower levels of HO-1 alongside higher SOD1
mRNA levels compared to Ang II treated TRPA1 WT mice.
Therefore differential effects mean overall antioxidant status is
unclear.
 Overall, data suggests that basal levels of oxidative stress would be
similar in TRPA1 WT and KO mice, however during Ang II
induced hypertension there may be increased oxidative stress in
TRPA1 KO mouse heart and aortas.
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Figure 5.19 NOX2 And NOX4 Gene Expression Measured By RT
qPCR From The Descending Aorta And Heart Of 14 day Ang II
Treated Or Control TRPA1 WT And KO Mice. Results of mRNA
expression measured by RT qPCR following 14 day infusion of Ang II
(1.1mg/kg/day by osmotic minipump), or operation control. A/B. NADPH
oxidase 2 (NOX2) in aorta and heart. C/D. NADPH oxidase 4 (NOX4) in
aorta and heart. All graphs show mixed gender mice. Statistics were
initially done are using one way ANOVA with Bonferroni’s post test, but
showed no significance except for that shown in D) *p<0.05, ***p<0.001,
compared to respective control groups.  Other graphs are statistically
analysed using unpaired, one way t-test between two groups of special
interest; *p<0.05 comparison to respective control, #p<0.05 comparison to





N=2 N=8 N=2 N=9




















N=8 N=17 N=9 N=17





















N=3 N=8 N=3 N=9





















N=6 N=8 N=7 N=7
















Figure 5.20 HO-1 And SOD1 Gene Expression Measured By RT
qPCR From The Descending Aorta And Heart Of 14 Day Ang II
Treated Or Control TRPA1 WT And KO Mice. Results show mRNA
expression measured by RT qPCR following 14 days infusion of Ang II
(1.1mg/kg/day by osmotic minipump), or operation control. A/B.
Haemoxygenase-1 (HO-1) in aorta and heart. C/D. Intracellular superoxide
dismutase (SOD1) in aorta and heart. All graphs show mixed gender mice.
There is no significant differences using one way ANOVA with
Bonferroni’s post test. Statistics shown are from one way, unpaired t-tests
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Essential hypertension is an inflammatory disease associated with an
increase in circulating chemokines and cytokines.
Figure 5.21, tissue expression of MCP-1 mRNA is measured from the aorta
and heart.  These locations have been chosen with respect to the pro-
fibrotic nature of MCP-1 and the hypertrophy that was seen in the
hypertensive mice.  MCP-1 is highly expressed in TRPA1 WT and KO
control mouse aortas and hearts.  A slight trend for decreased levels of
mRNA in TRPA1 KO mice is seen, but is not significant. Ang II induced
hypertension induces non-significant increases in MCP-1 mRNA
expression in the aorta and heart of TRPA1 WT mice, and in the Ang II
treated TRPA1 KO heart. No trend for upregulation is seen in the TRPA1
KO aorta.  As I am interested in differences between hypertensive TRPA1
WT and KO mice in particular, these two groups were analysed by t-test.
This analysis shows significantly higher MCP-1 mRNA expression in Ang
II treated TRPA1 WT aortas, compared to Ang II treated TRPA1 KO
aortas. A similar, non-significant trend is seen in the heart. Therefore
TRPA1 KO mice have blunted increase in MCP-1 expression in Ang II
induced hypertension.
Figure 5.22A and B show the IL-6 mRNA expression in the aorta and heart
of TRPA1 WT and KO mice.  Figure 5.22C shows plasma protein levels.
This data was analysed differently to that of previous expression data as it
did not comply with a normal distribution, as tested by the Shapiro-Wilks
test, thus is analysed with non-parametric tests.  In control mice, basal
levels of IL-6 mRNA expression and plasma protein are similar between
TRPA1 WT and KO mice.  In Ang II induced hypertension the levels of
IL-6 expression and protein increase in both genotypes, but far more so in
TRPA1 WT mice, showing significantly upregulated IL-6 mRNA in the
heart and higher plasma protein levels.  Data from the aorta follows an
identical non-significant trend. Ang II treated TRPA1 KO mice show a
blunted response, showing significantly less IL-6 mRNA in the heart and
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IL-6 plasma protein levels, compared to Ang II treated TRPA1 WT mice.
This data suggests that TRPA1 KO mice are unable to substantially
increase their IL-6 production, or that they reacted differently to Ang II
induced hypertension.
Plasma levels of KC, the murine analogue of IL-8, were also measured in
this study.  This will be referred to as mIL-8.  mIL-8 is a cytokine
associated with inflammatory cell infiltration and has been linked with
cardiac fibrosis. Similar to that of IL-6, this data did not fit a normal
distribution in the Shapiro-Wilks test, so is analysed with the Kruskall-
Wallis test, with Dunn’s post-test, a non-parametric form of ANOVA.  In
figure 5.23, plasma mIL-8 is shown to be similar in control TRPA1 WT
and KO mice. Ang II induced hypertension increases expression in both
genotypes, which was significant only in TRPA1 KO mice.
Summary 5 – Inflammatory Cytokines And Chemokines In Ang
II Induced Hypertension Or Control Operated TRPA1 WT And
KO Mice
 MCP-1 mRNA is highly expressed in the heart and aorta of TRPA1
WT and KO mice.  There are non significant trends for slightly
decreased basal levels in TRPA1 KO mice, and upregulation in
both genotypes in hypertension.  However, there is no upregulation
in TRPA1 KO aortas, significantly differing from the response seen
in TRPA1 WT aortas.
 IL-6 mRNA and protein expression is similar at basal levels in
TRPA1 WT and KO mice, with significant upregulation during
hypertension in TRPA1 WT mouse heart and plasma.  This increase
is significantly blunted in TRPA1 KO mouse heart and plasma.
 mIL-8 protein expression is similar between genotypes at baseline
and upregulated in both TRPA1 WT and KO mice during
hypertension.  This was significant only for TRPA1 KO mice but
did not show a strong genotype dependent effect.
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 All of these inflammatory markers are associated with
inflammatory cell infiltration and fibrotic remodelling.  Although
the overall impact of these findings is not clear.
Investigating The Ability Of Isolated Macrophages To
Produce Inflammatory Cytokines
The expression studies shown previously suggest that TRPA1 KO mice
may respond differently to Ang II induced hypertension.  In particular, data
suggests that oxidative stress may be increased in the aorta and heart of
Ang II treated KO mice, but that they can also have reduced inflammatory
cell infiltration and cytokine responses.  Data in this study shows that
upregulation of IL-6 and MCP-1 is blunted in TRPA1 KO mice.  IL-8 and
IL-6 are both typically produced by macrophages (Jovanovic et al., 1998).
When IL-8 is released in tissues, it causes accumulation of neutrophils into
the area (Jorens et al., 1992).  In tissues, IL-6 induces expression of other
pro-inflammatory markers such as MCP-1, a chemoattractant protein for
macrophages (Tieu et al., 2009). Therefore, all these molecules are
interlinked and are important for the functioning of the innate immune
system, but also induce inflammation that can precipitate cardiovascular
disease.  To further examine the role of macrophages in the production of
cytokines measured in my hypertension model, I developed an experiment
to measure cytokine production from isolated macrophages.  Figure 5.24A
and B shows data collected from a preliminary experiment, where
macrophages are collected from the peritoneal cavity of CD1 mice
following stimulation with 1% oysterglycogen to cause chemotaxis and
increase retrieval numbers.  These macrophages are plated and adhere to
the base of culture dishes, where they are stimulated with Ang II for
various lengths of time.
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Figure 5.21 MCP-1 Gene Expression Measured By RT qPCR
From The Descending Aorta And Heart Of 14 Day Ang II Treated
Or Control TRPA1 WT And KO Mice. Results show mRNA
expression measured by RT qPCR following 14 days infusion of Ang II
(1.1mg/kg/day by osmotic minipump), or operation control. A) Aorta, B)
Heart. All graphs show mixed gender mice. Statistics are one tailed,
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Figure 5.22 IL-6 Gene And Protein Expression In 14 Day Ang II
Treated Or Control TRPA1 WT And KO Mice. Results show IL-6
mRNA expression in the A. descending aorta and  B. Heart measured by
RT qPCR after 14 days infusion of Ang II (1.1mg/kg/day by osmotic
minipump), or operation control. C.  Plasma IL-6 levels measured at the
end of the 14 days infusion.  All graphs show mixed gender mice. As not
all groups show a normal distribution, statistics are from a Kruskal-wallis
test with Dunn’s post test, *p<0.05 compared to control. Following this,
our specific groups of interest were compared with a Mann-whitney U test
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Figure 5.23 Changes In Plasma mIL-8 Levels In Ang II Treated
Or Control TRPA1 WT And KO Mice. Results show mIL-8 plasma
protein measured after 14 days infusion of Ang II infusion (1.1mg/kg/day
by osmotic minipump), or operation control. Graph shows mixed gender
mice. Statistics from Kruskal-Wallis test with Dunn’s post-test due non-
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The supernatent is then analysed using an MSD multiplex ELISA,
quantifying the amount of IL-6 and mIL-8 produced.  Both IL-6 and mIL-8
are detectable 4 hours post Ang II stimulation, peaking at 12 hours.  Levels
decline towards 24 hours.  This data shows that our experiment is
functional, and that cytokine production can be effectively measured over
24 hours post stimulation.  It also highlights the 12 hours time point as the
peak of Ang II induced cytokine production.
This method was used to investigate the ability of macrophages from
TRPA1 WT and KO mice to produce IL-6 and mIL-8 following Ang II
stimulation. As shown in figure 5.25A and B.  IL-6 production occurs later
than expected from our preliminary experiments, peaking at the 24 hour
time point.  Although no significance was achieved within the data, trends
in the graph indicate that macrophages from TRPA1 KO mice do not
produce as much IL-6 as those from paired WT mice.  However, the graph
shows no effect of Ang II stimulation, suggesting that macrophages from
these mice behave differently than those from CD1 mice, and the protocol
may require further optimisation.
The same experiment was conducted to analyse mIL-8 production levels.
In macrophages from TRPA1 WT mice there was no effect of Ang II
stimulation, however, a small peak of mIL-8 is seen at 24 hours.  In
TRPA1 KO mice there seems to be some induction of mIL-8 production by
Ang II, however the profile is unclear.  Control macrophages from TRPA1
KO mice again show a small peak of mIL-8 production after 24 hours Ang
II stimulation.
Therefore, our studies using isolated macrophages are currently at a
preliminary stage, requiring further optimisation. However, loose
interpretation of the existing data could indicate potential trends showing a
reduction in IL-6 production from macrophages isolated from TRPA1 KO
mice, in parallel with increased mIL-8 production.
247
Figure 5.24 IL-6 And mIL-8 Production By Isolated CD1
Macrophages, Treated With Ang II. Results show cytokine protein
concentration in the culture supernatent measured at various time points












































Figure 5.25 IL-6 And mIL-8 Production By Isolated TRPA1 WT
And KO Macrophages, Treated With Ang II Or Vehicle. Results
show cytokine protein concentration in the culture supernatent measured at
various time points after addition of Ang II (1μM, (Ang)) or tissue culture
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In this chapter I have investigated the effect of Ang II induced
hypertension in TRPA1 WT and KO mice.  Similar trends in hypertension,
hypertrophy and systemic inflammation are seen in both genotypes of
mice, suggesting that TRPA1 has a limited role in the pathogenesis of this
experimental disease. Data analysis has been hampered by poor statistical
powering, likely due to low control group N values.  Further studies should
focus on confirmation of the findings by increasing control group numbers.
Significant findings and differences between genotypes found in this
chapter are summarised in table 5.1 and discussed below.
Hypertension; Using Tail Cuff Plethysmography And Telemetry
To Characterise The Profile Of Ang II Induced Hypertension In
TRPA1 WT And KO Mice.
At the beginning of this chapter I used TRPA1 WT and KO mice trained
for blood pressure recordings to be taken by tail cuff plethysmography in a
model of hypertension induced by Ang II infusion.  As discussed in chapter
3, naive TRPA1 KO mice present with a hypotensive phenotype; the
reason for which is unknown.  In this chapter I present serial blood
pressure recordings collected from control mice over a period of one month
by tail cuff plethysmography (Figure 5.3).  In this figure, a strong trend
was shown for a lower mean blood pressure in TRPA1 KO mice, which
reached significance on some occasions.  Whilst demonstrating the stability
of readings from the trained mice, it also suggests that the hypotensive
phenotype is not consistent and frequently lost at intervals coinciding with
weekends, when the animal facility is markedly quieter. This indicates that
housing environment could be a potential source of blood pressure
differences when measuring by tail cuff plethysmography and that these
may be influencing our genotypes differently. This was not followed up
with further investigation, but stress is known to be an important factor in
readings gained from tail cuff plethysmography (Kramer and Kinter, 2003).
To our knowledge, there is no current literature linking TRPA1 with stress.
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TRPA1 WT TRPA1 KO
Hypertension - Similar magnitude and
associated hemodyamics
- Possible trend for faster
onset
- Similar magnitude and
associated hemodyamics
Activity Levels - Unaffected by
hypertension
- Significantly increased
nocturnal activity levels basally
which increase during
hypertension compared to WT
comparable group, when
measured by telemetry.




hypertrophy in Ang II treated




- TRPA1 largely in the
DRG, upregulated in
hypertension
- TRPV1 widely expressed and
not effected by TRPA1 KO or
hypertension
Plasma CGRP - Similar between
genotypes, trend for
reduction in hypertension
- Similar between genotypes,
trend for reduction in
hypertension




SOD1 and heart HO-1 in
hypertensive TRPA1 WT
mice compared to KO
equivalent.




of aortic NOX2 and cardiac
NOX4 in Ang II treated TRPA1
KO mice compared to WT
equivalent.
-Significantly more aortic HO-1
and heart SOD1 in hypertensive




- Cardiac expression and
plasma levels of IL-6
significantly increased in
hypertension
- Significantly blunted increase
in aortic MCP-1, cardiac IL-6
mRNA expression and plasma
IL-6 protein in Ang II treated
KO mice compared to WT
equivalent.
- Significant increase in plasma
IL-8 levels in hypertension
Table 5.1 Summary Of Significant Findings From Data In
Chapter 5
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There are also no described links between TRPA1 and emotional state,
however it is not unfeasible that such a role exists, particularly in light of
the activity data.  In an attempt to learn more about this phenotype, a
preliminary investigation into TRPA1 mRNA expression in the brain was
conducted.  However, the receptor was found to be poorly expressed (see
figure 5.17).  Story et al (2003) have previously failed to find TRPA1 RNA
expression in the whole mouse and rat brain using northern blot analysis.
However this method is less sensitive than the RT qPCR method used in
this chapter.  My results show that there are low levels of TRPA1 mRNA
in the brain, suggesting that TRPA1 may be expressed in small nuclei, but
extraction of mRNA from large areas of brain tissue may well dilute the
signal.  Further investigation will be needed to identify the location of
TRPA1 expression in the brain.
Hypertension levels reached during Ang II infusion were of similar
magnitude in TRPA1 WT and KO mice when measured by tail cuff
plethysmography and telemetry.  This data clearly shows that TRPA1 does
not have a strong influence on the magnitude of hypertension in this model.
This study has produced several novel findings.  Current literature and
previously presented data has shown TRPA1 to be involved in local
vasorelaxation processes, which have been proposed to influence blood
vessel tone and blood pressure (Bodkin and Brain, 2010, Earley et al.,
2009).  There is also some evidence that TRPA1 activation can alter the
actions of the heart and systemic blood pressure (Pozsgai et al., 2010).  In
chapter 4, the various mechanisms described for TRPA1 mediated
vasoreactivity are discussed.  Our TRPA1 KO mice were shown to lack a
vasorelaxation pathway in mesenteric arteries, mediated by CGRP. This
neuropeptide has suggested compensatory effects in experimental and
essential hypertension, however the mechanism is unclear (See Smillie and
Brain, 2011).  Current data from our research group is demonstrating that
CGRP deletion is detrimental in the Ang II induced hypertension model.
These mice experience faster and more pronounced hypertension, along
with increased hypertrophy and inflammatory markers (Smillie,
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unpublished data). These traits are not seen strongly in the data presented
here, using TRPA1 KO mice, which I further hypothesised would have
blunted CGRP release in hypertension. However, this hypothesis is
supported somewhat by results suggesting increased pathology and
oxidative stress in hypertensive TRPA1 KO mice. The plasma protein
concentrations of CGRP in our TRPA1 WT and KO, control and
hypertensive mice were measured.  No significant differences were
observed between groups, despite the levels of expression and plasma
content being within reasonable expected levels (see figure 5.18).   Trends
for a reduction in plasma CGRP during hypertension were also seen in both
genotypes.  This may reflect a downregulation of CGRP by pressor agents,
a feature characteristic of established and severe hypertension (See Smillie
and Brain, 2010).  Lower doses of Ang II infusion, over a longer period
may produce a longer hypertension development window where
differences in CGRP levels may be apparent. The fast onset of
hypertension in this model may be masking any subtle roles of TRPA1.
In the current model, differences in the onset time of Ang II induced
hypertension were seen.  However, these differed depending on the method
of blood pressure measurement.  Using tail cuff plethysmography, TRPA1
WT mice showed significantly higher blood pressure than their controls at
an earlier time point, suggesting a quicker onset. Opposing trends are seen
in telemetry data, however these are lost when data from mice who died
prematurely is added.  Together, this suggests that onset patterns are likely
to be similar between genotypes and any non-significant differences seen
in the data are due to animal to animal variability. Increasing N numbers
would confirm this.
In hypertension measured by telemetry, the majority of pressure increase
occurs within the first two days of infusion, with stable readings achieved
after about 5 days.  However, using the tail cuff method, blood pressure
continued to increase over most of the 14 day Ang II infusion.  As tail cuff
measures blood pressure from a large peripheral artery, and telemetry
measures central blood pressure, differences in vascular tone and pressure
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wave deflection may be altering the appearance of measurable
hypertension.  Although correlations between central and peripheral blood
pressure are strong, antihypertensive strategies are known to differentially
influence each measurement.  For example, beta-blockers reduce peripheral
blood pressure more than central blood pressure (McEniery, 2009).
Various studies have been done to show that central blood pressure is the
best single measure for estimating cardiovascular event risks (Safar and
Jankowski, 2009).  However, detailed analysis of the pulse pressure wave
at different anatomical sites can be valuable in assessing pathology (Nelson
et al., 2010). During Ang II induced hypertension there is vascular
remodelling and peripheral vasoconstriction, which may act to alter
pressure wave deflections and thus peripheral blood pressure
measurements. Additionally, it is feasible that Ang II infusion induced
hypertension may be resisted for longer in peripheral arteries, which have
the capacity to dilate as systemic pressure increases. As both central blood
pressure and peripheral blood pressure are important in hypertension, both
are useful parameters to measure. Central blood pressure will better reflect
the stresses made on the heart and large blood vessels, whereas peripheral
blood pressure reflects the stress experienced by organs.
In addition to pressures, telemetry also allows collection of paired heart
rate, pulse pressure and activity measurements.  Apart from activity, which
will be discussed later, no significant differences were observed between
TRPA1 WT and KO mice in these parameters.  Both WT and KO mice
showed clear diurnal rhythms in their blood pressures and heart rate, in line
with their activity levels, throughout the Ang II infusion period.
Activity; TRPA1 KO Mice Display A Hyperactivity Phenotype.
As shown in chapter 3, TRPA1 KO mice demonstrate a previously
undescribed hyperactivity phenotype, measured using telemetry probes to
quantify spontaneous activity counts and wheels to assess nocturnal
exercise.  In this chapter, the effect of Ang II induced hypertension on
activity levels was examined.  Data collected by telemetry shows that
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nocturnal activity peaks in TRPA1 KO mice are gradually exacerbated
over the 14 days of Ang II infusion, while TRPA1 WT mouse activity
levels remain stable.  The difference between TRPA1 WT and KO mice is
significant when the total activity between day 8 and 14 is analysed.  The
reason for hyperactivity in TRPA1 KO mice is not clear, or is the nature of
the motions being made.  This finding is unexpected and deserves further
study. Ang II has not shown direct modulation of activity levels, however
exercise has been shown to reduce AT1 and NADPH expression,
associated with decreases in endothelial dysfunction (Rush and Aultman,
2008).  These features are unlikely to be present in my hypertension study
as the mice included in this experiment did not have access to running
wheels. Additionally, in my study Ang II and AT1 levels have not been
measured, but TRPA1 KO mice seem to have high NADPH expression
despite increased spontaneous activity.  This data will be further discussed
with that of basal activity levels in the general discussion.
Hypertrophy; TRPA1 KO Mice Show Significantly Exacerbated
Hypertrophy In The Ang II Model Of Experimental Hypertension
TRPA1 WT and KO mice both experience hypertension and hypertrophy
during Ang II infusion, in line with the expected outcome of this
experimental model (Simon et al., 1995).  However, necropsy based and
echocardiographical data show significantly increased hypertrophy of the
heart in hypertensive TRPA1 KO mice, compared hypertensive to TRPA1
WT mice.
Hypertrophy can occur through many mechanisms, for example increased
blood pressure or systemic inflammation.  Shear stress and pressure can be
a major initiator of inflammation and stress signalling in the
cardiomyocyte, causing hypertrophy (Hayashi and Naiki, 2009).
Hypertension was similar in TRPA1 WT and KO mice, and has
undoubtedly contributed to myocyte hypertrophy, but is not responsible for
the differences between TRPA1 WT and KO mice as blood pressures were
similar.  Further additions to this work would be to use slower onset or sub-
pressor doses of Ang II, allowing more accurate dissection of blood
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pressure and inflammatory changes.  Sub-pressor doses, causing
remodelling in the absence of hypertension, would allow more detailed
investigations into the potential protective effects of TRPA1 in
hypertrophy. Additionally, increasing N numbers to compensate for those
animals lost during the procedure would improve the statistical power of
this study, allowing trends to be better established as a starting point for
further investigation.
Cytokine and chemokine production from myocytes can also increase
inflammatory cell infiltration, perpetuating the inflammatory nature of the
environment and encouraging fibrosis through the activation of fibroblasts
(Kakkar and Lee, 2010).  The details of this data will be discussed later in
this chapter, however the main differences found in cytokine production
were blunted increases in IL-6 and MCP-1 in TRPA1 KO mice.  Literature
suggests that these findings should have a protective effect against
hypertrophy, which is not found in our data.  Although these inflammatory
mediators are not responsible for the differences in hypertrophy seen, Ang
II induced hypertension is associated with a wide range of cytokines and
chemokines which may well be influencing hypertrophy.
Oxidative stress and inflammation independent of those induced by
increased blood pressure are more likely to be mediating these changes.  I
have investigated several markers of oxidative stress, showing increased
levels of NOX isoforms in the heart of both TRPA1 WT and KO
hypertensive mice and in the aorta of hypertensive TRPA1 KO mice.
Significantly increased NOX2 mRNA expression in the aorta and NOX4
mRNA expression in the heart was seen in Ang II treated TRPA1 KO
mice, compared to Ang II treated WT mice.  This was met with varying
degrees of SOD1 and HO-1 expression.  In general, trends for increased
pro-oxidant and anti-oxidant gene expression were seen in both genotypes
of hypertensive mice. However, trends suggest there may be increased
oxidative stress in hypertensive TRPA1 KO mice compared to WT mice,
which could be inducing hypertrophy via activation of inflammatory and
remodelling genes in myocytes or fibroblasts.  Myocytes can move to a
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more fibrotic phenotype, producing extracellular matrix components and
remodelling enzymes (Sampson et al., 2011).  The levels of remodelling
enzymes have not been measured in this study, but would be a valuable
addition to the work.
Gene Expression Of TRP Receptors And CGRP; TRPA1 WT
Mice Display An Upregulation Of TRPA1 During Ang II Induced
Hypertension
TRPA1 has been demonstrated to be upregulated in diseases where sensory
neurones are activated (Diogenes et al., 2007) and in response to cytokines
such as IL-1α (Hatano et al, 2012).  I investigated the effects of Ang II
infusion on the mRNA expression of TRPA1.   Low copy numbers of
TRPA1 mRNA were found in vascular tissues of all sizes, namely the
mesenteric bed, aorta and heart.  TRPA1 was expressed at higher levels in
DRG, which additionally showed significant upregulation of TRPA1
during hypertension.  This suggests that sensory neurones are active in the
hypertension model, however their role is unclear.
In chapter 4, I demonstrate a role for TRPA1 in cinnamaldehyde induced
relaxation of mesenteric arteries.  The finding of low expression in this
location therefore suggests either that relatively few copies are needed for a
physiological effect, and/or that the expression seen in the mesenteric
arteries may have represented presence of innervating sensory neurones.
The same reverse transcribed cDNA pool was then used to investigate the
levels of TRPV1 and several housekeeping genes, which showed higher
copy numbers in all tissues, suggesting that the low TRPA1 expression
accurately reflects the situation in the tissue and is not a result of poor
cDNA template.  It is also not due to poor primers, as no TRPA1 copies
were found in TRPA1 KO animals and significant levels of TRPA1 were
found in the DRG, which is likely to represent the main expression site of
the receptor for consideration in this study.
Previous publications have suggested the activity and expression level of
TRPA1 can influence that of TRPV1, and vice versa (See Introduction).  In
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this study, I observed high levels of TRPV1 mRNA expression in the
DRG, aorta, heart and mesenteric vessels of TRPA1 WT and KO mice.
This suggests that TRPV1 expression is not regulated by TRPA1
expression in our mouse strain.  TRPV1 has been found in a number of
non-neuronal tissues including vascular smooth muscle and endothelial
cells (Bratz et al., 2008, Kark et al., 2008), thus some of this expression
may be related to non-neuronally expressed TRPV1.  The level of TRPV1
mRNA expression was increased in the aorta of both genotypes during
experimental hypertension, but not in the other tissues studied.  As
upregulation of TRPA1 was not seen in the aorta, and TRPV1 was not
upregulated on DRG, these results suggest that different expression
regulation mechanisms may be operating for each of the receptors and
show tissue specificity.  This may be related to non-neuronal expression of
TRPV1.
Upregulation of TRPA1 expression in DRG from hypertensive mice was
not associated with an increased plasma level of CGRP (figure 5.17). This
may be related to the inhibitory effect of Ang II on CGRP release
(Kawasaki et al., 1997). The detailed mechanisms that control the
transcription of TRPA1 in DRG’s have not been described but recent
reports have demonstrated upregulation of TRPA1 by NFκB and HIF1α
transcription factors activated by cytokines (Hatano et al, 2012). Studies
also show that TRPA1 is upregulated in diseases where sensory neurones
are activated (Diogenes et al., 2007), leading to the suggestion that sensory
neurones were active in our model. However the nature of their activity
cannot be found from our data.  These findings are in keeping with my
hypothesis that sensory neurone expressed TRPA1 may be part of the
protection mechanisms against hypertension onset.  The model of
hypertension used in this study appeared to be severe, with fast onset,





Pro-Oxidants; Hypertension Increases The Expression Of NOX
Isoforms
Inducing the production of ROS is an important component of Ang II
induced hypertension and vascular inflammation.  There are strong
correlations between the level of oxidative stress and the end organ damage
associated with hypertension (Touyz, 2004), which propagates the
progression of cardiovascular disease.  In this study, changes in mRNA
expression of NADPH oxidases, the main producers of Ang II induced
ROS, were quantified.  Although I did not measure the levels of tissue
oxidative stress, it is known that Ang II can activate these enzymes to
increase the level of ROS (Oudot et al., 2003).  It is also almost impossible
to know the enzymatic and anatomical source of ROS, even where tissue
levels are measured.
NOX2 is a form of NADPH oxidase. It predominantly produces
extracellular superoxide that can go on to damage surrounding cells
(Bedard and Krause, 2007).  NOX2 is found on immune cells and the
vasculature, heart and kidney, expressed within intracellular compartments
and at the plasma membrane (Bedard and Krause, 2007). It is not found in
vascular smooth muscle from large arteries (Wang et al., 2007).  NOX2 is
commonly associated with the severity and damage of Ang II induced
hypertension (Paravicini and Touyz, 2008). NOX2 KO mice have a lower
basal blood pressure (Bandell et al., 2007) and aortic NOX2 over-
expression significantly worsens hypertension (Bandell et al., 2007,
Lassègue and Griendling, 2010).  NOX2 is also implicated in hypertrophy,
independently of hypertension and blood pressure control.  Using the two
kidney two clip (2K2C) model of hypertension, which causes overactivity
of the RAS system, Wang et al (2007) show that AT1 activation
upregulates NOX2 in the left ventricle of the heart, correlating with
increased superoxide and cardiac hypertrophy.  Similarly, Johar et al
(2006) used NOX2 KO mice to show that Ang II activates NOX2 causing
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fibrosis in the heart, building on a previous study by Bendall et al (2002),
also using NOX2 KO mice to demonstrate NOX2 mediates cardiac
hypertrophy.  In light of these findings, I determined the gene expression of
NOX2 in the aorta and heart, using RT qPCR.
In this chapter, control TRPA1 KO mice showed some non-significant
trends for lower basal expression of NOX isoforms in the heart and aorta,
compared to that of TRPA1 WT mice.  This may mean that TRPA1 KO
mice have a lower level of basal oxidative stress, which would be
beneficial in terms of inflammatory diseases.  After inducing hypertension,
there was some evidence of NOX2 upregulation in the heart and aorta of
TRPA1 KO mice and in the heart of TRPA1 WT mice.  Upregulation of
mRNA expression seemed to be strongest in the KO mice, where NOX2
expression is significantly higher in aortas from hypertensive KO mice
compared to that of hypertensive WT mice.  Aortic expression of NOX2
likely represents that of endothelial cells, infiltrated phagocytes and
potentially fibroblasts.  Several reviews show NOX2 upregulation in the
aorta following Ang II infusion is associated with vascular hypertrophy,
endothelial dysfunction and increased blood pressure (Lassegue and
Clempus, 2003, Lassègue and Griendling, 2010).  In this study,
significantly upregulated NOX2 mRNA in TRPA1 KO mice was not
associated with increased blood pressure but may be linked to the observed
increase in cardiac hypertrophy.
The NOX4 isoform of NADPH oxidase also has strong links with
hypertension.  It is often found on intracellular membranes, is abundantly
expressed in the kidneys, but also found in all vascular cells, fibroblasts
and cardiomyocytes (Lassègue and Griendling, 2010).  NOX4 differs from
other isoforms in that it has been reported to predominantly produce H2O2
(Dikalov et al., 2008), which is a vasodilator (Matoba and Shimokawa,
2003) and the major signalling ROS form, possibly accounting for its more
favourable role in hypertension.  The role of NOX4 in the vasculature is
not well defined, as studies show it to be differentially regulated in
endothelial cells by different stress stimuli, and to have both positive and
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inhibitory influences on vascular smooth muscle growth (Lassègue and
Griendling, 2010).  Wang et al (2007) have shown AT1 dependent
upregulation of NOX4 in the heart and aorta in rats undergoing 2K2C
induced hypertension, associated with elevated blood pressure and cardiac
remodelling.  However, Ang II reduced NOX4 expression in cultured
vascular smooth muscle cells in a study by Lassegue et al (2001), and
Chabrashvili et al (2003) also show Ang II infusion in vivo causes AT1
dependent reduction of renal NOX4.  NOX4 also has influences on Ang II
pressor responses.  Ray et al (2011) have shown endothelial NOX4 over-
expressing mice to have a lower blood pressure, as a consequence of
increased H2O2.  A role for NOX4 in cardiac fibrosis has also been
suggested, as it has been shown to correlate with TGF-β induced
conversion of cardiomyocytes to myofibroblasts (Cucoranu et al., 2005).
Anilkumar et al (2008) found over-expression of NOX4 in HEK293 cells
to substantially increase basal ROS level, leading to ERK and JNK
signalling. Therefore, there appears to be location specific changes in Ang
II regulation of NOX4 expression.
In this chapter, basal levels of NOX4 mRNA expression in the aorta and
heart were lower than that of NOX2, with a trend for lower expression
levels in the TRPA1 KO aorta compared to the WT aorta.  NOX4 was
significantly upregulated in the heart of both TRPA1 WT and KO
hypertensive mice, and also in the aorta of TRPA1 KO mice, bringing it up
to comparable levels with control and Ang II treated TRPA1 WT mice.
Additionally, significantly higher levels of NOX4 mRNA expression were
seen in hearts from hypertensive TRPA1 KO mice compared to hearts from
hypertensive WT mice.  The consequences of this are not clear, but are not
linked to genotype specific changes in blood pressure.  They may be linked
to increased hypertrophy in KO Ang II treated mice.
Combined, these findings demonstrate that Ang II increases the expression
of NADPH oxidases, which is likely to increase the production of ROS.
These increases are frequently of significantly larger magnitude in TRPA1
KO mice, where if these changes are not balanced by an increase in anti-
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oxidant mechanisms, increased levels of damaging oxidative stress will
exist and may have pathological consequences.
Anti-oxidant defences; Hypertension Increases Anti-Oxidant
Gene Expression
Evidence of the role of exogenous anti-oxidants in protecting against
hypertension is conflicting.  Several preliminary animal and patient studies
have shown benefits of antioxidant supplements in essential hypertension,
however large clinical studies have been disappointing (See Sedeek et al
(2009), Paravicini and Touyz (2008) and Touyz and Briones (2011)).
Despite this, effective endogenous anti-oxidant mechanisms are needed to
counter Ang II induced ROS production if the creation of damaging levels
of oxidative stress is to be avoided.  In order to gauge the amount of
oxidant defences mounted in our hypertensive model, the expression of
some anti-oxidant enzymes were measured, namely HO-1 and intracellular
SOD.
Intracellular SOD, or SOD1, is known to participate in redox signalling
involved in inflammation, angiogenesis and vascular function.  SOD is an
antioxidant gene which converts superoxide to H2O2, in order for its
degradation.  Studies using extracellular SOD KO mice in Ang II induced
hypertension have shown that it provides a protective mechanism in large
arteries, reducing oxidative stress and blood pressure (Gongora et al.,
2006).  This SOD isoform is heavily implicated in the control of vascular
tone in a variety of vessel types, both due to its ability to reduce NO
inactivation by superoxide, and to produce dilative H2O2 (Fukai and Ushio-
Fukai, 2011).   Similarly, intracellular SOD KO mice show increased
myogenic tone in carotid artery rings, impaired endothelial dependent
relaxations and augmented vasoconstrictor responses (Didion et al., 2002).
Wang et al (2002) have previously shown intracellular SOD expression to
be increased by Ang II infusion in mice, lowering the superoxide levels. In
my study, basal levels of intracellular SOD were similar in the aorta and
showed a non significant trend for lower levels in the heart of TRPA1 WT
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mice, compared to KO mice. Ang II induced hypertension caused some
trends for upregulation in the hearts of both genotype, however this was
stronger in the KO, where significantly higher levels were measured
compared with hypertensive WT mouse hearts. Conversely, in the aorta,
Ang II treated mouse aortas showed significantly less SOD1 mRNA
expression than Ang II treated TRPA1 WT mouse aortas.  These
differences make the level of antioxidant defences in each tissue hard to
conclude and suggest different regulation pathways occur in each tissue,
with differing effects of TRPA1.  This may depend on the predominant cell
types present. These findings are consistent with some of our other results,
showing increased expression of inflammatory molecules and anti-oxidant
defence genes in hypertension.
HO-1 was also measured in the aorta and heart.  HO-1 is an antioxidant
mechanism induced by oxidative stress, thus can be used as both an
indicator of ROS production and as a level of mounted anti-oxidant
defence.  The protective effects of HO-1 activity are multifold (Turkseven
et al., 2005).  HO-1 breaks down heme to form bilirubin and carbon
monoxide (CO).  CO is a vasodilator in all vascular beds, inducing vascular
smooth muscle relaxation via induction of cGMP and by stimulation of
calcium activated potassium channels (Chen et al., 2003).  It also reduces
the production of vasoconstrictor agents such as endothelin-1 (Morita and
Kourembanas, 1995) and induces antioxidant defence genes (Peterson et
al., 2009).  CO acts on vascular smooth muscle cells in a similar manner to
NO; however, although it is more stable, it is 1000x less potent at relaxing
vessels (Furchgott and Jothianandan, 1991).  Bilirubin is a potent
antioxidant, mopping up potentially harmful ROS that may mediate
increases in blood pressure and end organ damage during hypertension.
Following Ang II application, bilirubin has been shown to reduce migration
and ROS production from monocytes, and oxidative stress damage to
endothelial cells (Peterson et al., 2009).   It can also inhibit the action of
neutrophil NOX2 (Kwak et al., 1991).  In endothelial cells, HO-1 acts to
increase eNOS expression and decrease inflammatory gene expression,
including cell adhesion molecules; an effect likely to be occurring via
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bilirubin (Peterson et al., 2009).  However, i.p. administration of biliverdin,
the precursor of bilirubin, does not alter blood pressure in rats (Johnson et
al., 1995). Together, these findings suggest that HO-1 is an important
mediator in essential and experimental hypertension, providing a protective
effect and opposing disease progression.
In this chapter, control mice showed similar levels of HO-1 mRNA
expression, which was not affected by TRPA1 deletion.  The induction of
hypertension caused non-significant increases in HO-1 expression in both
tissues. Similarly to SOD the magnitude of increase was tissue and
genotype dependent.  This produced significantly higher levels of HO-1
expression in the aorta, and significantly lower levels of HO-1 in the heart
of TRPA1 KO mice treated with Ang II, compared to the Ang II treated
TRPA1 WT group.  This again makes interpretation of anti-oxidant
defence levels difficult.
The combined analysis of SOD1 and HO-1 gene expression suggest anti-
oxidant defences are increased during hypertension, as expected from the
increase in pro-oxidant proteins.  ROS can induce upregulation of both pro-
and anti-inflammatory genes via a range of signalling pathways, such as
NF-κB, MAPK, AP-1 etc (Fukai and Ushio-Fukai, 2011, Touyz and
Briones, 2011).  Potential links to TRPA1 activity also exist as ROS and
their products are known to activate the receptor (Andersson et al., 2008).
Cytokines And Chemokines
Cardiovascular diseases are pro-inflammatory in nature, and are associated
with several inflammatory biomarkers.  In this study, IL-6, mIL-8 and
MCP-1 were selected as markers of inflammation, as they are linked to
hypertrophy and inflammatory cell infiltration.  Cytokines and chemokines
are produced from cells activated by stress, via signalling pathways such as
NF-κB.  IL-6 and IL-8 are both typically produced by macrophages
(Jovanovic et al., 1998), whereas MCP-1 is produced by a range of cells,
including those of the vasculature wall.  The main function of IL-8 is to
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attract neutrophils to a tissue site (Jorens et al., 2009), whereas MCP-1 is
used to traffic monocytes.  Both of these chemokines are linked to cardiac
remodelling (Collier et al., 2011).  IL-6 has more diverse functions, but in
the context of hypertension it is linked to cardiac stress.
MCP-1
MCP-1 is a key chemokine expressed by vascular, renal and cardiac cells.
It can be expressed by all vascular tissues, including endothelial cells,
fibroblasts, vascular smooth muscle and cardiomyocytes (Niu and
Kolattukudy, 2009). It has a role in the physiological trafficking of
monocytes into tissues, where it is upregulated by inflammatory stimuli
such as increased shear stress, oxidative stress and Ang II, under the
control of NFκB (Zhuo, 2004). MCP-1 can be attached to the lumen wall
by proteoglycans, or can be free in the tissue.  Its primary function is as a
chemotactic source for monocytes.  MCP-1 is a potential biomarker for
chronic inflammatory diseases, with plasma levels correlating with disease
severity (Yao et al., 2006).  Treatment of isolated leukocytes with MCP-1
causes respiratory burst, expression of pro-inflammatory cytokines and
upregulation of matrix metalloproteins (Niu and Kolattukudy, 2009).  In
the heart, MCP-1 expression is associated with fibrosis, remodelling and
upregulation of stress response genes.  Behr et al (2004), previously used
Ang II infusion to induce experimental hypertension, showing a low dose
of AT1 antagonist Eprosartan, which does not affect blood pressure, to
reduce MCP-1 expression in the myocardium whilst also reducing
macrophage infiltration, disease progression and mortality.  This suggests
that MCP-1 is important in Ang II induced inflammatory responses
associated with organ damage.  Furthermore, Kolattukudy et al (1998)
have produced a mouse overexpressing MCP-1 specifically in the
myocardium.  This mouse strain presented with myocarditis, characterised
by monocyte infiltration, remodelling and a decrease in contractile
function.  This also indicates that inflammatory cell migration may be an
important step in initiating the pro-inflammatory conditions in the heart,
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leading to harmful complications and cardiovascular disease progression in
hypertension.
In this chapter, MCP-1 expression increased in hearts from both genotypes
during hypertension, however this does not show statistical significance.
In the aorta, increased expression only occurred in WT mice, created a
significant difference between Ang II infused WT and KO mouse aortas.
This suggests MCP-1 production in the aorta is blunted by TRPA1 KO.
These findings were not consistent with the end points of my study, where
TRPA1 KO display more cardiac hypertrophy.   The reasons for this, and
the role played by MCP-1 in my experimental model, are currently unclear.
Further analysis could benefit from measurement of protein levels, as these
do not necessarily follow on from mRNA expression patterns.
mIL-8
IL-8 has powerful chemoattractant properties for inflammatory cells.  It has
recently been correlated with hypertensive diastolic dysfunction, where
cardiac fibrosis reduces heart function (Collier et al., 2011).  The mouse
homolog of IL-8 is KC, which was measured in this study and will be
referred to as mIL-8.  In this chapter, mIL-8 plasma levels were similar in
control TRPA1 WT and KO mice, and show similar magnitudes of
increase following Ang II infusion, but only reaching significance in
TRPA1 KO mice.  The effect of Ang II stimulation of isolated
macrophages was further investigated, where it appeared that macrophages
from TRPA1 KO may produce more mIL-8 than those from WT mice.
The data is potentially conflicting, however the isolated macrophage
studies show the effects of acute application, which may differ from the
effects of chronic stimulation.  Therefore, in balance, mIL-8 is unlikely to
be a mediator of increased hypertrophy in hypertensive TRPA1 KO mice.
Studies of cell infiltration into heart and vessel samples would be of value
to back up this data suggesting inflammatory cell infiltration.
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IL-6
Lastly, I have measured the mRNA expression and plasma levels of IL-6.
IL-6 is produced in large amounts from macrophages, but can also be
produced by other cell types, notably fibroblasts, endothelial cells, vascular
smooth muscle and exercising skeletal muscle. IL-6 has positive actions
relating to exercise and the clearance of bacterial infection (See Fisman and
Tenenbaum, 2010).  IL-6 is rapidly produced and released by skeletal
muscle during exercise, in an amount proportional to duration, intensity,
muscle mass and endurance capacity.  Its main effect is to increase insulin
sensitivity, allowing more effective glucose uptake to exercised muscles
(Fisman and Tenenbaum, 2010).  IL-6 levels are positively correlated with
all-cause mortality, often showing parallels with other biomarkers
reflecting harmful processes (Fisman and Tenenbaum, 2010).  IL-6 has
been linked to hypertension, as a marker of severity and end organ damage.
IL-6 is a plasma biomarker of diastolic dysfunction in asymptomatic
hypertensive patients (Collier et al., 2011). Previous studies have shown a
strong association between IL-6 plasma levels and gene polymorphisms
with systemic inflammation and risk of cardiovascular disease (Liu et al.,
2006, Aker et al., 2009).
A recent study by Melendez et al (2010), where IL-6 is infused
subcutaneously in normotensive rats, this cytokine caused myocardial
fibrosis, hypertrophy and diastolic dysfunction, independently of blood
pressure.  IL-6 has been described as a dominant marker of myocardial
cytokine activity in a model of spontaneously hypertensive rat heart failure
(Haugen et al., 2008).  It is produced from isolated vascular smooth muscle
cells upon stimulation with pro-inflammatory cytokines, such as IL-1, and
during proliferation, but does not stimulate further direct effects on
endothelial or smooth muscle cells (Loppnow and Libby, 1990).
Therefore, the actions of IL-6 may be targeted on activation of
accumulated inflammatory cells, which in turn produce more ROS and
cytokines, causing myocardial hypertrophy and leading to heart failure in
hypertension.  IL-6 expression is known to be upregulated following Ang
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II treatment and related to the expression of other chemokines, attracting
inflammatory cells to the tissue (Manhiani et al., 2007).
In this chapter, IL-6 expression and plasma levels were similar in TRPA1
WT and KO control mice.  A similar level of IL-6 release was also seen
from TRPA1 WT and KO isolated macrophages.  Following experimental
hypertension, IL-6 levels were significantly increased TRPA1 WT mice
but less so in KO mice. IL-6 expression in hypertensive TRPA1 WT mouse
hearts and plasma protein levels were both significantly increased
compared to hypertensive TRPA1 KO mice.  Similar non-significant trends
were seen in IL-6 expression in the aorta.  In isolated macrophages,
changes in IL-6 production were unclear, potentially suggesting a lower
capacity for production in TRPA1 KO mouse macrophages. However,
these studies are acute rather than for chronic angiotensin stimulation and
require further optimisation.  Our findings are not consistent with those in
the literature, suggesting that high IL-6 levels induce cardiac hypertrophy
in WT mice, whereas KO mice should show some protection.
The findings of blunted MCP-1 and IL-6 increase during hypertension in
TRPA1 KO mice are interesting.  This indicates that TRPA1 KO mice have
an anti-inflammatory pathway in operation, which is not at play in WT
mice, blocking the rise in these cytokines associated with cell infiltration
and cardiac fibrosis.  This suggests TRPA1 expression may be pro-
inflammatory and combines well with the literature and previous work
from our lab, showing TRPA1 activation to cause inflammatory cell
infiltration (Silva et al., 2011, Bodkin et al, Unpublished data).  However,
our findings contrast with those from single cell cultures by Hatano et al
(2012), who show TRPA1 activity in synoviocytes inhibits their production
of IL-6 and IL-8.  Furthermore, the effects of reduced IL-6 in our model
are not as expected, as KO mice showed increased pathology. This
suggests complex interactions I attempted a preliminary study of the
capacity for Ang II to stimulate cytokine release from macrophages
isolated from TRPA1 WT and KO mice, investigating whether the low
levels of cytokine production are based around inherent changes to
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macrophages.  However, this protocol needs further work to provide clear
conclusions.
Conclusion
In this chapter I have conducted a novel study investigating the effect of
genetic TRPA1 deletion in a model of experimental hypertension, mediated
by the infusion of Ang II.  My original hypothesis was that TRPA1 KO
mice would far worse in terms of hypertension, associated pathology and
biomarkers.  This would be due to a lack of dilative and anti-inflammatory
mechanisms, mediated by CGRP, which would compensate for the onset of
these disease characteristics.  Results stemming from this study are
complex, and summarised at the beginning of this discussion, but suggest
that TRPA1 has only a mild influence on the pathogenesis involved in our
model of Ang II induced hypertension.  The magnitude and onset of
hypertension was not significantly different in TRPA1 WT and KO mice,
neither were heart rate measurements.  Similar to data presented in chapter
3, KO mice showed a hyperactivity phenotype which will be discussed
further in the general discussion.  Hypertrophy, a pathological change in
hypertension associated with diastolic function and heart failure, occurred
significantly in the heart of both genotypes.  However, data consistently
showed more hypertrophy in Ang II treated TRPA1 KO mice compared to
Ang II treated WT mice.  Further analysis of biomarkers was used to
associate this with potentially higher levels of hypertensive oxidative stress
in TRPA1 KO mouse vasculature. Significant increases in pro-oxidative
markers occurred in both genotypes of hypertensive mice, but of
significantly larger magnitude in TRPA1 KO mice.  This appeared not to
be compensated for by consistently increased antioxidant markers.  Levels
of inflammatory chemokines and cytokines, which may mediate
remodelling, were increased in both hypertensive mouse groups, however
TRPA1 KO mice showed significantly blunted increases in MCP-1 and IL-
6 production.  This is surprising considering the suggested increase in
pathology and is indicative that TRPA1 mediates some pro and anti-
inflammatory effects.
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A further important finding was made in terms of TRPA1 expression,
where TRPA1 mRNA was found to be predominantly expressed on DRG
neurones, where it was upregulated in Ang II induced hypertension.
TRPA1 mRNA was found to be poorly expressed at all levels of the
vasculature and brain, in contrast to TRPV1 and TRPC5 respectively.  This
finding supports our previous conclusions of a sensory neurone mediated
effect of TRPA1 activation.  However, TRPA1 KO or upregulation in the
DRG during hypertension in WT mice, was not associated with changes in
plasma CGRP levels.  This disproves my hypothesis, at least for the
hypertension model used and time points investigated.  However, as
detailed above, TRPA1 was seen to have some interesting modulatory
responses in Ang II induced hypertension, which suggest both pro and anti-
inflammatory actions exist for the receptor in vivo.  These, along with the
findings of similar blood pressure and hyperactivity in TRPA1 KO mice,
are novel additions to the current knowledge of the TRPA1 role in
pathophysiology.
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Chapter 6 - General Discussion
My hypothesis was that TRPA1 is involved in the control of resistance
vessel tone. In vivo, it contributes to the control of blood pressure by
keeping peripheral resistance low and will resist the onset of hypertension
by releasing neuropeptides when it is activated by elevated levels of
endogenous agonists.  Genetic deletion of TRPA1 will lead to a loss of this
process, increasing basal blood pressure and resulting in susceptibility to
hypertension, with increased vascular inflammation and worsened
hypertensive endpoints.
Using the evidence presented in this thesis, I am now able to address the
previously stated aims and comment on how the evidence collected fits
with my hypothesis.
Aim 1
Investigate the basal cardiovascular phenotype of TRPA1 KO mice
compared to matched WT mice.  I wish to particularly focus on basal blood
pressure control and will measure this in conscious animals by both tail
cuff plethysmography and telemetry.
This study was novel, producing new information for the field.  To achieve
this aim, I characterised the basal cardiovascular phenotype of mixed
gender TRPA1 WT and KO mice. The majority of data relating to this aim
is presented in chapter 3.  Measurements of basal blood pressure were
collected by tail cuff plethysmography and telemetry on different sets of
experimental animals.  Tail cuff plethysmography measured peripheral
blood pressure, whereas telemetry measured central blood pressure.  Whilst
TRPA1 KO mice were seen to show higher basal blood pressure using
telemetry, a significant hypotensive phenotype was seen in TRPA1 KO
mice measured by tail cuff.  The reasons for these differences are discussed
in chapter 3, but are likely to represent methodological differences, where
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the contribution of stress and temperature were suggested to play a role.
My conclusion from this data is that TRPA1 deletion does not influence
basal blood pressure.  Further measurements of heart size, heart rate and
heart function showed no effect of TRPA1 deletion.  Additionally, data
presented in chapter 5 showed basal levels of plasma CGRP to be similar in
TRPA1 WT and KO mice.  Together, this data suggests that TRPA1 is
either not involved in basal cardiovascular control, or that the effect of
TRPA1 deletion has been compensated for in the KO mice.   The outcome
contrasts with my hypothesis, but adds valuable evidence to the field.
Compensation could be further investigated using systemic administration
of TRPA1 antagonists to WT mice.  These are currently being developed
for respiratory and inflammatory conditions.  If my data is further
substantiated, this supports the development of such antagonists for clinical
use, as it suggests cardiovascular side effects may be few.
The most interesting and unexpected findings made in chapter 3 were
related to activity levels.  Similar findings have not been observed
previously.  In telemetered animals, TRPA1 KO mice showed increased
nocturnal activity counts.  I further investigated this phenotype using
voluntary running wheels to measure exercise in the home cage of naïve
mouse pairs.  This again showed TRPA1 KO mice to participate in an
increased amount of voluntary activity compared to WT mice.  In addition
to this, in chapter 5 TRPA1 was shown to be poorly expressed in grossly
dissected brain segments, and the spontaneous activity levels of TRPA1
KO mice to be exacerbated during hypertension.  This indicated that the
hyperactivity phenotype could be peripherally mediated.  Further




Analyse the role of TRPA1 in the vasorelaxant response to
cinnamaldehyde.  I will use isolated mesenteric arteries in a wire
myograph to study the nature of TRPA1 involvement in this process and
attempt to dissect the contributing signalling.
Several groups, including ours, have previously shown that TRPA1
agonists can induce vasorelaxation of vessels from many vascular beds.
This leads to an increase in blood flow in vivo. The studies of relevance
have been summarised in table 1.1.  However, despite a number of
investigations, the dependence of this phenomenon on the TRPA1 receptor
is poorly defined.  Additionally, a range of mechanisms have been
attributed.  Therefore, I conducted a series of investigations into the
mechanism of cinnamaldehyde induced vasorelaxation of murine
mesenteric arteries.  This agonist was chosen for its suitability for in vivo
use, along with evidence of receptor selectivity and previously defined
cardiovascular effects via TRPA1 (Pozsgai et al., 2010).  The mesenteric
artery was selected as the tissue of interest as together they comprise a
large component of total peripheral resistance, a major determinant of
blood pressure.
In chapter 4, cinnamaldehyde was shown to cause concentration dependent
vasorelaxation, in a partially TRPA1 dependent manner, occurring
independently of the endothelium.  These findings were made using
TRPA1 WT and KO arteries, with and without functional endothelium.
The in vivo relevance of this was demonstrated in our group by Aisah
Aubdool; using Laser Doppler flowmetry, topically applied
cinnamaldehyde was shown to cause an increase in ear blood flow which
was significantly reduced by addition of a TRPA1 antagonist or in TRPA1
KO mice. In the myograph, isolated mesenteric artery vasorelaxation to
cinnamaldehyde was found to be CGRP mediated, as it was significantly
reduced in CGRP KO mice and after pre-treatment with a non-peptide
CGRP receptor antagonist. Using elevated potassium to block
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hyperpolarisation, I also showed hyperpolarisation to mediate the
relaxation, but this was not occurring via the BKCa channel, as shown by a
lack of effect of the antagonist paxilline.  Together, this data suggests that
TRPA1 is involved in a vasorelaxant mechanism via the release of CGRP
which acts to hyperpolarise the vascular smooth muscle.  The majority of
TRPA1 expression was shown to be in DRG neurones, supporting a
sensory neurone derived mechanism.  Specifics of the data are discussed in
chapter 4, where significant difficulties were encountered with the use of
several antagonists and limited availability of TRPA1 WT mice lead to the
use of CD1 WT mice for some pharmacological studies. Although the data
is in no way conclusive, the findings from this chapter are in line with
those proposed in my hypothesis, and suggest that this mechanism may
occur in vivo.  The relevance of this during normal physiology and
pathophysiology are unknown, however data from chapters 3 and 5 suggest
that it is not involved in the control of systemic blood pressure.
Aim 3
Study the onset and endpoints of experimental hypertension in TRPA1 WT
and KO mice, investigating the potential roles of TRPA1.  This will be done
in terms of blood pressure, hypertrophy and endpoint inflammation
measures in matched TRPA1 WT and KO mice treated with Ang II.
Despite findings showing no clear role for TRPA1 in the control of basal
cardiovascular parameters, there are clear potential roles for the receptor,
and its dilative response, in pathological settings.  For example, CGRP KO
mice used in our group do not differ in their basal blood pressure, but fair
worse in an experimental model of hypertension similar to the one used
here (Smillie et al, Unpublished data).  As CGRP was shown to mediate
cinnamaldehyde induced vasorelaxation, a similar effect may be seen in
TRPA1 KO mice.  This is in line with my hypothesis. Similarly, TRPV1
KO do not alter from WT mice in terms of basal blood pressure (Pacher et
al., 2004) but show susceptibility to hypertension models (Wang et al.,
2008, Yang et al., 2010).
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TRPA1 WT and KO mice were made hypertensive over 14 days using
infusion of pressor doses of Ang II.  Both genotypes showed significantly
elevated blood pressure when measured by tail cuff plethysmography and
telemetry.  The onset profile was also similar.  These findings are discussed
in chapter 5 and disprove part of my hypothesis.  They suggest that TRPA1
does not have a strong influence on blood pressure either basally or during
the model of Ang II induced hypertension used in this study.  The reason
that TRPA1 does not have a protective role in hypertension, but that CGRP
does, is interesting and deserves further study, particularly in light of my
myography findings where CGRP is implicated in TRPA1 mediated
vasorelaxation.
The endpoints of hypertension were analysed in this study, in terms of
hypertrophy, and mRNA expression of TRP receptors,
cytokines/chemokines and pro and anti-oxidant proteins, along with the
plasma protein levels of cytokines and CGRP.  Only mild differences were
seen between TRPA1 WT and KO mice, suggesting that there is little
influence of TRPA1 on the pathogenesis occurring in this model.
However, some interesting findings were made. These are fully discussed
in chapter 5, but include significantly increased cardiac hypertrophy in Ang
II treated TRPA1 KO mice compared to Ang II treated TRPA1 WT mice.
The reasons for this are unclear, but may relate to increased oxidative stress
in hypertensive TRPA1 KO mice.  This was suggested as both genotypes
of mice show significant upregulation of pro-oxidative genes NOX2 and
NOX4 during hypertension, but these were frequently of significantly
larger magnitude in TRPA1 KO mice.  Upregulation of anti-oxidative
genes HO-1 and SOD1 were also seen, but were of similar magnitude
between genotypes. Together, this data suggest a potential protective role
for TRPA1 in remodelling and some aspects of inflammation, but further
work will be needed to investigate these finding.  Potentially, increased
oxidative stress may be mediating excessive remodelling in hypertensive
TRPA1 KO mice, perhaps via inflammatory cell infiltration.
275
TRPA1 KO mice showed significant upregulation of plasma mIL-8, an
effect seen more mildly in WT mice. Measurement of other inflammatory
markers, such as MCP-1 and IL-6, suggest that TRPA1 KO mice may be
protected from some aspects of systemic inflammation.  The levels of these
markers are significantly higher in hypertensive WT mice than
hypertensive KO mice.  This effect was shown strongly for IL-6, where
KO mice showed this trend consistently, through gene expression and
plasma protein analysis.  This suggests a pro-inflammatory mechanism
occurs via TRPA1 in WT mice which may influence inflammation at
multiple levels and could potentially influence cardiovascular disease
progression.
Additional studies in this chapter showed that TRPA1 expression was low
at all levels of the vasculature.  Predominant expression was found in DRG
neurones.  This occurs in line with my hypothesis that the majority of
TRPA1 activity occurs through sensory neurone activation and
neuropeptide release.  The levels of TRPV1, a related TRP channel, were
not affected by genotype and are only non-significantly increased by Ang
II treatment in the aorta.  During hypertension, TRPA1 mRNA expression
was significantly increased in the DRG of WT mice.  This suggests that
TRPA1 and sensory neurones may be playing a role in hypertension
pathogenesis, although inflammation induced from non-neuronal TRPA1
cannot be dismissed (Nassini et al, 2012).  As discussed in chapter 5,
sensory neurones are thought to play a compensatory role in hypertension,
but the role of TRPA1 activity may be mild and thus masked by the
severity of acute hypertension in my model.   The finding that TRPA1 is
upregulated is of importance aside from the other data.  It suggests
involvement of DRG neurones in hypertension, particularly a role for
TRPA1.  My hypothesis was based on TRPA1 activation causing the
release of CGRP, which would compensate for the introduction of Ang II
as a pressor agent.  To investigate this, CGRP plasma levels were measured
from hypertensive mice, but showed no genotype or treatment dependent
differences.  Therefore TRPA1 may not be acting in this way.  However,
previous reviews of the literature have shown that CGRP levels can
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become depleted in established hypertension (Smillie and Brain, 2011), and
its release inhibited by Ang II (Kawasaki et al., 1998), which may reflect
the situation in our hypertension model as CGRP levels tended to be lower
than those of control animals.  Therefore, a protective role for TRPA1
and/or CGRP in this model may have been missed and deserves further
study.
One of the most interesting findings of this thesis was of hyperactivity in
TRPA1 KO mice.  This has been previously discussed in the context of
chapter 3, but was also shown in chapter 5, where Ang II induced
hypertension exacerbated the hyperactivity phenotype.  These findings are
novel and of special interest, they will therefore be discussed for the
remainder of this chapter.
TRPA1 Deletion Induces A Hyperactivity Phenotype
The data presented in this thesis demonstrates that TRPA1 KO mice are
more active during basal conditions.  Significant increases in spontaneous
activity counts measured by telemetry were also mirrored when pairs of
mice were allowed to voluntarily exercise in a running wheel placed in
their cage.  Here, TRPA1 KO mice ran further, and showed a significant
preference for running at faster speeds than TRPA1 WT mice.  The
additional increase in running speed further indicates that there are
potential physiological differences between the strains, allowing an
increased capacity for exercise.  Conversely, this may also support a
psychological motivation for increased activity, where an increased feeling
of reward allows more intensive exercise.
There are a number of mechanisms that may mediate spontaneous
locomotion.  The typical human disease associated with this trait is
attention deficit hyperactivity disorder (ADHD).   There are several mouse
models used to investigate the causes of this condition, which largely focus
genetic effects on activity mediators in the brain.  One of these models is
the spontaneously hypertensive rat (Meneses et al., 2011), however the
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causes of the ADHD are not thought to be related to blood pressure control
or RAS.
The mechanisms controlling both spontaneous activity and voluntary
exercise levels in mice are currently unclear.  However, several lines of
evidence suggest that activity levels are modulated by central pathways.
This process can be modulated by a variety of neurotransmitters.  Several
transmitters are involved with the initiation of locomotion in mammals,
including dopamine, glutamine, serotonin, noradrenaline,
endocannabinoids and neuropeptides linked to appetite, see reviews by
Jordan et al (2008) and Garland et al (2011).  Within the brain, there are
some areas particularly rich in specific neurotransmitters and are linked to
motor activity control, however it is commonly thought that the end effect
of modulation of any of these neurotransmitters will be alteration of
dopamine neurotransmission, as the motivation behind increased activity of
laboratory mice is commonly reward based (Garland et al., 2011).  It is
also thought that activity levels may be linked to several personality traits
and disposition, as exercise can drive neurogenesis in the hippocampus, an
effect that has been linked to several neuropsychiatric diseases (Fuss and
Gass, 2010, Thakker-Varia and Alder, 2009). Several animal ADHD
models have been linked to changes in the neurotransmitter release in the
striatum, cortex and medulla (Magara et al., 2000, Wilson, 2000, Jordan et
al., 2008, Kamimura et al., 2001).
Hyperactivity was correlated with deletion of TRPA1; however, there have
been no previous reports of TRPA1 expression in the brain.  A preliminary
investigation of TRPA1 mRNA expression was conducted in grossly
dissected striatum, cortex and medullas from TRPA1 WT and KO control
mice, and Ang II treated WT mice. TRPA1 was poorly expressed in all
areas of the WT brain and was not affected by Ang II infusion. As
expected, KO mice expressed no detectable TRPA1 in any brain areas.  As
a positive control, I also measured the levels of several housekeeping genes
and TRPC5, which is a TRP channel highly expressed in brain (figure
5.18).  This suggests that TRPA1 may not be involved in a central
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modulation of activity, unless via stimulation in the periphery, causing
signalling to the brain.  This is a possibility, via both afferent neurones and
blood borne factors.  To investigate this, I would need to measure the levels
of neurotransmitters in specific nuclei related to activity.  In line with these
suggestions, I show TRPA1 mRNA to be upregulated on DRG neurones in
WT mice undergoing experimental hypertension.  On the other hand,
expression studies were completed on grossly dissecting brain.  This may
mean that small areas of rich TRPA1 expression are diluted by the
presence of other tissue, giving us low mRNA copy numbers per μl.
Further investigation of this will demand isolation of these areas, but a
single TRPA1 rich area is unlikely as low copy numbers were found
throughout the brain.
Mood modulation is another possible determinant of spontaneous activity,
with increased physical activity seen to be an effective anti-depressive
therapy (Byrne and Byrne, 1993).  Depression has been recently correlated
with plasma IL-6 levels in male twins, where increased IL-6 was shown to
be genetically linked to the risk of experiencing depressive symptoms (Su
et al., 2009).  My data shows the hyperactivity phenotype in TRPA1 KO
mice is not associated with a basal change in IL-6.  In hypertensive mice,
activity is further increased in KO mice, but the IL-6 level does not change.
This pattern is not supported by publications showing that plasma IL-6
levels to be consistently and reliably linked to the levels of skeletal muscle
activity (Febbraio and Pedersen, 2002, Fisman and Tenenbaum, 2010).
However, these IL-6 peaks may have been absent in my data due to their
transient nature, and that the mice in which IL-6 was measured did not
have access to a wheel.  Therefore the magnitude of exercise needed to
induce this IL-6 peak may not have been reached.   IL-6 has is also
suggested to be responsible for the insulin sensitivity and anti-
inflammatory effects of exercise (Febbraio and Pedersen, 2002), showing
short term positive effects.  Previous studies have shown that IL-6 KO
mice have a lower capacity for exercise, due to poorer endurance, leading
to inactivity induced obesity (Fäldt et al., 2004).  However, IL-6 is also
produced by adipocytes (Hoch et al., 2008) and moderate training in men
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lowers plasma levels of IL-6 as receptor sensitivity increases (Thompson et
al., 2010), suggesting that inverse relationships with activity can also
occur.  I am not able to comment on the emotional status of the mice, yet
several easily available tests could be done to investigate this.  For
example, defecation can be a good indicator of emotional stress (Gentsch et
al., 1981), and stress is a modulator of blood pressure.
IL-6 production can also be linked to the TRPA1 receptor, as patients with
sulphur mustard poisoning show increased IL-6 levels, which correlate
with severity (Attaran et al., 2010).  TRPA1 agonist’s cinnamaldehyde and
gingerol have both been shown to reduce spontaneous activity in animal
model, albeit without mechanistic links to the TRPA1 receptor (Harada and
Ozaki, 1972, Suekawa et al., 1984).  These studies link activity levels to
TRPA1 receptor activity, but suggest opposing correlations to my data
from TRPA1 KO mice.  In contrast, use of the TRPA1 antagonist HC-
300031 is not associated with changes in activity measured by the rotor-rod
system (McNamara et al., 2007).  My findings may be related to some
compensatory changes occurring following deletion of the receptor, or
indicate that different pathways are involved in exercise associated
pathways in these mice.  It may also suggest that the hyperactive mice
could be more sensitive to IL-6, or that their spontaneous movements are
not of the right kind to elicit IL-6 release.
The effect of Ang II on activity levels in TRPA1 KO mice is also
unexplained.  During days 8-14, activity counts from telemetered and Ang
II infused TRPA1 KO animals was significantly higher than those of the
comparable WT group.  This increase could have been due to Ang II
infusion, exacerbating the hyperactivity phenotype. Both WT and KO
hypertensive mice lost weight during the protocol, compared to control
mice, however this could not be related to activity levels. Ang II infusion
is associated with a loss of skeletal muscle mass in mice, which may be
partially mediated by ROS produced from NOX2 (Semprun-Prieto et al.,
2011) or by increased protein degradation (Brink et al., 2001).  This is
supported by my RT qPCR data, showing Ang II infused mice to express
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higher levels of vascular NOX2 mRNA, correlating with their reduction in
body weight.  However there is no evidence this weight reduction is due to
muscle loss as this would require further measurements to be taken. Ang II
infusions themselves are unlikely to be affecting appetite, unless as a side
effect of hypertensive pathology. Ang II positively correlates with leptin
and body fat levels in obese patients (Saiki et al., 2009) linking it to
metabolic syndrome pathology. Ang II is also commonly associated with
water retention, increasing blood volume and thus potentially body weight.
In my mice, the cause of body weight reduction in hypertensive mice is
unclear.  It is most likely to be due to changes in appetite due to
hypertensive morbidity and not the procedure itself, which was also
undergone by control mice.  These suggestions could be further examined
by measuring food and water intake and using metabolic cages.  Analysis
of the data also did not exclude the conclusion that activity levels were
reduced following surgery, and that the significant difference seen between
hypertensive TRPA1 WT and KO mice is a reoccurrence of the
hyperactivity phenotype seen at baseline.  As previously discussed, there
are currently limited known links between TRPA1 and activity levels.
To conclude, my findings demonstrate a hyperactivity phenotype in the
TRPA1 KO mice, which may be exacerbated on Ang II infusion.
However, the current evidence cannot link these changes to central
pathways, mood, changes in body weight or IL-6 production, all factors are
linked to initiation of, or involvement in, spontaneous exercise.  Further
investigations would need to analyse more specific measures of activity,
such as specialist cages or open field tests.  These would be required, along
with learning tests, to fully determine if our TRPA1 KO mouse qualifies as
a model of ADHD.  If so, more detailed physiological tests would then be
warranted to investigate the role of TRPA1.
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Limitations
Based on results as a whole, several limitations of the present study and
potential future directions have been highlighted;
1. Myography studies presented in chapter 4 show some shortfalls,
which were discussed in the text and could be addressed in future
studies. These include the lack of positive control for TRPA1
antagonists used, particularly HC-030031.  Attempts were made to
obtain this in other rodent tissues; namely the bronchi, cerebral and
pulmonary arteries, however I was unable to demonstrate an
inhibition of a cinnamaldehyde response in the wire myograph
preparation despite established use of HC-030031 within our group
to inhibit the in vivo actions of cinnamaldehyde.  My study has
focussed on cinnamaldehyde as a TRPA1 agonist, which showed
consistent relaxation actions in all tissues studied and evidence of
neuropeptide dependence in the mesentery and bronchi.
Concentrations of TRPA1 antagonists used were in the range shown
to have TRPA1 inhibitory activity in published studies, but were
not effective in blocking the cinnamaldehyde responses in my
preparations.  Therefore, I cannot currently conclude if my data
represents a TRPA1 independent neuropeptide release by
cinnamaldehyde, or problems with antagonist activity in vitro.
A similar lack of activity was seen with the CGRP receptor
antagonist CGRP8-37, where I was able block exogenous CGRP-
induced vasorelaxation but not cinnamaldehyde-induced
vasorelaxation. This suggested that cinnamaldehyde activity is
CGRP independent; however this conclusion was challenged when
another CGRP receptor antagonist was able to strongly inhibit the
cinnamaldehyde response. Collectively, findings suggest that there
may be difficulties with the use of some antagonists in the wire
myograph preparation.
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The investigation of pharmacological interventions would also
ideally have been carried out in vessels from TRPA1 WT and KO
mice; in particular, the use of BIBN and 30mM potassium
treatments.  A lack of activity in TRPA1 KO mice would imply a
CGRP and hyperpolarisation is induced specifically in the TRPA1
dependent component of cinnamaldehyde induced vasorelaxation.
However a particular concern with BIBN is its current lack of
commercial availability, which limits our study.
Further limitations are associated with the use of mice from
different strain backgrounds, which has been discussed in chapter 4.
The cinnamaldehyde response demonstrated TRPA1 dependent and
independent components using mesenteric arteries from TRPA1
WT and KO mice. On-going studies would ideally have been
conducted in vessels from WT and KO mice, but was not feasible
due to availability and the necessity to use genetically modified
strains on a different mouse background. Contractile abilities were
shown to be similar in CD1, C57/BL6 and mixed background
TRPA1 WT mice, also demonstrating comparable EC50 values for
cinnamaldehyde vasorelaxation.   Although this does not rule out
strain related mechanistic differences, I suggest that this does not
represent a major factor in the response to cinnamaldehyde.
Finally, although the findings from the myography studies are not
conclusive, they do provide some novel insight on the mechanism
of cinnamaldehyde induced vasorelaxation in the mouse mesenteric
artery, a tissue not previously investigated for TRPA1 activity.
Further studies could consolidate this investigation around the
TRPA1 dependent component, perhaps using more selective
TRPA1 agonists, antagonists of candidate potassium channels or by
direct measurement of smooth muscle membrane potential. There
are additional considerations of how this mechanism may translate
to the in vivo scenario, where central reflexes play a major role in
controlling resistance artery tone.  These challenges could be
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approached by further use of Laser Doppler flowmetry and
measurement of localised/systemic changes in blood pressure.
2. The Ang II induced hypertension model used in this study produced
an acute and severe hypertension model.  Characterised by a
systolic blood pressure of >160mmHg and diastolic blood pressure
>120mmHg after only a week of Ang II infusion.  This was useful
to us because it allowed the rapid development of pathology over
the 14 days infusion, but the strength of the model may have
masked some of the compensatory changes of interest to us.  This
includes changes in CGRP levels.  In response to my hypothesis,
my aim was to investigate potential compensatory mechanisms
initiated by TRPA1 during hypertension.  I have some evidence that
sensory neurones, and potentially TRPA1, were active during the
experimental period through upregulation of TRPA1 receptor
expression on DRG.  However, CGRP plasma levels were lower
than in control mice for both hypertensive groups. Together, this
suggests that any compensatory role for sensory neurones in my
hypertension model occurred before the end of the experimental
protocol.
Future experiments may benefit from using a lower dose of pressor
agent, possibly infused over a longer time.  This would also allow
groups of mice to be sacrificed at time points along the protocol,
demonstrating how the pathology develops.  This approach would
be more likely to highlight a role for TRPA1 and neuropeptides in
hypertension.  Alternatively, other methods of hypertension could
be used, for example L-NAME or high fat feeding models.
However, these models have different pathologies.
3. The statistical outcomes of this study have suffered from
underpowering. Initial power calculations were based on the
numbers needed in similar studies which are both published and
have been carried out within this laboratory, as the size of any
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differences could not be predicted in such a novel study. The N
numbers needed were expected to be around 5-8 for blood pressure
studies, and were met in much of the study. During the experiment,
several areas reduced available N numbers and increased variability
around the mean. Individual animals were lost in each protocol,
likely due to acute hypertensive events. Animals were also grouped
into several batches due to availability of time and materials,
meaning that each protocol was conducted on 2-3 separate
occasions and an extra aspect of variability was introduced into the
data.  This was compounded by the grouping of tail cuff and
telemetry measured mice for ex vivo analysis.  As I frequently
serially used tissue from each animal for several analyses, this then
led to some problems with under powering and lack of statistical
significance in places.  This is disappointing as it does not allow me
to confirm the findings mathematically.  With more time,
interesting findings seen in this thesis could be followed up with
increased experimental numbers.  Ideally this would then also allow
proper splitting of the data by gender, which seems not to be a
determinant in this study, but would be of value to establish
conclusively.
4. The breadth of this study has highlighted several areas of interest
for further investigation.  The first is the novel findings of
hyperactivity in TRPA1 KO mice.  This is of interest for future
studies where the mechanisms can be further investigated.
5. Despite findings showing a mild role for TRPA1 in cardiovascular
regulation.  Several potentially interesting findings were made that
deserve further investigation.  In particular, the significantly
increased hypertrophy and oxidative stress, and blunted increase in
IL-6 and MCP-1 in hypertensive TRPA1 KO mice, suggesting that
TRPA1 may mediate both pro and anti-inflammatory mechanisms.
During chapter 5, I detailed how investigations have continued to
study the source of IL-6 in the Ang II induced hypertension model.
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Further investigation of oxidative stress would particularly be
useful as TRPA1 is reported to be activated by ROS (Bessac, 2008),
therefore a lack of anti-oxidant defence induction in KO mice
suggests that TRPA1 may be important in sensing oxidant levels in
vivo.  This study would benefit from measurement of tissue ROS
levels in particular.  Lastly, several markers of inflammation
measured in chapter 5 suggested that TRPA1 may be involved in
inflammatory cell infiltration.  TRPA1 KO mice showed
significantly blunted increases in MCP-1, in addition to IL-6.
However, mIL-8 upregulation was significant in hypertensive
TRPA1 KO mice, but not in TRPA1 WT mice.  Previous studies
from this group have shown TRPA1 activation cause inflammatory
cell infiltration (Bodkin, Unpublished data).  A TRPA1 mediated
cell infiltration mechanism would fit well with data in this thesis,
however the mechanism is unclear.  Sun et al (2007) show that
treatment with NK1 antagonists reduces the expression of MCP-1
on leukocytes during acute pancreatitis, suggesting that SP is
chemotactic for granulocytes in particular, occurring via MCP-1.
TRPA1 KO may be associated with decreased SP release, thus
explaining the decreased MCP-1 expression and IL-6 production,
through a reduced cell accumulation.  This hypothesis cannot be
fully determined until cell accumulation is quantified by histology,
but currently available aortic sections do not show striking
differences in cell accumulation.  Therefore the mechanism behind
these differences is currently unknown, but of potential value for
the development of anti-TRPA1 therapeutics.  As TRPA1
antagonists are currently in development for airway disease, which
is often cellular based, part of their anti-inflammatory effect may be
derived from a reduction in cell accumulation.  Further in vivo and
ex vivo cell accumulation assays would be of value to support these
conclusions.
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Future Studies To Clarify Mechanisms Discussed In This
Thesis
- Extension of myography studies using TRPA1 WT and KO mice
with more selective TRPA1 agonists and channel specific
antagonists.
- An in vivo, long term low dose pressor study, with increased N
numbers to improve the power of the study.
- Investigation of the exercise capacity in TRPA1 WT and KO mice.
- Investigation of TRPA1 WT and KO mice in other inflammatory
diseases areas, particularly those which show a major role for IL-6
Conclusion
This thesis has described my novel study, investigating the role of TRPA1
in cardiovascular regulation.  Though the role of TRPA1 proved to be mild,
there were some valuable findings which add to current knowledge in the
field.  Firstly, the finding that TRPA1 is poorly expressed in the
vasculature, but is expressed at high levels in DRG and upregulated during
hypertension.  Secondly, that TRPA1 activation on mesenteric arteries
leads to endothelial independent vasorelaxation, which shows a
hyperpolarisation and CGRP component.  Thirdly, that TRPA1 may
potentially modulate the production of inflammatory mediators, in
particular IL-6.  Fourthly, that TRPA1 may be protective against heart
hypertrophy.  Finally, and maybe most importantly, that TRPA1 deletion
causes a previously undescribed hyperactivity phenotype in mice.
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Appendix
This appendix is to be used alongside chapter 4, containing representative
myograph traces collected in LabChart software from the DMT wire
myograph, as described in the methods section.  These images are
screenshots of the raw data, which is collected by direct reading of the mN




Appendix Figure 1: Representative Traces Of Responses To High K+
And Assessment Of Endothelial Function Using Carbachol. Basal tone
in mouse mesenteric arteries was set using a normalisation procedure (to
13.3kPa).  Vessels were challenged with Krebs containing a depolarising
level of K+ (80mM) for two minutes, followed by 3 washouts with basic
Krebs and a 5 minute rest.  This is depicted in the first 3 peaks of panel A.
Vessel were then pre-constricted using U46619 (10nM in 5µl water, 5
minutes) at a concentration used for all vessels and previously shown to
approximate the EC70, followed by an addition of Carbachol (10μM in 5µl
water). Relaxation >60% at 2 minutes, is indicative of the vessels holding
intact endothelium.  The vessel shown in panel A is a mesenteric artery
from a TRPA1 KO mouse. Panel B shows a more detailed trace with the 3rd
‘High K+’, U46619 and carbachol additions only, and is taken from a




Appendix Figure 2; Representative Traces Showing The Effect Of
Single Cinnamaldehyde Concentrations On TRPA1 WT And KO
Mesenteric Arteries Without Functional Endothelium. TRPA1 WT (A)
and KO (B) mesenteric arteries without endothelium were mounted on a
wire myograph.  Peaks show pre-constriction to U46619 (10nM in 5µl
water, 5 minutes), followed by an addition of cinnamaldehyde in 5µl
ethanol. Each consecutive peak shows effect of an incremental
cinnamaldehyde concentration (3-300μM). % relaxation from pre-
constriction is calculated 5 minutes after each cinnamaldehyde addition.




Appendix Figure 3: Representative Trace Of The Effect Of MO On A
Mouse Mesenteric Artery. A TRPA1 WT mouse mesenteric artery
without functional endothelium is pre-constricted to U46619 (10nM in 5µl
water, 5 minutes), followed by addition of 3 or 30μM MO (AITC on the
trace) in 5ul ethanol, for 10 minutes.  This is followed by a 3 wash-outs
with basic Krebs and a 10 minute rest. % relaxation from pre-constriction
is calculated 10 minutes after each MO addition.
Appendix Figure 4: Representative Trace Of Cinnamaldehyde Vehicle
Additions On U46619 Pre-constriction. A CD1 (TRPA1 WT) mesenteric
artery with functional endothelium is pre-constricted with U46619 (10nM
in 5ul water, 5 minutes). Additions of 1.5μl of ethanol are made every 3
minutes for 15 minutes, representing the vehicle of cinnamaldehyde.  Final
5ml bath contains 7.5μl of ethanol. This is followed by 3 wash-outs with
basic Krebs. % relaxation from pre-constriction is calculated 3 minutes
after each vehicle addition.
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Appendix Figure 5; Representative Trace Showing The Effect Of HC-
030031 Or Vehicle On The Concentration Dependant Relaxation To
Cinnamaldehyde. A CD1 (TRPA1 WT) mouse mesenteric artery without
functional endothelium is pre-treated for 15 minutes with either the TRPA1
antagonist HC030031 (30μM) or its vehicle (DMSO, 5μl) before pre-
constriction with U46619 (10nM in 5µl water, 5 minutes).  Cumulative
concentrations of cinnamaldehyde are then added every 3 minutes (3-
300μM, each in 1.5μl ethanol). The same vessel received vehicle first,
followed by antagonist treatment.  % relaxation from pre-constriction is
calculated 3 minutes after each cinnamaldehyde addition.
+ HC030031+ Vehicle
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Appendix Figure 6; Representative Trace Showing The Effect Of
TCS5861528 Or Vehicle On The Concentration Dependant Relaxation
To Cinnamaldehyde. A CD1 (TRPA1 WT) mouse mesenteric artery
without functional endothelium is pre-treated for 15 minutes with either the
TRPA1 antagonist TCS5861528 (30μM) or its vehicle (DMSO, 5μl) before
pre-constriction with U46619 (10nM in 5µl water, 5 minutes). Cumulative
concentrations of cinnamaldehyde are then added every 3 minutes (3-
300μM, each in 1.5μl ethanol). The same vessel received vehicle first,
followed later by antagonist treatment.  % relaxation from pre-constriction
is calculated 3 minutes after each cinnamaldehyde addition.
+ TCS5861528+ Vehicle
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Appendix Figure 7; Representative Trace Showing The Effect Of
TRPA1 Antagonists On Bronchial Ring Relaxation To
Cinnamaldehyde and SP. Bronchial rings with functional epithelium,
from CD1 (TRPA1 WT) mice, are pre-treated with HC-030031 (50µM in
0.05% DMSO/Krebs), AP-18 (100µM in 0.1% DMSO/Krebs) or normal
Krebs for 15 minutes before pre-constriction with carbachol (1µM in 5µl
water, 3 minutes or to plateau). % relaxation from pre-
constriction/cinnamaldehyde response is calculated 3 minutes after
application of cinnamaldehyde (60µM in 10µl ethanol), then SP (1µM in
5µl 0.01% BSA/water). Between peaks there are 3 wash-outs with basic
Krebs and a 20 minute rest period.
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Appendix Figure 8; Representative Trace Showing The Effect Of NK1
Antagonists On Bronchial Ring Relaxation To Cinnamaldehyde and
SP. Bronchial rings with functional epithelium, from CD1 (TRPA1 WT)
mice, are pre-treated with SR140333 (1µM in 5µl water) or normal Krebs
for 15 minutes before pre-constriction with carbachol (1µM in 5µl water, 3
minutes or to plateau).  % relaxation from pre-constriction/cinnamaldehyde
response is then calculated 3 minutes after application of cinnamaldehyde
(60µM in 10µl ethanol), then SP (1µM in 5µl 0.01% BSA/water).
Between peaks there are 3 wash-outs with basic Krebs and a 20 minute rest
period. Traces are from separate bronchi run in parallel.
+ SR140333Control
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Appendix Figure 9; Representative Trace Showing The Contractile
Effect Of U46619 On Rat Cerebral Arteries. Wistar rat cerebral arteries
without functional endothelium were mounted in a wire myograph and
tested for maximum contractile ability using three sets of 2 minute
treatments with Krebs containing a depolarising concentration of potassium
(80mM).  Following a 10 minute rest, vessels were constricted with
cumulative concentrations of U46619 (0.3nM-1µM in 1-5µl water), with
additions every 2 minutes.  Baseline tension was set using normalisation to
a physiological tension (9kPa).  Completion of the curve is followed by 3
wash-outs with basic Krebs. Traces are from separate bronchi run in
parallel.  % contraction from baseline is calculated 2 minutes after each
addition.
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Appendix Figure 10; Representative Trace Showing The
Concentration Dependent Vasorelaxation Of Rat Cerebral Arteries To
Cinnamaldehyde. Wistar rat cerebral arteries with functional endothelium
were mounted in a wire myograph and constricted with U46619 (30nM in
3µl water, 5 minutes) before addition of cumulative concentrations of
cinnamaldehyde (3-1000µM in 1.5µl ethanol each addition, one every 2
minutes).  % relaxation from pre-constriction is calculated 3 minutes after
each addition.
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Appendix Figure 11; Representative Trace Showing The
Vasorelaxation Of Rat Cerebral Arteries To Cinnamaldehyde With
And Without Pre-Treatment With A TRPA1 Antagonist. Wistar rat
cerebral arteries without functional endothelium were mounted in a wire
myograph and pre-treated with HC-030031 (10µM), normal Krebs or
vehicle (0.05% DMSO in Krebs) for 15 minutes before pre-constriction
with U46619 (30nM in 3µl water, 5 minutes) and addition of
cinnamaldehyde (300µM) or vehicle (5µl ethanol) for 5 minutes.  This is
followed by 3 wash-outs with Krebs and a 15 minute rest. 2 separate
arteries are shown, conducted in parallel. % relaxation from pre-
constriction is calculated 5 minutes after cinnamaldehyde addition.
CA 300µM Vehicle Controls + HC (10µM)
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Appendix Figure 12; Representative Trace Showing The Contractile
Effect Of U46619 On Rat Pulmonary Arteries. Wistar rat pulmonary
arteries with functional endothelium were mounted in a wire myograph and
tested for maximum contractile ability using three sets of 2 minutes
treatments with Krebs containing a depolarising concentration of potassium
(80mM).  Following a 10 minute rest, vessels were constricted with
cumulative concentrations of U46619 (0.1-300nM in 1-5µl water), with
additions every 2 minutes.  Baseline tension was set using normalisation to
a physiological tension (2kPa).  Completion of the curve is followed by 3
wash-outs with basic Krebs. % contraction from baseline is calculated 2
minutes after each addition.  Traces are from separate vessels run in
parallel
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Appendix Figure 13; Representative Trace Showing The
Concentration Dependent Vasorelaxation Of Rat Pulmonary Arteries
To Cinnamaldehyde. Wistar rat pulmonary arteries with functional
endothelium were mounted in a wire myograph and constricted with
U46619 (100nM in 5µl water, 5 minutes) before addition of cumulative
concentrations of cinnamaldehyde (3-300µM in 1.5µl ethanol each
addition, every 2 minutes). This is followed by 3 wash-outs with basic
Krebs.  % relaxation from pre-constriction is calculated 3 minutes after
each addition.  Traces are from separate vessels run in parallel
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Appendix Figure 14; Representative Trace Showing The
Vasorelaxation Of Rat Pulmonary Arteries To Cinnamaldehyde With
And Without Pre-Treatment With A TRPA1 Antagonist. Wistar rat
pulmonary arteries with functional endothelium were mounted in a wire
myograph and pre-treated with HC-030031 (10µM), normal Krebs or
vehicle (0.05% DMSO in Krebs) for 15 minutes before pre-constriction
with U46619 (100nM in 5µl water, 5 minutes) and addition of
cinnamaldehyde (300µM) or vehicle (5µl ethanol).  This is followed by 3
wash-outs with basic Krebs and a 15 minute rest. % relaxation from pre-
constriction is calculated 5 minutes after cinnamaldehyde addition.
CA 300µM Vehicle Controls + HC (10µM)
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Appendix Figure 15; Representative Trace Showing The Effect Of
CGRP And Substance P On Mesenteric Artery Tone. Mesenteric artery
without functional endothelium from a CD1 (TRPA1 WT) mouse is
mounted on a wire myograph and pre-constricted with U46619 (10nM, 5
minutes).  This is followed by cumulative concentrations of αCGRP (1-
100nM, in 1-5µl 0.01% BSA in water, left side of the panel) or SP (10-
1000nM in 1-5µl 0.01% BSA in water, right side of the panel) every 3





Appendix Figure 16; Representative Traces Showing Concentration
Dependant Relaxation To Cinnamaldehyde And CGRP In CGRP WT
And KO Mesenteric Arteries. Mesenteric arteries from CGRP WT (A)
and KO (B) mice without functional endothelium are pre-constricted to
U46619 (10nM, 5 minutes) before cumulative concentrations of
cinnamaldehyde (3-300µM in 1.5ul ethanol per addition, left of the panel)
or αCGRP (1-100nM in 1-5µl 0.01% BSA/water, right of the panel) are
added every 3 minutes. % relaxation from pre-constriction is calculated 3
minutes after each addition.  This is followed by 3 wash-outs with basic






Appendix Figure 17; Representative Trace Showing The Effect Of
CGRP 8-37 On Concentration Dependant Relaxation To CGRP And
Cinnamaldehyde In A Mesenteric Artery. Mesenteric arteries without
functional endothelium from a CD1 (TRPA1 WT) mouse are mounted on a
wire myograph and pre-treated with the CGRP receptor antagonist CGRP
8-37 (3µM) or vehicle (10µl 0.01% BSA/water) for 15 minutes before pre-
constriction with U46619 (10nM in 5µl water, 5 minutes) followed by
cumulative concentrations of αCGRP (1-100nM in 1-5µl 0.01%
BSA/water, panel A) or cinnamaldehyde are shown (3-300µM in 1.5µl
ethanol, panel B).  % relaxation from pre-constriction is calculated 3
minutes after each addition. Both A and B show the same vessel.
+ CGRP 8-37
+ CGRP 8-37 - CGRP 8-37
- CGRP 8-37
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Appendix Figure 18; Representative Trace Showing The Effect Of
BIBN 4096 BS Vehicle On Concentration Dependant Relaxation To
Cinnamaldehyde. Mesenteric arteries without functional endothelium
from a CD1 (TRPA1 WT) mouse are mounted on a wire myograph and
pre-treated with the non-competitive CGRP antagonist BIBN 4096 (10µM)
or vehicle (5µl DMSO) for 15 minutes before pre-constriction with
U46619 (10nM in 5µl water, 5 minutes) and cumulative concentrations of
cinnamaldehyde (3-300µM in 1.5ul ethanol per addition, every 3 minutes).
% relaxation from pre-constriction is calculated 3 minutes after each
addition.
+ Vehicle + BIBN
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Appendix Figure 19; Representative Trace Showing The Effect Of Pre-
constriction With 30mM K+ On Concentration Dependant Relaxation
To Cinnamaldehyde. Mesenteric arteries without functional endothelium
from a CD1 (TRPA1 WT) mouse are mounted on a wire myograph and
pre-constricted with a Krebs solution containing a slightly depolarising
concentration of potassium which blocks hyperpolarisation of the tissue
(30mM K+). This is followed by cumulative concentrations of
cinnamaldehyde (3-300µM in 1.5ul ethanol per addition, every 3 minutes,
left of the panel) or without additions over a similar timecourse (right of
the panel). This is followed by 3 wash-outs with basic Krebs and a 10
minute rest.  % relaxation from pre-constriction is calculated 3 minutes
after each addition or at the equivalent time-point.
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Appendix Figure 20; Representative Trace Showing The Effect Of
Paxilline Or Vehicle On Concentration dependant Relaxation To
Cinnamaldehyde. Mesenteric arteries without functional endothelium
from a CD1 (TRPA1 WT) mouse are mounted on a wire myograph and
pre-treated with the non-competitive BKCa channel antagonist paxilline
(1µM) or vehicle (5µl DMSO) for 15 minutes before pre-constriction with
U46619 (10nM in 5µl water, 5 minutes) and cumulative concentrations of
cinnamaldehyde (3-300µM in 1.5ul ethanol per addition, every 3 minutes).
% relaxation from pre-constriction is calculated 3 minutes after each
addition.
+ Paxilline + Vehicle
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